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Human immunodeficiency virus type 1 (HIV-1) isolates can be differentiated based 
on their ability to use particular coreceptors – R5 viruses use CCR5, X4 viruses use 
CXCR4 and R5X4 (dual tropic) viruses use both CCR5 and CXCR4. It is widely 
reported that HIV-1 subtype C (HIV-1C) has a unique viral coreceptor evolution 
pattern in that a complete switch from the predominant CCR5 (R5) to CXCR4 (X4) 
phenotype is less common for this subtype compared to other subtypes. However, 
dual tropic HIV-1C isolates have occasionally been described. Furthermore, it has 
been reported that certain highly active antiretroviral drugs (HAART) may select for 
X4 viral variants. Therefore, this thesis study was undertaken to better understand the 
functional and genotypic characteristics of dual tropic HIV-1C isolates, and to 
characterize drug resistance and coreceptor usage patterns in HAART-naïve versus 
HAART-failing HIV-1C infected patients. 
 
Thirty-five functional HIV-1 env clones derived from seven dual tropic HIV-1C 
strains were generated and their coreceptor usage characterized in transformed cell 
lines. All 35 env clones efficiently infected transformed cells expressing CXCR4. 
Twenty of 35 clones (57%) also utilized the CCR5 receptor. No R5-only clones were 






The ability of the HIV-1C env clones to facilitate infection of primary lymphocytes 
and monocyte-derived macrophages was next investigated. The majority of clones 
characterized as X4 or R5X4 on cell lines used either CXCR4 alone or CXCR4 and 
CCR5, respectively, in primary cells. A few viruses displayed comparable CCR5 and 
CXCR4 usage and clones from one virus preferred CCR5 usage in macrophages. 
Thus in a few cases coreceptor phenotyping in transformed cell lines does not predict 
usage in primary cells. Genetic determinants for coreceptor usage in primary cells 
require further investigation.  
 
Finally the patterns of drug resistance mutations were studied and coreceptor usage 
among 45 HAART-naïve and 45 HAART-failing HIV-1C infected patients analyzed. 
Ninety-five percent of HAART-failing patients had viruses with at least one drug 
resistance mutation. Thymidine analog resistance mutations (TAMs) were present in 
55% of patients. HAART-failing patients had significantly higher prevalence (59%) 
of X4/R5X4-utilizing viruses compared to HAART-naïve patients (30%) (p<0.02) 
using the Trofile Co-receptor Tropism Assay while 41% of HAART-failing patients 
used CCR5 and 70% of HAART-naïve patients  used CCR5. Functional results 
correlated with predictive algorithm methods.  
 
This study enhances our understanding of HIV-1 pathogenesis and the results have 
important implications for the use of coreceptor antagonists for the clinical 
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Acquired immune deficiency syndrome (AIDS) is caused by the human immunodeficiency 
virus (HIV) and is characterized by a serious disorder of the immune system in which the 
body’s protective defenses against infection cannot function leaving the body vulnerable to 
severe infections. According to the UNAIDS (Joint United Nations Programme on 
HIV/AIDS) and WHO (World Health Organization) 2007 AIDS epidemic update report the 
estimated number of people living with HIV worldwide was 33.2 million (Figure 1.1). This 
was a reduction of 16% when compared to the published estimate in 2006 (UNAIDS 2007; 
UNAIDS 2008). 
 
HIV is the most serious infectious disease challenging the public health sector with more than 
6,800 persons becoming infected with the virus and approximately 5,700 deaths daily 
(UNAIDS 2006). The most seriously affected region in the world is Sub-Saharan Africa and 
HIV/AIDS is the leading cause of death in this region. In 2007, the estimated number of 
deaths as a result of HIV/AIDS was 2.1 million (Figure 1.2) and of these 75% were in Sub-
Saharan Africa. Of the 2.5 million new infections in 2007, 68% occurred in Sub-Saharan 
Africa (Figure 1.3) (UNAIDS 2007; UNAIDS 2008). South Africa accounts for the highest 





Figure 1.1: Global distribution of adults and children estimated to be living with 






                                                
Figure 1.2: Global distribution of the estimated number of adults and children 





                                                      
Figure 1.3: Global distribution of estimated adult and child deaths from AIDS 
during 2007 
 
HIV-1 is divided into 3 groups, HIV-1 major group (HIV1-M), Outlier (HIV1-O) and HIV1-
N group. This is Non-M or Non-O or may be also be referred to as “New”.  The strains of 
HIV-1 isolated from people in U.S.A. and Europe are genetically diverse from strains isolated 
in Africa and Asia. HIV-1 major group can be further classified into subtypes or clades 
designated A through K. Such subtypes have envelope gene sequences that vary by 20% or 
more between subtypes. In addition other circulating recombinant forms (CRF) exist, and 




In South Africa, the most prevalent circulating HIV subtype is HIV-1 subtype C (HIV-1 C). 
This subtype accounts for approximately 56% of infections worldwide (Esparza 2005; 
Hemelaar et al. 2006; Visawapoka et al. 2006). Subtype C is unique from all other subtypes 
as it is the only subtype that has been reported to retain predominant CCR5 coreceptor usage 
throughout infection whereas other subtypes show a switch in coreceptor usage from CCR5 
to CXCR4 (Bjorndal and Sonnerborg 1999; Cecilia et al. 2000; Cilliers et al. 2003; Ndung'u 
et al. 2006; Tscherning et al. 1998). Subtypes differ based on sequence variations within all 
gene and non-coding regions, but it is the envelope gene (env) that accounts for the most 
dramatic differences of over 20% amino acid differences between subtypes (Gao et al. 1998).  
The env gene product, the envelope glycoprotein (Env) plays an important role in viral 
transmission by determining which coreceptor the virus binds to upon entry into the body 
(Rizzuto et al. 1998; Wyatt 1998). 
 
1.2. Viral Genome and Structure  
The HIV-1 viral genome is approximately 9.8 kb and encodes several major structural genes 
and several non structural genes. The structural and enzymatic proteins include Gag, Pol and 
Env. The gag (group-specific antigen) gene codes for the protein that constitutes the physical 
infrastructure of the virus encoding the components of the inner capsid protein . The pol gene 
codes for viral enzymes integrase, reverse transcriptase, HIV protease and RNAse H. The env 
(envelope) gene codes for the glycoprotein precursor gp160, which consists of gp 120 and gp 
41 which are proteins that are embedded in the viral envelope and enable the virus to attach 
to and fuse with target cells. The RNA-binding regulatory proteins include transactivators Tat 
and Rev; and the accessory proteins include other regulators Vif, Vpr, Vpu and Nef. All these 
assist the virus in entering the host cell and enhance reproduction. The long terminal repeats 
(LTR) are positioned on either end of the genome. These LTRs are used by the integrase 
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enzyme to insert the HIV genome into the host DNA. Once they are integrated into the host 
genome they act as enhancers/promoters which influence the cell components which 
transcribe DNA (McCance and Huether 2006) (Figure 1.4). Transactivation of the LTR by 
the Tat protein is essential  for both
 
viral gene expression and virus replication. 
Transactivation involves the binding of the HIV-1 LTR to the TAR sequence
 
along with other 
cellular factors, resulting in increased viral
 








Figure 1.4: Schematic representation of the HIV-1 genome 
gag codes for the protein that constitutes the physical infrastructure of the virus encoding the 
components of the inner capsid protein; pol codes for viral enzymes integrase, reverse 
transcriptase and HIV protease and env codes for the glycoprotein precursor gp160, which 
consists of gp 120 and gp 41. The RNA-binding regulatory proteins include transactivators 
Tat and Rev; and the accessory proteins include other regulators Vif, Vpr, Vpu and Nef. 
 
1.3. Viral Life Cycle  
The first step in the viral life cycle is binding and fusion of the virus to the host cell. The 
virus attaches to the surface of a CD4 +
 
T lymphocyte cell by binding to a CD4 receptor and 
one of two cellular coreceptors. The viral envelope undergoes a conformational change 




















fusion, the virus releases RNA into the host cell cytoplasm. Reverse transcription then occurs 
as the HIV enzyme reverse transcriptase converts the single-stranded HIV RNA to a double-
stranded HIV DNA provirus. Integration then follows as the HIV DNA provirus migrates to 
and enters the nucleus of the host cell and the HIV enzyme integrase incorporates the HIV 
DNA into the host cell DNA. The provirus may remain latent and upon activation of the 
infected cell (e.g. by cytokines) the provirus is transcribed and translated into viral protein 
precursors. These precursor proteins are modified by viral and cellular proteases (Gag and 
Env proteins respectively) into smaller proteins i.e. the HIV enzyme protease cleaves the HIV 
proteins into functional proteins which are used to package the viral RNA into new virions 
i.e. assembling into a new virus particle. The newly assembled particle buds from the host 
cell taking with it a part of the cell outer envelope containing the HIV glycoproteins which 
are necessary for the virus to bind CD4 and coreceptors continuing the cycle. The virus buds 
as an immature particle and only once full cleavage is completed is it a mature infectious 
particle (McCance and Huether 2006; Zhang and Moore 1999).   
 
1.4.Viral Entry into Host Cell 
The entry of HIV requires the interaction of the viral Env glycoprotein (gp120) with two host 
surface proteins, the CD4 glycoprotein and a chemokine receptor located on the cell surface 
resulting in the fusion of the viral and cellular membranes. When the viral Env binds to the 
CD4 glycoprotein which serves as the primary receptor, a conformational change occurs in 
the gp120 glycoprotein resulting in the exposure and/or formation of a specific binding site 
for a chemokine receptor. These chemokine receptors are secondary receptors for viral entry 
and are most often CCR5 and CXCR4 (Alkhatib et al. 1996a; Choe et al. 1996; Deng and Liu 
1996; Dragic and Litwen 1996; Feng et al. 1996; Kwong et al. 1998; Lusso 2006; Rizzuto et 
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al. 1998; Wyatt et al. 1995). Thereafter, additional structural changes occur allowing the gp41 
glycoprotein to initiate the fusion process (Trkola et al. 1996; Wu et al. 1996).         
              
1.4.1. The HIV-1 Envelope Glycoprotein 
1.4.1.1. Structure of the Envelope protein 
The Env glycoprotein is a single chain glycoprotein precursor, gp160 consisting of two 
functional subunit glycoproteins gp120 and gp41 which assemble non-covalently on the 
virion surface as trimers (Cilliers and Morris 2002; Wyatt 1998). Located within gp120 are 
five hypervariable regions interspaced between 5 constant regions (Figure 1.5). 
 
        
Figure 1.5: Schematic representation of gp160 
 The five variable regions (V1-V5) are interspaced between the conserved regions 
(C1-C3). 
 
The CD4 binding site within gp120 is located within a cavity at the interface of the outer 
domain, inner domain and bridging sheet and is fairly well conserved (Figure 1.6). For the 
formation of the gp120-CD4 structure, 22 CD4 amino acid residues and 26 gp120 amino acid 
residues are required to interact. Three CD4 molecules are required to bind to gp120 for the 
resultant conformational changes to occur, causing the virus to then bind to the chemokine 
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receptor. This leads to the formation of a ninety degree angle between the CD4-binding site 
and the chemokine receptor-binding site consisting of the bridging sheet and the base of the 
first two variable loops (V1/V2) (Rizzuto et al. 1998). Upon binding, of gp120 to CD4, a 
displacement of V1/V2 and the third variable loop (V3) occurs allowing chemokine receptor 
binding. Further conformational changes are induced that activate the fusion machinery of 
gp41. Fusion of the viral Env and cellular membrane occurs by insertion of the gp41 subunit 
into the lipid bilayer of the target cell. The ribonucleic acid (RNA) and enzymes required for 
viral replication contained within the viral core is released into the host cell cytoplasm where 
reverse transcription and incorporation into the host genome takes place. A series of events 
then occur allowing the virus to bud out of the cell enabling the infection of new cells 
(Cilliers and Morris 2002; Kwong et al. 1998; Masciotra et al. 2002; Rizzuto et al. 1998).  
 
Figure 1.6: Three dimensional structure of gp120 indicating the inner and outer 
domains, bridging sheet and variable regions (accessed 11 April 2009) 




1.4.1.2. Genetic Diversity and the Envelope Glycoprotein  
The Env is an important target of humoral immune responses and is a crucial determinant of 
overall viral fitness (Ball et al. 2003; Marozsan et al. 2005).  This protein plays an important 
role in viral transmission by determining which coreceptor the virus binds to upon entry of 
the cells. During transmission and subsequent to infection, viral fitness and target cell tropism 
properties are thought to be important determinants of infectivity and the rate of disease 
progression. The importance of the Env as a major target of humoral immunity and as a 
major contributor to overall fitness during transmission and in the rate of disease progression 
make it a particularly attractive target for vaccine and drug development, although progress 
towards these goals has been greatly hampered by the extreme genetic variability of the env 
gene. This is because viral populations within an individual are evolving continually and can 
differ by as much as 10% in sequence by the end stage of disease (Shankarappa et al. 1999). 
Genetic variation is largely due to the escape from host selective pressures such as 
neutralizing antibodies. Genetic variation is also facilitated by recombination, high viral 
replication rate and an error prone reverse transcriptase. Env changes include various 
parameters – variable loop length, the number and position of predicted N-linked 
glycosylation sites as well as amino acid substitutions causing a change in the net charge 
(Coetzer et al. 2007).    
 
1.4.1.3. The V3 Region and Coreceptor Usage 
The V3 region is critical for coreceptor binding and is a major determinant of whether 
CXCR4 or CCR5 will be the accessory protein used by the virus for membrane fusion 
(Cilliers et al. 2003; Coetzer et al. 2007; Coetzer et al. 2006; Fouchier et al. 1992; Huang et 
al. 2005; Morris et al. 2007; Ndung'u et al. 2006). The V3 region typically consists of 
approximately 35 amino acids in CCR5-tropic viruses (Coetzer et al. 2006; Mefford et al. 
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2008). Variations within this region such as length, the amino acids at positions 11 and 25, 
changes within the crown motif and the overall net charge may all contribute to coreceptor 
usage (Coetzer et al. 2007; Coetzer et al. 2006; Jensen et al. 2006; Jensen et al. 2003; Renjifo 
et al. 1999). X4 variants among different subtypes appear to select basic amino acid 
substitutions in the V3 loop as a strategy for evolving to use CXCR4 as a coreceptor. They 
are more variable than R5 viruses in this region particularly at positions 11 and 25 which 
frequently have a positively charged amino acid most often arginine (R), lysine (K) or 
histidine (H) situated here. Insertions in the V3 region particularly between positions 13 and 
14 are indicative of CXCR4-usage. This contributes to an increased length of the V3 loop in 
such viruses. X4 variants may also be distinguished from R5 viruses as they usually have an 
increased net V3 charge and a more diverse V3 loop sequence (Cilliers et al. 2003; Coetzer et 
al. 2007; Coetzer et al. 2006; Morris et al. 2007; Ndung'u et al. 2006). Additionally, changes 
in the crown motif may also determine coreceptor usage. The crown motif is a conserved 
region in the tip of the V3 loop. In subtype C R5 viruses, where a switch in coreceptor usage 
is rarely seen, the crown motif sequence reads GPGQ. In X4 viruses where a switch in 
coreceptor usage is seen, GPGQ changes to GPGX where X may be any other amino acid. 
Therefore, the crown motif in X4 viruses show variation and frequently display positively 
charged amino acids. A predicted N-linked glycosylation site is generally present at position 
6-8 of R5 viruses. A loss of this glycosylation site has been correlated with X4-usage 
(Coetzer et al. 2006; Hartley et al. 2005; Morris et al. 2007). Further mutations have been 
described. For example, a recent study by Polzer and colleagues showed that R5-tropic 
viruses exhibited higher infection rates when N-linked glycosylation site (g15) was present. 
Infection was impaired by mutations deleting this site. X4-tropic viruses lacking this site 
showed higher infection rates resulting in these viruses becoming highly sensitive to 
neutralization (Polzer et al. 2009). Another study where a single mutation at position 13 of 
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V3 was introduced resulted in the Env being selectively resistant to one group of anti-V3 
monoclonal antibodies (Patel et al. 2008).    
   
Other additional biological properties of the V3 region have been proposed. Huang et al., 
(2005) have proposed that V3 acts as a molecular hook having two uses. It may be used for 
“trapping” the coreceptor as well as for modulating subunit associations within the viral 
spike. Crystallization structures show three regions of the V3 loop. These include a conserved 
base which is closely associated with the bridging sheet on the gp120 core, a flexible stem 
extending away from the core and a conserved β-hairpin tip. The bridging sheet and the V3 
base comprise a surface that interacts with the coreceptor amino (N) terminus, while the more 
distal V3 regions engage the coreceptor extracellular loops (Dragic and Litwen 1996; Hartley 
et al. 2005; Huang et al. 2005). Another study in 2008 has shown that although Env 
interactions with both the N terminus and the extracellular loops of the coreceptor occur, the 
interaction of the bridging sheet and the base of the V3 with the coreceptor N terminus is 
critical for R5 tropism while the interaction between the more distal part of the V3 and the 
coreceptor extracellular loops is critical for X4 tropism (Nolan et al. 2008) (Figure 1.7). 
Considering these, the amino acids within the tip and the base of the V3 loop are important in 




Figure 1.7: Interaction of V3 base and bridging sheet with coreceptor N terminus 
is critical for R5 tropism and interaction with the distal regions of V3 and 
coreceptor extracellular loops is critical for X4 tropism 
 
 
1.4.1.4. Other Regions Contributing to Coreceptor Usage  
Coreceptor utilization is genetically determined by sequence characteristics within the env 
gene, primarily specific amino acid changes within three of the five hypervariable regions 
namely the V1/V2 and V3 loops, as well as the number and pattern of predicted N-linked 
glycosylation sites. The HIV Env glycoprotein gp120 is among the most heavily glycosylated 
proteins in nature containing approximately 24 N-linked glycosylation sites and alterations 
within these sites may affect protein folding and distant parts of the protein through masking 
or conformational alterations. Changes in the glycosylation pattern therefore affect and 
influence receptor binding and phenotypic properties of the virus (Fouchier et al. 1992; 
Nabatov et al. 2004; Pastore and Nedellec 2006; Pollakis et al. 2001). Pollakis et al., have 
shown that the V1/V2 region was significant in providing the virus with dual tropic 
properties. They also demonstrated that the loss of an N-linked glycosylation site within the 
14 
 
V3 loop was significant causing the virus to switch from an R5 to X4 phenotype.  Masciotra 
and colleagues (2002) have shown that an elongated V2 region is correlated with consistent 
CCR5 usage. Another study by Coetzer et al., in 2008  has shown that the V4/V5 region is 
involved in coreceptor usage. Additional sequence changes within the env gene have also 
been implicated in coreceptor determination or the coreceptor switching process (Aasa-
Chapman et al. 2006a; Coetzer et al. 2008).  
 
1.4.2. HIV-1 Coreceptors 
1.4.2.1. Major Coreceptors 
The two main coreceptors involved in HIV-1 replication in vivo are CCR5 and CXCR4 
(Alkhatib et al. 1996b; Deng and Liu 1996; Dragic and Litwen 1996; Feng et al. 1996). These 
coreceptors are seven-transmembrane molecules belonging to the G-protein-coupled receptor 
family and are activated by chemotactic cytokines (chemokines) (Platt et al. 2001). These 
receptors consist of a single polypeptide chain containing an extracellular N terminal domain 
and three extracellular loops on the cell surface. Four cysteine residues are contained within 
the extracellular domain. These form disulfide bonds between the N terminus and the third 
extracellular loop as well as between the first and second extracellular loops. Both 
coreceptors share approximately 32% amino acid identity but this is reduced to 20% when the 
amino acids located on the extracellular surface are compared. CCR5 and CXCR4 both 
consist of 352 amino acids (Cilliers and Morris 2002). CCR5 and CXCR4 are natural 
chemokine receptors. They belong to one of two major subfamilies: the CXC and CC 
subfamilies, based on the arrangement of the first two of the 4 cysteine residues. The 2 
cysteines are separated by a single amino acid in CXC chemokines while the 2 cysteines are 
adjacent in CC chemokines (Vila-Coro et al. 2000). The natural ligands for CC chemokines 
i.e. for the CCR5 receptor are RANTES (now known as CCL5), macrophage inflammatory 
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proteins, MIP-α (now known as CCL3) and MIP-β (now known as CCL4). Stromal cell-
derived factor, SDF-1α is the natural ligand for CXCR4 (Chen et al. 1997; Nabatov et al. 
2004; Pollakis et al. 2004; Shalekoff and Tiemessen 2001). The CCR5 coreceptor plays a 
vital role in the entry of the virus as it is this coreceptor that is initially used by the virus 
during transmission. Its importance in HIV-1 infection has been illustrated by the effect of a 
32-base pair (bp) deletion in the CCR5 gene. The resultant mutant gene ∆32CCR5, encodes a 
truncated CCR5 molecule which is not expressed at the cell surface. Individuals heterozygous 
for this gene progress slowly in infection and homozygotes are usually resistant to infection 
(Arien et al. 2006; Carrington et al. 1997; Ditzel et al. 1998; Lin et al. 2002; Taylor et al. 
2001).                
   
1.4.2.2. Alternate Coreceptors  
Although the two major coreceptors involved in HIV-1 infection are CCR5 and CXCR4, 
other coreceptors may also play a role. Previous studies have shown alternate coreceptor use 
on coreceptor-transfected cell lines. These included CCR1, CCR2b, CCR3, GPR1, CX3CR1 
(V28), Bob/GPR15, CXCR6 (Bonzo/STRL33/THYMSTR), APJ, Chem R23, RDC-1, US28 
and CCR8 (Chan et al. 1999; Cilliers et al. 2003; Cilliers et al. 2005; Deng et al. 1997; 
Edinger et al. 1998; McKnight et al. 1998; Ohagen et al. 2003; Pohlmann et al. 1999; Xiao et 
al. 1998; Zhang et al. 1998a; Zhang and Moore 1999). Although the use of alternate 
coreceptors in primary cells is rare (Cilliers et al. 2003), some of these receptors such as 
CXCR6 and CCR8 have been demonstrated to facilitate entry in primary cell lines (Lee et al. 
2000; Sharron et al. 2000; Zhang et al. 2000; Zhang et al. 2001). Some studies have 
suggested that CCR3 may possibly play a larger role in primary cell viral tropism (Aasa-
Chapman et al. 2006b; Zhang et al. 1998a). It has been reported that CCR3 tropism depends 
on sequences located within the V1/V2 region but does require the presence of a CCR5-tropic 
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V3 sequence in cis (Ross and Cullen 1998).  The use of alternate coreceptors has also been 
illustrated in studies where the major coreceptors were either absent or blocked and viral 
entry was still observed (Zhang et al. 2000). Agents that target CCR5 preventing entry and 
infection in vitro include the natural ligand, RANTES; PRO 140, a mouse monoclonal 
antibody; TAK-779, a small molecule that binds to the pocket within transmembrane helices 
1, 2, 3 and 7; and SCH-C, a small molecule which acts as a CCR5 antagonist (Baba et al. 
1999; Dragic et al. 2000; Olson et al. 1999; Strizki et al. 2001; Zhang et al. 1998b). CXCR4 
antagonist AMD3100 is a small molecule binding to CXCR4 coreceptors (Donzella et al. 
1998).  Further, these studies also made use of peripheral blood mononuclear cells (PBMCs) 
containing the mutant gene ∆32CCR5 in the presence of a CXCR4 inhibitor. No viral entry 
was observed (Zhang et al. 2000). However, their significance for HIV-1 replication in vivo 
and disease progression is unclear (Aasa-Chapman et al. 2006b; Cilliers et al. 2005; Dash et 
al. 2008).     
  
1.4.3. Phenotype and Tropism 
HIV-1 isolates are differentiated based on the coreceptors they use. Viruses that use CCR5 
are termed R5 viruses and viruses that make use of CXCR4 are termed X4 viruses. Dual 
tropic viruses use both coreceptors and are termed R5X4 viruses (Ohagen et al. 2003; Pontow 
and Ratner 2001; Verhofstede et al. 2009). It has been argued that these isolates replicate in 
cells containing CCR5 and CXCR4 but probably do so because they contain a mixture of 
CCR5 and CXCR4-tropic viruses (Moore et al. 2004). There have been studies however, that 
have characterized viruses proving them to be truly dual tropic (Coetzer et al. 2006). Those 
viruses that primarily use CCR5 are macrophage-tropic (M-tropic) viruses and grow in 
primary macrophages and primary lymphocytes. Those that use CXCR4 are T cell line-tropic 
(T-tropic) viruses and grow in T cell lines and primary lymphocytes. T-tropic viruses are able 
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to cause syncytia in cell lines and were formerly referred to as syncytium-inducing (SI) 
viruses. M-tropic viruses do not induce syncytia and were referred to as non syncytium-
inducing (NSI). SI viruses are called rapid/high viruses as they cause rapid progression and 
occur late in infection. NSI viruses are slow/low viruses and occur early in infection and 
during the acute and asymptomatic phase (Figure 1.8) (Baribaud et al. 2001; Cilliers and 
Morris 2002; Ohagen et al. 2003; Ping et al. 1999; Platt et al. 2001; Zhang and Moore 1999). 
It has been documented that it is the CCR5 tropic (R5) viruses that play a critical role in viral 
entry as these viruses are associated with viral transmission. CXCR4 tropic (X4) viruses are 
found later in infection and are associated with a decline in CD4 cells and disease 
progression. There have been a number of studies in subtype B-infected individuals as well as 
other major non-B subtypes that have shown that in 50% of infected individuals a switch in 
coreceptor usage was seen where the viruses initially used CCR5 and as the disease 
progressed, the more pathogenic X4 variant became dominant (Aasa-Chapman et al. 2006a; 
Arien et al. 2006; Ping et al. 1999; Pollakis et al. 2001). However, HIV-1 subtype C-based 
studies have not reported similar observations. HIV-1C is associated with an epidemic that is 
rapidly expanding. There have been numerous studies showing that the use of CXCR4 by 
isolates of this subtype is rare and that R5 variants dominate (Bjorndal and Sonnerborg 1999; 
Cilliers and Morris 2002; Coetzer et al. 2006; Johnston et al. 2003; Ndung'u et al. 2001; 
Ndung'u et al. 2006; Ping et al. 1999). This suggests that there may be some constraining 
factors that are limiting the development of X4 viruses in this subtype and it is not clear 










1.4.3.1. V3 Region and Phenotype Prediction 
Since the V3 is a major determinant of coreceptor usage and viral tropism this region has 
been used to predict viral phenotype (Jensen and van't Wout 2003). Phenotype prediction is 
important in studies requiring coreceptor usage information for a patient who for example is 
receiving antiretroviral (ARV) therapy. Phenotypic assays are expensive and laborious and a 
prediction method based on sequence information would provide rapid results and would be a 
less expensive process (Garrido et al. 2008). There are a number of factors used to examine 
the V3 region that provide an indicator of phenotype prediction.  
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The “11/25 charge rule” assists in determining viral phenotype. This method is based on the 
presence of basic amino acids at positions 11 and/or 25. If basic (positively charged) amino 
acids are present, this is indicative of virus with the X4 phenotype. If there are neutral or 
acidic (negatively charged) amino acids present this indicates R5 viruses (Fouchier et al. 
1992; Low et al. 2007). This method has shown >90% sensitivity and specificity for 
predicting the SI phenotype in clonal sequences but the sensitivity is reduced to <60% for 
R5X4 clonal sequences. This percentage is reduced further in bulk (population-based) 
sequences from clinical sequences (Jensen and van't Wout 2003).  The overall net charge is 
also an indicator of biological phenotype. A V3 region having an overall net charge of >+4.5 
is indicative of X4 usage. Charges lower than this indicates R5 usage (Coetzer et al. 2006).  
In addition, the crown motif, a conserved region at the tip of the V3 region provides an 
indicator of coreceptor usage. In subtype C R5 viruses, the crown motif sequence reads 
GPGQ. X4 viruses usually display a crown motif with the sequence GPGX where X 
represents a basic amino acid (Coetzer et al. 2006).   
Insertions and deletions are also indicators of coreceptor usage in the V3 region. Previous 
studies have shown that insertions particularly at positions 13-14 occur in X4 viruses and a 
deletion such as a deletion of an N-linked glycosylation site at position 15 will drive the virus 
to use CXCR4. The presence of this site will restore R5 usage. A loss of predicted N-linked 
glycosylation site at positions 6-8 also indicates X4 usage (Coetzer et al. 2006; Polzer et al. 
2009).     
 
A web- based programme, Position-Specific Scoring Matrix (PSSM) 
(http://indra.mullins.microbiol.washington.edu/pssm/) also assists in determining viral 
phenotype. PSSM is a bioinformatic tool used for predicting HIV-1 coreceptor usage from 
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the amino acid sequence of the V3 loop. This programme detects a non-random distribution 
of sequences at a specific site within an alignment. It then compares the target sequence to a 
group of sequences with known phenotypes (Jensen et al. 2003). Higher PSSM scores 
indicate X4 usage.   
 
1.5. Antiretroviral Therapy 
Antiretroviral therapy (ART) has substantially decreased the rates of morbidity and mortality 
(Palella et al. 1998). There are six classes of HIV-1 drugs. To date, there are approximately 
25 ARV drugs that have been licensed for HIV-1 treatment. These consist of nine nucleoside 
reverse transcriptase inhibitors (NRTI), four non-nucleoside reverse transcriptase inhibitors 
(NNRTI), nine protease inhibitors (PI), one fusion inhibitor, one CCR5 inhibitor and one 












Table 1.1: Classes of Antiretroviral Drugs 






















   




   




   
TDF (tenofovir)  LPV/r 
(lopinavir/r) 
   
d4T (stavudine)  FPV/r 
(fosamprenavir/r) 





   
ddC (zalcitabine)  NFV   
(nelfinavir) 




 RTV (ritonavir)    
/r indicates boosting with ritonavir (Division of Clinical Pharmacology 2006; 
http://hivdb.stanford.edu ; Shafer and Schapiro 2008). 
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ARV drugs function at various stages of the HIV life cycle. These drugs target the virus and 
interfere with the virus’ replication process by attaching to one of the enzymes or proteins 
required for replication of the virus and effectively stop viral replication. NRTI and NNRTI 
target the reverse transcriptase enzyme required for the transcription of single stranded RNA 
into double stranded DNA. Integrase inhibitors bind to the integrase enzyme and prevent the 
integration of viral DNA into the host cell DNA which enables the virus to make use of the 
host cell machinery to produce more viral particles. PI bind and inhibit HIV protease 
resulting in deformed viral particles reducing infectious capacity. Currently, entry inhibitors 
are used by those individuals who have had previous treatment experience, developed multi-
drug resistance and are intolerant to other ARV drugs. This class of drugs functions by 
preventing the attachment of gp120 to CD4, preventing the interaction of this complex with a 
coreceptor and by preventing the gp41 mediated membrane fusion process. Fusion inhibitors 
target gp41 and prevent the fusion of the viral envelope with the target cell membrane 
(Morris et al. 2007; Weston et al. 2006; Yeni 2006). As these drugs do not completely 
eradicate HIV infection their goal is to decrease the viral load to undetectable levels and to 
maintain this reduction (Yeni et al. 2004). It has been shown that undetectable viral loads 
coupled with an increase in CD4+ T cell count toward the normal range has been the most 
effective in controlling viral replication and hence the duration of antiretroviral therapy is 
lifelong and may change according to the drugs currently available (Yeni 2006).       
  
1.6. Drug Resistance  
According to surveillance data obtained from antenatal clinics in South Africa, there is some 
hope that HIV infection levels might be reaching a plateau. There was a 1% reduction in 
infection from 2005 to 2006. A decrease in HIV prevalence has been observed among young 
pregnant women between the ages of 15 to 24 years suggesting a decline in new infections 
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(UNAIDS 2007). One factor contributing to this decline may be the widespread 
implementation of antiretroviral (ARV) therapy (Yeni 2006). However, although ARV 
therapy has been extremely effective and greatly valuable in assisting in the control of 
HIV/AIDS, the emergence of drug resistance has posed a major problem. There are several 
factors contributing to drug resistance. These include intolerance to certain drug regimens, 
treatment adherence and interruptions in the supply of drugs (Marconi et al. 2008). 
Resistance to ARV therapy is divided into two categories. These include primary resistance, 
which is the acquisition of a drug resistant strain of HIV by a newly infected individual and 
secondary resistance. Secondary resistance is acquired resistance and only develops after a 
period of HIV treatment (Taylor et al. 2008).  
 
As it is the pol gene which is responsible for the mechanism by which the virus reproduces 
and because it encodes for viral enzymes integrase, reverse transcriptase, HIV protease and 
RNAse H, this is a region of interest for drug resistance mutations. Resistance mutations may 
vary between populations (Brenner et al. 2003; Morris et al. 2003) but some important 
resistance mutations within the reverse transcriptase regions include M184V, thymidine 
analog mutations (TAMs), L74V, K65R, Q151M, T69ins, K103N, Y181C, Y188C and 
others. ZDV and d4T select for TAMs which decrease susceptibility to these NRTIs and to 
ABC, ddI and TDF to a lesser extent (Whitcomb et al. 2003). These mutations are common in 
economically disadvantaged countries where thymidine analogs are frequently used, as well 
as in viruses from individuals who began treatment with incompletely suppressive thymidine 
analog-containing regimens prior to the introduction of HAART. There are 2 distinct 
pathways for the accumulation of TAMs. The TAM1 pathway includes the mutations M41L, 
L210W, and T215 and the TAM2 pathway includes D67N, K70R, T215F, and K219Q/E 
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(Shafer and Schapiro 2008). There are also a number of protease inhibitor mutations in the 
protease region (Meintjies 2005).  
 
Currently, the patterns of drug resistance are only partially understood largely due to the fact 
that most of the drug resistance data that has been generated is based on subtype B infections 
whereas the circulating subtypes in developing countries are in most part subtypes other than 
subtype B (Wallis et al. 2009). Contradictory data suggests that drug resistance patterns may 
differ among various subtypes after failure of first-line treatment. An early study by in 
Zimbabwe showed that drug resistance mutations in subtype C were similar to those in 
subtype B (Kantor et al. 2002) whereas other studies identified subtype C-specific mutations 
(Brenner et al. 2003; Morris et al. 2003).  
 
1.7. Drug Resistance and Coreceptor Usage 
During the early stages of infection, R5 viruses are usually seen to predominate whereas X4 
and dual tropic variants, which are associated with rapid disease progression, emerge in the 
late chronic phase of disease in a significant proportion of patients (Connor et al. 1997; 
Scarlatti et al. 1997). Several studies have shown that all subtypes can undergo the switch 
from the utilization of CCR5 to CXCR4 but this is less frequently observed in HIV-1 C 
infections even in late stages of disease (Bjorndal and Sonnerborg 1999; Cecilia et al. 2000; 
Cilliers et al. 2003; Ndung'u et al. 2006; Tscherning et al. 1998). This switch in coreceptor 
usage was initially identified in untreated patients but X4 viral variants have also been 
identified in a significant number of patients receiving highly active antiretroviral therapy 
(HAART). A study in Zimbabwe found that a high frequency (50%) of X4-tropic viruses 
were observed in patients failing ARV therapy while no such viruses were found in ARV-
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naïve patients although their CD4 cell counts were comparable suggesting that ARV therapy 
may be selecting for the more virulent CXCR4-tropic strains in subtype C infection (Johnston 
et al. 2003). According to a study in 2006, a higher proportion (41%) of dual/mixed or X4-
tropic viruses was also encountered in treated individuals as compared to 18% of treatment-
naïve individuals (Hunt et al. 2006). Several reasons have suggested that ARVs may alter the 
prevalence of X4 viruses. An increase in HIV-specific T cell responses may be a result of 
partially suppressive therapy and because X4-virus variants are more susceptible to cytotoxic 
T cell responses, an increase in these HIV-specific T cell responses during viral suppression 
may select against X4 viruses (Deeks et al. 2004). Antiretroviral therapy also decreases the 
expression of CCR5 on T cells thereby selecting for CXCR4-using viruses (Andersson et al. 
1998; Giovannetti et al. 1999). In addition, certain drugs such as enfurvirtide may select for 
one virus population because of enhanced activity against X4 viruses (Yuan et al. 2004). 
Other drugs such as zidovudine may select for one virus population due to poor drug 
metabolism in the cellular reservoirs for X4 viruses (Boucher et al. 1992). Therefore, 
coreceptor tropism among individuals initiating or failing ARV therapy particularly in HIV-1 
subtype C infections needs to be understood as this may impact on the use of CCR5 
antagonists as first line or salvage therapy.  
 
1.8. Coreceptor Usage and Primary Cells       
Macrophage-tropic, NSI, R5 HIV-1 virus variants replicate in primary lymphocytes and 
macrophages but not in transformed cell lines. They are poorly cytopathic in vitro and use 
CCR5 as their major coreceptor of entry. T cell line-tropic, SI, X4 virus variants replicate in 
lymphocytes and CD4+ transformed cell lines but not in macrophages. These viruses are 
highly cytopathic in vitro and use CXCR4 as their principle coreceptor of entry. Dual tropic 
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viruses, which may be intermediate viruses in the evolution from R5 to X4 variants infect 
both macrophages and CD4+ T-cell lines as well as primary lymphocytes (Carrington et al. 
1997; Follis et al. 1998; Li et al. 1999; Naif et al. 2002; Simmons et al. 1998; Yi et al. 1999; 
Zerhouni et al. 2004). Alternatively, there have been reports that late-stage X4 variants were 
able to retain their capacity to infect macrophages suggesting that these variants are more 
similar to dual tropic isolates than to T-tropic isolates (Connor et al. 1997).   Other reports 
have shown that minor coreceptors may also be used by some viruses in transfected cell lines 
(Chan et al. 1999; Cilliers 2005; Cilliers et al. 2003; Deng et al. 1997; Edinger et al. 1998; 
McKnight et al. 1998; Ohagen et al. 2003; Pohlmann et al. 1999; Xiao et al. 1998; Yi et al. 
1999; Zhang et al. 1998a; Zhang and Moore 1999), but are rarely used by primary cells 
(Cilliers et al. 2003). Some of these receptors however, have exhibited entry in primary cell 
lines (Lee et al. 2000; Sharron et al. 2000; Zhang et al. 2000; Zhang et al. 2001). It is 
therefore uncertain if coreceptor usage in transformed cell lines is indicative of coreceptor 
usage in vivo i.e. in the infection of primary cells. There have been a number of interesting 
studies in primary cells. Contrary to earlier beliefs, CXCR4 is also present on macrophages 
and studies have shown that some viral isolates use this coreceptor for entry even though 
macrophages do not permit the entry of prototype T-tropic X4 strains (Yi et al. 1999). Other 
studies have used dual tropic strains to investigate coreceptor usage in primary lymphocytes. 
CCR5 usage in transformed cell lines was correlated with coreceptor usage in primary 
lymphocytes and the entry pathways for infection of primary lymphocytes by dual tropic 
strains were investigated. Results showed that several dual tropic primary and prototype 
strains used CXCR4 for entry and infection in primary lymphocytes even though CCR5 was 
present. In macrophages however, these strains used both CCR5 and CXCR4. From these 
observations, it was concluded that although HIV-1 strains were phenotypically characterized 
as dual tropic viruses in transformed cell lines this does not necessarily mean that they will 
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have dual coreceptor use in primary cells (Yi et al. 2005). These findings that coreceptor 
usage differs between transformed cell lines and primary cells were observed in subtype B 
infections and there is a need to determine if these findings are reproducible in subtype C 
infections.       
 
1.9. Coreceptor Usage in South Africa 
Significant differences between HIV-1 subtype C and other HIV-1 subtypes exist. A cross-
sectional study in Kenya showed that women infected with subtype C had significantly lower 
CD4 cell counts and higher plasma RNA levels than those infected with subtypes A or D 
(Neilson et al. 1999). Another study reported that subtype C appears to have been introduced 
after subtypes A and D were already established in Tanzania. HIV-1 C quickly became one of 
the major subtypes while subtype D appears to have declined (Renjifo et al. 1998). A further 
study in a mother-to-child transmission cohort, observed that mothers infected with subtype 
C and intersubtype recombinants were more likely to transmit the virus to their children 
compared to those infected with subtype D viruses (Blackard et al. 2001). These studies 
indicate that subtype-specific differences exist, and suggest that HIV-1 C in particular may be 
epidemiologically unique. The utilization of coreceptors other than CCR5 is rare for HIV-1 
C, even in isolates obtained from late-stage AIDS patients (Bjorndal and Sonnerborg 1999; 
Cecilia et al. 2000; Tscherning et al. 1998). The observation that HIV-1 C viruses 
predominantly use CCR5 as the principle coreceptor for entry into cells even in late stages of 
disease is intriguing, because in approximately 50% of HIV-1 subtype B infections, 
progression to AIDS is associated with development of viral variants that utilize CXCR4 as 
coreceptor (Aasa-Chapman et al. 2006a; Arien et al. 2006; Ping et al. 1999; Pollakis et al. 
2004).  This suggests that HIV-1 C is unique in maintaining its predominant CCR5 tropism 
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throughout infection and these observations may indicate that infection with subtype C may 
have a different outcome from other subtypes. 
 
1.10. Outline of Thesis 
This study examines the coreceptor usage in HIV-1C strains in South Africa. Firstly, we 
investigated whether dual tropic HIV-1C strains represented truly dual tropic viruses at the 
clonal level, or mixed R5 and X4 clones. In view of the fact that variation within the env 
gene, particularly the V3 region is associated with cellular tropism and coreceptor affinity, 
we analyzed the env sequences of 5 clones each from 7 dual tropic HIV-1C primary viral 
isolates and correlated the genotype of each clone to its respective phenotype in transformed 
cell lines that express either CCR5 or CXCR4. Secondly, since there have been studies in 
subtype B infections showing that coreceptor usage in transformed cell lines does not 
necessarily predict coreceptor usage in primary cells, we investigated coreceptor utilization in 
primary cells for the HIV-1 subtype C clones. Thirdly, we investigated the emerging patterns 
of drug resistance mutations among persons failing highly active antiretroviral therapy in 
Durban, KwaZulu-Natal, South Africa.  Furthermore, since some studies in both HIV-1 
subtypes B and C infections have suggested that ARV therapy (especially partially 
suppressive therapy) may be selecting for the more virulent X4 stains, we investigated and 
coreceptor usage in our cohort of ARV treated patients failing therapy and ARV-naïve 
patients. The aims of this thesis were to answer the following questions:  
• Are dual tropic viruses truly dual tropic at the clonal level or are they a mixture of 
dual tropic, X4 and R5 viruses?  
• What pathways do dual tropic and CXCR4-tropic subtype C viruses use to enter 
primary cells?  
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• Are there differences in chemokine receptor utilization between transformed cell lines 
and primary cells?  
• What drug resistance mutations and patterns of resistance are emerging as HAART is 
rolled out widely in South Africa? 
• What is the prevalence of X4 variants in HIV-1 infected individuals requiring or 
receiving ARV therapy?  
• Is Virologyogical failure among HIV-1 subtype C infected persons receiving ARV 
therapy associated with higher proportion of the more virulent X4 tropic strains in 
HIV-1C infection?  
The results of this thesis study have important implications both for HIV pathogenesis in 
HIV-1 subtype C infected individuals, for monitoring of persons on therapy and for future 













CHAPTER 2  




HIV/AIDS remains the leading cause of death in the Sub-Saharan region and in 2007 alone, 
76% of deaths were as a result of HIV/AIDS, with 68% of all new HIV infections occurring 
in this region. Southern Africa is the most seriously affected sub-region and in 2007 
accounted for 32% of all new infections and AIDS-related deaths world-wide. South Africa 
constitutes the highest number of HIV infections globally (UNAIDS 2007). The main 
circulating HIV-1 subtype in South Africa is HIV-1 subtype C (HIV-1C), which accounts for 
approximately 56% of infections worldwide (Esparza 2005; Hemelaar et al. 2006; 
Visawapoka et al. 2006).  
 
Subtype groupings are based on sequence variations that occur within all gene and non-
protein coding regulatory regions, but the most dramatic differences are found in the 
envelope (env) gene (Gao et al. 1998).  The envelope is an important target of humoral 
immune responses and is a crucial determinant of overall viral fitness (Ball et al. 2003; 
Marozsan et al. 2005). The env gene plays an important role in viral transmission by 
determining which coreceptor the virus uses to mediate entry. During transmission and 
subsequent to infection, viral fitness and target cell tropism properties are thought to be 
important determinants of infectivity and the rate of disease progression (Troyer et al. 2005). 
The importance of the envelope as a major target of humoral immunity, its contribution to 
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overall fitness during transmission, and its role in the rate of disease progression make it a 
particularly attractive target for vaccine and drug development. However, progress towards 
these goals has been greatly hindered by the extreme genetic variability of the env gene. 
 
HIV-1 utilize members of the seven transmembrane chemokine receptor family as 
coreceptors for entry into target cells (de Roda Husman et al. 1999; Oppermann 2004; Ross 
and Cullen 1998; Vila-Coro et al. 2000; Xiao et al. 1999). The virus gp120 envelope 
glycoprotein first binds to the primary CD4 receptor on target cells, which induces 
conformational changes on the envelope exposing the coreceptor binding site (Rizzuto et al. 
1998; Wyatt et al. 1995). The two main coreceptors that the HIV-1 envelope binds to 
subsequent to the conformational change are CCR5 or CXCR4 (Alkhatib et al. 1996a; Choe 
et al. 1996; Deng and Liu 1996; Doranz et al. 1996; Dragic and Litwen 1996; Feng et al. 
1996). HIV-1 strains can be classified based on their coreceptor utilization, with CCR5 tropic 
viruses termed R5, CXCR4 tropic viruses termed X4 and viruses that use both coreceptors 
(dual tropic viruses) termed R5X4 (Berger 1998; Berger et al. 1999). R5 viruses predominate 
in the early stages of HIV-1 infection, whereas dual tropic and X4 variants, which are 
associated with rapid disease progression, emerge in the late chronic phase of disease in a 
significant proportion of patients (Connor et al. 1997; Scarlatti et al. 1997). It is well 
established that while all subtypes are capable of undergoing coreceptor utilization switch 
from CCR5 to CXCR4, this is less frequently encountered in HIV-1 subtype C infections, 
even in late stages of disease (Bjorndal and Sonnerborg 1999; Cecilia et al. 2000; Cilliers et 
al. 2003; Ndung'u et al. 2006; Tscherning et al. 1998). Furthermore, expanded coreceptor 
usage beyond CCR5 and CXCR4 has also been occasionally reported but its significance for 
HIV-1 replication in vivo and disease progression is unclear (Aasa-Chapman et al. 2006b; 
Cilliers et al. 2005; Dash et al. 2008). 
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Coreceptor utilization is genetically determined by sequence characteristics within the env 
gene, primarily specific amino acid changes within three of the five hypervariable regions 
namely the V1/V2 and V3 loops, as well as the number and pattern of predicted N-linked 
glycosylation sites (Fouchier et al. 1992; Pastore and Nedellec 2006; Pollakis et al. 2001). 
Additional sequence changes within the env gene have also been implicated in coreceptor 
determination or the coreceptor switching process (Aasa-Chapman et al. 2006b; Coetzer et al. 
2008).  
 
In several instances where HIV-1 subtype C isolates able to mediate cell entry via CXCR4 
have been described, dual tropic (R5X4) strains that utilize both CCR5 and CXCR4 have 
been more frequently encountered compared to X4 monotropic viruses (Cilliers et al. 2003; 
Coetzer et al. 2006; Dash et al. 2008; Johnston et al. 2003; Ndung'u et al. 2006; van Rensburg 
et al. 2002). However, despite the occasional isolation of dual tropic HIV-1C viruses, such 
viruses have rarely been extensively characterized at both the functional and genetic clonal 
level. It is therefore largely unknown whether dual tropic HIV-1C strains represent a mixture 
of R5 and X4 viruses or truly dual tropic strains (or both) at the clonal level. Furthermore, 
genetic determinants associated with change in coreceptor usage have rarely been described 
for HIV-1 subtype C, particularly those that may reside outside of the V3 loop region. This 
study investigated whether dual tropic HIV-1C primary isolates represented truly dual tropic 
viruses at the clonal level, or mixed R5 and X4 clones. The generation of functional envelope 
clones from dual tropic HIV-1C isolates and the sequence characteristics in the HIV-1C env 
gene, both within and outside of the V3 region that are associated with coreceptor utilization 




2.2. Materials and methods 
       2.2.1. Viral isolates  
Seven primary viral isolates were analyzed in this study. 96BW17 is a dual tropic HIV-
1C virus isolated in 1996 from an infected person with acquired immunodeficiency 
syndrome (AIDS) in Botswana (Ndung'u et al. 2006). 99ZATM1B; RP1; 99ZASW20; 
99ZASW30; 99ZACM9 and 01ZADu36_5 were obtained from the AIDS Virus Research 
Unit, National Institute for Communicable Diseases, Johannesburg, South Africa and 
were from patients at various disease stages: acute infection (01ZADU36_5), slow 
progressor (99ZATM1B), rapid progressor (RP1) and AIDS (99ZASW20; 99ZASW30; 
99ZACM9)  (Choge et al. 2006; Cilliers et al. 2003; Coetzer et al. 2006). Previously 
well-characterized dual tropic (Du179) and CCR5-tropic (96BWM01_5) primary isolates 
were used as positive controls. CXCR4-tropic 96BW17#10 was also used as a positive 
control. 
 
2.2.2. Cells and Cell lines 
U87.CD4 cells with or without the expression of the chemokine receptors CCR5 or 
CXCR4 were obtained from the NIH AIDS Research and Reference Reagent Program 
(Rockville, MD). U87.CD4 cells without chemokine receptors were cultured in 
Dulbecco’s modified eagles medium (DMEM) containing L-glutamine (Gibco, NY, 
USA) supplemented with 15% heat inactivated fetal bovine serum (FBS) (Gibco, NY, 
USA), 300 µg/ml G418 (Sigma, Germany) and 50 µg/ml  penicillin-streptomycin 
(Gibco, NY, USA). U87.CD4 cells expressing CCR5 or CXCR4 were propagated in the 
same medium but additionally supplemented with 1 µg/ml puromycin (Sigma, 
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Germany). 0.5 x 10
6 
cells were cultured in 6-well flat-bottomed plates in a total of 2 ml 
culture medium at 37 
ο
C and 5% CO2. 
293T cells were obtained from the American Type Culture Collection (ATCC) and were 
cultured in DMEM containing L-glutamine supplemented with 10% heat inactivated FBS 
and 50 µg/ml gentamicin (Sigma, Germany). 50,000 293T cells per well were seeded in a 
total volume of 0.3 ml per well of a 48-well flat-bottomed plate. These cells were 
incubated at 37 °C in 5% CO2 overnight before transfection. 
 
2.2.3. Viral isolate Propagation and DNA extraction 
PBMCs from anonymous low risk HIV negative volunteers were separated by density-
gradient centrifugation on Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden). The 
vacutainer tubes containing approximately 24 ml blood were gently inverted to ensure 
that the blood was properly mixed. The blood was then pipetted into a 50 ml tube 
containing Ficoll-Paque and centrifuged for 15 minutes at 2200 rpm at room 
temperature. The plasma was removed. The PBMC layer was then carefully transferred 
to a 50 ml tube and was diluted to 50 ml by adding 1% PBS and mixed by inverting the 
tube several tubes. The cells were then pelleted by centrifugation at 1200 rpm for 10 
minutes and the supernatant decanted. Cells were resuspended in 10 ml 1% PBS and 
mixed well. Cell counts were performed using  Guava technology (as per manufacturer’s 
instructions) and approximately 15 million cells were stored in the required volume of 
freezing solution which consisted of 10% Dimethylsulfoxide (DMSO) in FBS.  
Samples were confirmed to be HIV-negative by performing HIV RNA testing on the 





from 2 donors were combined and stimulated by culturing in RPMI 1640 with 
penicillin/streptomycin (50 µg/ml and 50 U/ml), 10% heat inactivated FBS, 5 µg/ml 
phytohaemagglutinin (PHA) (Sigma, Germany) and 20 U/ml interleukin-2 (IL-2) (Roche 
Applied Science, Germany) at 37 
ο
C and 5% CO2 for 72 hours in a T-25 flask. For 
infection of the stimulated PBMCs, 5 ng p24 antigen equivalent of virus was used. On 
days 1, 4, 7, and 10, 50% of the media was removed and replaced with fresh medium. 
Aliquotted supernatant was retained for quantification of p24 antigen using the 
Vironostika HIV-1 Antigen Microelisa System (Biomerieux, Boxtel, Netherlands) as per 
manufacturers instructions. On day 14, supernatant was removed and preserved for p24 
antigen quantification. Cells were harvested and resuspended in 200 µl PBS. DNA was 
then extracted using the QiaAmp DNA Blood Mini kit (Qiagen, Germany) as per 
manufacturers instructions. 
 
2.2.4. Confirmation of dualtropism of primary viral isolates 
PBMC-grown virus corresponding to 2 ng of p24 HIV-1 antigen was used for infection 
of U87.CD4 cells expressing either CCR5 or CXCR4. On days 0, 4, 7 and 10 half of the 
media was removed and replaced with fresh medium. The removed supernatant was 








2.2.5. Amplification of envelope (env) gene 
The 3 kb env gene was amplified by polymerase chain reaction (PCR) using Phusion Hot 
Start High-Fidelity DNA Polymerase (Finnzymes, Finland) with the following primers: 
Env1A 5’-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3’ and EnvM 5’-
TAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3’. The forward primer Env1A was 
designed to include the 4 base pair sequence (CACC) necessary for directional cloning 
on the 5’ end. 1 µl of template was used in the reaction. Cycling conditions were as 
follows: a 5 minute denaturation at 94 °C, followed by 35 cycles of 30 seconds at 94 °C, 
30 seconds at 55 °C, and 4 minutes at 72 °C. The final extension was at 72 °C for 10 
minutes. The amplified product was then run on a 1% agarose gel in 1 x Tris-Borate-
EDTA (TBE) buffer and visualised using the Syngene gel documentation system. The 
amplified product was then gel purified using the Qiaquick gel extraction kit (Qiagen, 
Germany). 
 
2.2.6. Cloning  
Once the DNA was purified, the env of each primary viral isolate was cloned into the 
pcDNA3.1D/V5-His-TOPO vector (Invitrogen, Carlsbad, CA). The reaction mixture 
consisted of the following – 10 ng fresh PCR product, 1 µl salt solution, 1 µl TOPO 
vector and distilled water adjusted to a total volume of 6 µl.  For the transformation 
procedure, Stratagene XL-10 Gold Ultracompetent cells (Stratagene, USA) were used. 
Molecular clones were screened as follows. A colony PCR was performed after the 
colony was incubated for 1.5 hours at 37 °C with continuous shaking (225 rpm) in a 96-
well plate containing 100 µl Luria Bertani (LB) media (Sigma, Germany) and ampicillin 
(100 µg/ml) (Calibiochem, Darmstadt, Germany) to determine positivity of the cloned 
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insert. This is a directional env insert-specific PCR as it uses the forward primer T7 (5’ 
TAATACGACTCACTATAGGG 3’) found on the vector and reverse primer Env M 
which is env specific. SuperTherm Taq Polymerase (Southern Cross Biotechnology, 
Cape Town, South Africa) was used and cycling conditions were as follows: 
denaturation for 5 minutes at 94 °C, followed by 35 cycles of 30 seconds at 94 °C, 30 
seconds at 55 °C, and 4 minutes at 68 °C. The final extension was for 10 minutes at 68 
°C. The amplified products were then run on a 1% agarose gel. Clones were considered 
positive if they yielded a 3 kb band on an agarose gel. These clones were then grown up 
at 37 °C overnight with shaking in 3 ml LB broth containing 100 µg/ml ampicillin. 
Plasmid DNA was then isolated using Qiaprep Spin Miniprep kit by following the 
manufacturer’s instructions (Qiagen, Germany). The first five functional env clones 
identified from each isolate were selected for further analysis.          
 
2.2.7. Limiting endpoint dilution PCR 
A limiting endpoint dilution PCR from DNA was performed on one primary viral isolate, 
01ZADU36_5 in order to determine whether the bulk PCR resampling bias resulted in 
clones biased towards either CCR5 or CXCR4 coreceptor usage. Single genome 
amplification was undertaken as previously described (Salazar-Gonzalez et al. 2008). 
Primers and cycle conditions were the same as used in the bulk PCR reactions. Once 
confirmed by agarose gel electrophoresis, 30 PCR products were purified and cloned and 





2.2.8. Coreceptor usage assays 
Cotransfection was carried out by first combining 50 µl serum free DMEM and 2.5 µl 
Fugene reagent (Roche Applied Science, Germany) and incubating for 5 minutes at room 
temperature. This was then incubated at room temperature together with 0.6 µg gp160 
env DNA (i.e. cloned product) and 0.3 µg pNL4-3.Luc.R-E- (Connor et al. 1995; He et 
al. 1995). pNL4-3.Luc.R-E- is a full-length HIV plasmid with two frameshifts that render 
the clone env and vpr deleted. The reporter firefly luciferase gene has been inserted into 
the nef gene. The transfection mixture was incubated for 30 minutes, and then added to 
assigned wells of the plate seeded with 293T and incubated at 37 °C and 5% CO2 for 48 
hours. The supernatant together with 7.5 µg/ml DEAE-Dextran (Sigma, Germany) was 
added to U87.CD4 cells as well as U87.CD4 cells expressing the coreceptors CXCR4 or 
CCR5. This was incubated at 37 °C and 5% CO2 for 48 hours. The cells were lysed using 
Glo Lysis buffer (Promega, Madison, WI, USA) and incubated with Bright-Glo Assay 
reagent (Promega, Madison, WI, USA). The luciferase activity was then determined 
using the Turner-Biosystems Modulus Microplate instrument (Promega, Madison, WI, 
USA) (Figure 2.1). A negative control consisting of the plasmid pNL4-3.Luc.R-E- and 
various positive controls were used in each coreceptor expressing cell line. The positive 
controls were previously characterized env clones Du179 (dual tropic), 96BWM01_5 
(R5), and 96BW17#10 (X4).  In addition, for each assay plate, 100 nM of CCR5 
inhibitor RANTES and 500 nM of CXCR4 inhibitor AMD3100 were used with the 
respective controls to confirm specificity of entry into target cells. Experiments were 
done in duplicate and the average relative luminescence units (RLUs) for each clone was 
calculated. A positive result was considered to be twice the average of the negative 




Figure 2.1: Coreceptor usage using the DEAE-dextran method of infection 
 48 hours post transfection, infection of U87.CD4 cells with/without coreceptors is performed 
using DEAE-Dextran. 
 
2.2.9. Sequencing and sequence analysis 
The env gene was sequenced after cloning using the ABI PRISM Big Dye Terminator 
Cycle Sequencing Ready Reaction kit version 3.1 (Applied Biosystems, CA, USA). The 
primers used for sequencing are listed below:  
 envM 5’-TAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3’ 
 ES7 5’-CTGTTAAATGGCAGTCTAGC-3’ 
 ES8 5’-CACTTCTCCAATTGTCCCTCA-3’ 





 SQ14FC 5’-ACTCACGGTCTGGGGCATTA-3’ 
 SQ3R(2)C 5’-GCTATGGTATCAAGCAGACTAATAGCACTC-3’  
 EF00 5’-AAAGAGCAGAAGACAGTGGCAATGA-3’ 
The sequence reaction consisted of 0.4 µl terminator ready reaction mix, 2 µl 5 x 
sequencing buffer, 3.2 pmol primer, 100 ng DNA template and distilled water adjusted to 
a total volume of 10 µl. Cycle conditions were as follows: the initial denaturation at 96
o
C 
for 1 minute followed by 35 cycles of 96
o
C, 10 seconds; 50
o
C, 5 seconds and a final 
extension of 60
o
C for 4 minutes. Sequences were assembled and edited using Sequencher 
4.8. They were then aligned with Mega 4. Phylogenetic trees were constructed in Paup 
4.0 to evaluate the clustering of these sequences with each other and with subtype 
references. Phylogenetic trees were then visualized using Treeview 1.6.6. The consensus 
sequence for clones from each isolate was generated using BioEdit Sequence Alignment 
Editor Software (Tom Hall, North Carolina State University). Coreceptor utilization was 
predicted using the web-based subtype C-specific position specific scoring matrix (C-
PSSM) programme (http://indra.mullins.microbiol.washington.edu/pssm/), a 
bioinformatics tool that reliably predicts coreceptor phenotype using V3 loop sequences 
(Jensen et al. 2006). Predicted N-linked glycosylation sites were examined using the 
web-based programme N-GLYCOSITE (www.hiv.lanl.gov). All reference sequences 






2.3.1. Viral infection of stimulated PBMCs 
Seven HIV-1 subtype C dual tropic isolates from individuals in South Africa (Cilliers et 
al. 2003) and Botswana (Ndung'u et al. 2006) were selected for this study. In addition, a 
well characterized CCR5-only utilizing HIV-1 subtype C isolate, 96BWM01_5 was used 
as a positive control (Ndung'u et al. 2006). Infection of the stimulated PBMCs was 
assessed by HIV-1 p24 antigen ELISA over a 14-day culture period. As shown in Figure 
2.2, p24 antigen concentration increased in culture supernatant for all the isolates. The 
isolates replicated to different levels and with different replication kinetics. On day 14, 




Figure 2.2: Viral infection of PBMCs 
5000 pg p24 antigen equivalent of virus was used to infect stimulated PBMCs. Virus growth 
was monitored by p24 antigen concentration increased over a 14-day period. 96BWM01_5 is 
an R5 monotropic viral isolate and was used as a positive control.  
42 
 
2.3.2. Confirmation of dualtropism of primary viral isolates 
Seven primary viral isolates propagated in PBMCs were first analyzed for their ability to 
use multiple coreceptors on cell lines. Specifically, the ability to mediate cell entry via 
CCR5 or CXCR4 was analyzed because these are the main coreceptors previously 
described for a significant proportion of HIV-1 primary isolates. In order to assess the 
ability of the isolates to utilize these coreceptors, virus equivalent to 2 ng of p24 antigen 
each was used to infect U87.CD4 glioma cell lines with or without the co-expression of 
the coreceptors. Table 2.1 shows the highest amounts of p24 antigen reached by the 
primary isolates over a 10-day period in culture. All 7 primary viral isolates replicated in 
cells expressing CXCR4 and CCR5. It was noteworthy that while all the isolates 
replicated efficiently in CXCR4 expressing cells, 3 isolates (RP1, 99ZASW30 and 
99ZACM9) replicated to relatively low titers in cells expressing CCR5. Isolates 
99ZACM9 and 99ZASW30 were previously shown to replicate efficiently in both CCR5 
and CXCR4 expressing cell lines (Cilliers et al. 2003) and therefore our results could 















Table 2.1: Coreceptor usage characterization of primary viral isolates 
    Isolate CD4 Count  












96BW17 NA NA (19) 630 (25) 707,297 (10) 209,119 
99ZATM1B NA 190,000 (13) 610 (151) 32,012 (126) 98,654 
RP1 7 178,830 (0.9) 610 (1.2) 2,120 (646) 961,835 
99ZASW20 2 43,595 (0.2) 0 (0.2) 160,683 (1.5) 47,787 
99ZASW30 2 73,860 (0.8) 1 (0.8) 2,141 (1.0) 158,623 
99ZACM9 24 NA (1.1) 2 (1.2) 2,201 (1.1) 11,979 
01ZADu36_5 25 54,944 (1.3) 1 (2.1) 1,658 728 (1.0) 46,525 
96BWM01_5 NA NA - - - 
Du179 279 2,640 - - - 
 
Note: NA- not available. All patients were ART naïve. 2000 pg of p24 viral supernatants from PBMC 
co-cultures were used to infect U87.CD4 cells expressing different coreceptors i.e. CCR5 or CXCR4 
coreceptors. The U87.CD4 cell line was used as a control cell line.  2000 pg of HIV-1 p24 equivalent 
of virus was used for infection and cells were washed 3 times after overnight incubation with 
infecting stock.  Virus growth above 2000 pg (amount used to infect) was considered productive 
infection of target cells. All italicized figures in brackets indicate background level i.e. the p24 
antigen (pg/ml) on day 0.  
 
2.3.3. Determination of coreceptor usage by env clones 
The env gene (approximately 3kb) was then amplified from PBMC genomic DNA by 
PCR, gel purified and cloned into a mammalian cell expression plasmid vector 
(pcDNA3.1D/V5-His-TOPO). Five clones for each patient isolate were generated.  
Pseudoviruses were prepared by cotransfecting 293T cells with each of the 35 env 
plasmid clones with the pNL4-3.Luc.R-E- construct (Connor et al. 1995; He et al. 1995). 
This construct contains the infectious NL4-3 provirus backbone but is env and vpr 
deleted and nef has been replaced by the firefly luciferase gene. Virus supernatant from 
the transfected 293T cells equivalent to 2 ng p24 antigen was then used to infect U87 
cells expressing the chemokine receptors CCR5 or CXCR4. A previously characterized 
Highest p24 antigen (pg/ml) reached by primary isolates 
over 10-day period in culture 
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dual tropic env clone Du179 (Coetzer et al. 2006) was used in parallel as a positive 
control. Productive entry of target cells was determined by measurement of firefly 
luciferase activity in cell lysates of infected U87 cells. All 35 env clones were able to 
efficiently infect cells expressing CXCR4 (Table 2.2). Five of 35 (14.3%) clones tested 
were also able to mediate entry via the CCR5 receptor, indicating that they were dual 
tropic. Two of the clones able to utilize CCR5 were from isolate RP1 while the other 
three were from isolate 99ZACM9. Surprisingly, there were no CCR5 monotropic clones 
detected from the bulk PCR envelope analysis of dual tropic isolates in this study.   
 
Table 2.2: Coreceptor usage characterization of the HIV-1C env clones 
Clone U87.CD4.CCR5 U87.CD4.CXCR4 
96BW17 #2             -           +++ 
96BW17 #3              -           +++ 
96BW17 #6             -           +++ 
96BW17 #7             -           +++ 
96BW17 #15             -           +++ 
99ZATM1B #3             -           +++ 
99ZATM1B #5             -           +++ 
99ZATM1B #6              -            ++ 
99ZATM1B #8             -            ++ 
99ZATM1B #13             -            ++ 
RP1 #5             -            ++ 
RP1 #6             -            ++ 
RP1 #8             -            ++ 
RP1 #10            ++            ++ 
RP1 #13            ++            ++ 
99ZASW20 # 2             -            ++ 
99ZASW20 #3             -            ++ 
99ZASW20 #11             -            ++ 





















Note: For each experiment, a positive result was considered to be 2 x the average relative 
luminescence units (RLUs) of the negative control wells + standard deviation. RLUs above 
this but less than 3 x this cut off value are indicated by “+” values 3 x to 10 x above cut off 
are shown as “++” and values above 10 x the cut off are indicated as “+++”. *96BWM01_5 
is an R5-only control, 96BW17#10 is an X4-only control and Du179 is a dual tropic control. 
pNL4-3.Luc.R-E- is the negative control. 
  
These results could be explained by two possibilities; one is that CCR5 monotropic 
envelopes are present at very low frequencies and therefore are virtually undetectable as 
clones from amongst the primary isolate viral quasispecies or that the CXCR4 viruses 
may be more fit and outcompeting CCR5 clones when propagated in PBMCs. In order to 
differentiate between these two possibilities, we infected U87.CD4.CCR5 cells with each 
99ZASW20 #15             -            ++ 
99ZASW30 #1             -            ++ 
99ZASW30 #2             -           +++ 
99ZASW30 #3             -           +++ 
99ZASW30 #6              -           +++ 
99ZASW30 #9             -           +++ 
01ZADu36_5 #2             -           +++ 
01ZADu36_5 #7             -           +++ 
01ZADu36_5 #8             -            ++ 
01ZADu36_5 #9             -            +++ 
01ZADu36_5 #10             -            ++ 
99ZACM9 #1            ++           +++ 
99ZACM9 #2            ++           +++ 
99ZACM9 #16             -           +++ 
99ZACM9 #18             -           +++ 
99ZACM9 #21             +           +++ 
96BWM01_5*           +++              -      
96BW17#10*              -           +++ 
Du179*           +++           +++ 
pNL4-3.Luc.R-E-*              -              - 
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of the primary viral isolates, with the objective of amplifying or favouring the CCR5-
tropic clones in CCR5-only expressing cells. RNA was then extracted from the viral 
supernatant from U87.CD4.CCR5 cells, functional env clones generated and coreceptor 
usage determined as described for the PBMC-derived clones. All clones generated from 
U87.CD4.CCR5 cell supernatants showed dualtropism. This result suggests that env 
clones using CCR5 only were virtually absent or present at very low frequencies within 
the quasispecies of the 7 primary isolates analyzed here. 
  
2.3.4. Limiting endpoint dilution PCR 
There is also the possibility that bulk PCR env amplification and cloning could result in 
resampling bias and explain the absence of CCR5-only env clones. A single genome 
amplification approach to generate diverse clones from isolate 01ZADU36_5 was used. 
This clone was selected for this analysis because it showed a bias towards CCR5 
utilization and yet we had failed to identify CCR5-only tropic clones from this isolate.    
Thirty clones of 01ZADU36_5 were amplified and cloned by this limiting endpoint 
dilution PCR approach. These clones were then tested for coreceptor usage in the 
U87.CD4.CCR5 and U87.CD4.CXCR4 cell lines. Of the 26 functional clones, 24 were 
dual tropic, one clone used CXCR4 exclusively and one clone showed exclusive R5-
usage.  
 
2.3.5. Genotypic Analysis of the env gene 
All 35 env full-length clones generated in this study by bulk PCR were sequenced to 
investigate phylogenetic relationships and to correlate coreceptor usage phenotype to 
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genotype data.  Phylogenetic analysis showed that all clones clustered with subtype C 
references with a high degree of confidence (Figure 2.3). Furthermore, the clones from 
each primary viral isolate clustered together. As described above, sequences were also 
generated from U87.CD4.CCR5 and U87.CD4.CXCR4 cells infected with each of the 
primary isolates. These clones utilized both CCR5 and CXCR4, and their sequences were 
virtually phylogenetically indistinguishable from those obtained from PBMC cultures. 
Results obtained by using position-specific scoring matrix for HIV-1 subtype C (C-
PSSM), a phenotype predictive tool based on HIV-1 subtype C sequences (Jensen et al. 




Figure 2.3: Neighbour-Joining phylogenetic tree constructed from the env gene 
sequences 
All clones (represented in red) of a particular viral isolate cluster closely together. 













The envelope V3 loop is an important determinant of coreceptor utilization (Briggs et al. 
2000; Cann et al. 1992; Fouchier et al. 1992; Rizzuto et al. 1998; Wu et al. 2006). 
Therefore, the V3 loop of the functionally characterized env clones was further analyzed 
in order to identify and describe sequences associated with dualtropism and CXCR4 
utilization (Figure 2.4 and Table 2.3). Of particular interest was the crown motif, a 
conserved tetrapeptide located at the tip of the V3 loop. Changes within this region may 
influence coreceptor usage. The consensus crown motif for clones from isolate RP1 was 
GPGQ, which is the conventional V3 loop crown sequence observed in CCR5-tropic 
subtype C sequences. The crown motifs for clones generated from 01ZADu36_5 and 
99ZACM9 were GPGR and GPRY respectively, sequence substitutions that are 
indicative of CXCR4 tropism (Coetzer et al. 2006). Clones from 96BW17, 99ZATM1B 
and 99ZASW20 each displayed consensus crown motif sequences that read GRGQ. The 
consensus crown motifs of 99ZASW30, 01ZADu36_5 and 99ZACM9 read GRGH, 
GPGR and GPRY respectively. Thus CXCR4 utilization in HIV-1 subtype C is 
commonly associated with a basic amino acid substitution in the V3 tetrapeptide 






Consensus C  CTRPNNNTRKSIRI..GPGQTFYATGDIIGDIRQAHC  
96BW17 #2  -----------M--GIGRGQ----M-R----------  
96BW17 #3  -----------M--GIGRGQ----M-R----------  
96BW17 #6  -----------M--GIGRGQ----M-R----------  
96BW17 #7  -----------M--GIGRGQ----M-R----------  
96BW17 #15  -----------M--GIGRGQ----M-R----------  
Consensus  -----------M--GIGRGQ----M-R----------  
  
99ZATM1B #3  ----------NV--GIGRGQ----N-----N------  
99ZATM1B #5  ----------NV--GIGRGQ----N-----N------  
99ZATM1B #6  ----------NV--GIGRGQ----M-R---N------  
99ZATM1B #8  ----------NV--GIGRGQ----N-----N------  
99ZATM1B #13  ----------NV--GIGRGQ----N-----N------  
  
RP1 #5  -I--G-----RV-LGIGPGQ------RV-R-------  
RP1 #6  -I--G-----RV-LGIGPGQ------RV-R-------  
RP1 #8  -I--G-----RV-LGIGPGQ------RV-R-------  
RP1 #10  -I--G-----RV-LGIGPGQ------RV-R-------  
RP1 #13  -I--G-----RV-LGIGPGQ------RV-R-------  
Consensus  -I--G-----RV-LGIGPGQ------RV-R-------  
  
99ZASW20 #2  -------------TGIGRGQ------Q---V-----  
99ZASW20 #3  -------------TGIGRGQ------Q---V-----  
99ZASW20 #11  -------------TGIGRGQ------Q---V-----  
99ZASW20 #14  -------------TGIGRGQ------Q---V-----  
99ZASW20 #15  -----------V-IGIGRGHA--T—KV--N-------  
Consensus  -------------TGIGRGQ------Q---V-----  
  
99ZASW30 #1  -----------V--GIGRGHA--T-GKV--N------  
99ZASW30 #2  -----------V--GIGRGHA--T-GKV--N------  
99ZASW30 #3  -----------V--GIGRGHA--T-GKV--N------  































Figure 2.4: Alignment of V3 sequences of clones of primary viral isolates 
 
The crown motif for each sequence is indicated in red and dual tropic clone sequences are 



















99ZASW30 #9  -----------V--GIGRGHA--T-GKV--N------  
Consensus  -----------V--GIGRGHA--T-GKV--N------  
  
01ZADu36_5 #2  ----D-KINMKRIKI.GPGRA-V--KG-R---R--Y-  
01ZADu36_5 #7  ----D-KISMKRIKI.GPGRA-V--KG-K---R--Y-  
01ZADu36_5 #8  ----D-KINMKRIKI.GPGRA-V--KG-K---R--Y-  
01ZADu36_5 #9  ----D-KINMKRIKI.GPGRA-V--KG-R---R--Y-  
01ZADu36_5 #10  ----D-KISMKRIKI.GPGRA-V--KG-K---R--Y-  
Consensus  ----D-KINMKRIKI.GPGRA-V--KG-K---R--Y-  
  
99ZACM9 #1  -A--G---I-R---..GPRYA---KET----------  
99ZACM9 #2  -A--G---I-R---..GPRYA---KET----------  
99ZACM9 #16  -A--G---I-R---..GPRYA---KET----------  
99ZACM9 #18  -A--G---I-R---..GPRYA---KET----------  
99ZACM9 #21  -A--G---I-R---..GPRYA---KET----------  
Consensus  -A--G---I-R---..GPRYA---KET----------  
52 
 
Table 2.3: Summary table of V3 characteristics of clones of primary viral isolates 
 
 
Another feature of the env V3 loop associated with tropism determination is the property 
of amino acids at positions 11 and/or 25 (Fouchier et al. 1992). The consensus sequences 
for all isolates with the exception of 99ZASW20 showed a positively charged amino acid 
substitution at one or both of these positions. 96BW17 has serine (S) (neutral charge) and 

















R-5 only virus 
96BWM01_5 





# 2; 3; 6; 7; 15 
37 7 7 Ser (S)/Arg(R) GRGQ CXCR4-using CXCR4-using or dt 
 
99ZATM1B 
# 3; 5 ;6; 8; 13 
37 8 8 Asp(N)/Arg(R) GRGQ CXCR4-using CXCR4-using or dt 
 
RP1 
# 5; 6; 8; 10; 13 
37 8 8 Arg(R)/Arg(R) GPGQ CXCR4-using CXCR4-using or dt 
 
99ZASW20 
# 2; 3; 11; 14; 15 
37 6 6 Ser(S)/Glut(Q) GRGQ CXCR4-using CXCR4-using or dt 
 
99ZASW30 
# 1; 2; 3; 6; 9 
























CXCR4-using or dt 
 
CXCR4-uing or dt 
 
99ZACM9 
# 1; 2; 16; 18; 21 





99ZASW20 has serine and glutamine (Q) both of which carry neutral charges, 
99ZASW30 has serine and lysine (K), 01ZADu36_5 has arginine and glycine (G) and 
99ZACM9 has arginine and threonine (T) at positions 11 and 25 respectively. RP1 has 
arginine at both positions. The number of amino acids in the V3 loop can also be 
indicative of coreceptor usage. The typical V3 loop from CCR5 tropic viruses has 35 
amino acids. Clones from 99ZACM9 were 35 amino acids long in the V3 loop, whereas 
clones from 01ZADu36_5 were 36 amino acids long.  Clones from isolates 99ZATM1B, 
99ZASW30 and 96BW17 had 2-amino acid insertions, increasing the length of the V3 
loop to 37 amino acids. The insertions occurred at positions 13 and 14 of the V3 loop for 
clones from isolates RP1 and 99ZASW20 and at positions 6 and 7 for clones from 
01ZADu36_5. Clones from 99ZATM1B, 99ZASW30 and 96BW17 had insertions 
between positions 15 and 16. Amino acid insertions in the V3 loop, particularly at 
positions 13 and 14 are features consistent with CXCR4 utilization as previously 
described (Coetzer et al. 2006). None of the insertions observed in the V3 loop of the 
clones from this study were noted in HIV-1 subtype C R5 sequences downloaded from 
the Los Alamos database (www.hiv.lanl.gov). The V3 region was also analyzed by 
manually calculating the overall net amino acid charge, another indicator of env 
coreceptor tropism (Table 2.3). C-PSSM, a web-based bioinformatic tool used for 
predicting HIV-1C coreceptor usage from the amino acid sequences of the V3 loop 
(Jensen et al. 2006) was also used. Both manual and C-PSSM calculations were 
comparable except for the clones from 99ZASW30 where calculated scores were slightly 
higher than C-PSSM generated scores. Higher overall net V3 charges are associated with 
X4-usage. A charge less than +4.5 is regarded as R5-using and charges above +4.5 are 
regarded as X4-using (Coetzer et al. 2006; Fouchier et al. 1995; Fouchier et al. 1992; 
Kuiken et al. 1992). Therefore, based on the multiple V3 loop sequence based algorithms 
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available for phenotype prediction, all clones generated in this study were either only 
CXCR4-using or dual tropic, consistent with the functional data. 
 
The V1/V2 and V4/V5 regions of the env gene were also analyzed as these regions have 
also been implicated in playing a role in viral tropism. Sequence features in these regions 
that may influence coreceptor utilization are the amino acid length and the number of 
predicted N-linked glycosylation sites (Chohan et al. 2005; Coetzer et al. 2007; Coetzer 
et al. 2008; Masciotra et al. 2002; Pollakis et al. 2001). The number of predicted N-
linked glycosylation sites in clones from this study varied from 23 to 33. Clones for RP1, 
99ZASW20 and 99ZASW30 all had 30 predicted N-linked glycosylation sites. Within 
the V1/V2 and V3 regions, the N-linked glycosylation sites varied between isolates but 
occurred at the same positions for all clones of the same isolate irrespective of whether 
they were X4-using or dual tropic except for one clone from 99ZATM1B which had 2 
predicted N-linked glycosylation sites in the V2 region whereas the other 4 clones of this 
isolate had 3. The sites within the V4/V5 regions for all clones of all isolates showed 
slight variations in position. However, all clones from 01ZADu36_5 exhibited CXCR4-
usage and showed variation in the positions of the sites in all five hypervariable regions. 
The positions of N-linked glycosylation sites varied from clone to clone and based on 
these positions no pattern emerged that could distinguish CXCR4-using clones from 
those that used both CCR5 and CXCR4. 
 
When the total number of predicted N-linked glycosylation sites within the env as well as 
within the V1/V2 and V4/V5 regions were analysed, no significant difference was 
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observed between the CXCR4-using clones and dual tropic clones. However, the median 
number of N-linked glycosylation sites for X4/R5X4 clones from this study was 
significantly higher at (30) compared to (21) for R5 clones (30 sequences downloaded 
from the Los Alamos HIV-1 database) (p < 0.0001) (Figures 2.5A-C). R5 sequences 
showed a lower number of predicted N-linked glycosylation sites within the entire env as 
well as within the V1/V2 and V4/V5 regions when compared to R5X4/X4 clonal 


























































































































































































































































































































































































Figure 2.5: Box plots of predicted N-linked glycosylation sites (PNLGS) and env 
variable loop lengths 
A) shows the total number of PNLGS within the env. B) the number of PNGLS within 
the V1/V2 region  C) the number of PNGLS within the V4/V5 region D) the number of 
PNLGS within the V3 region E) the V1/V2 loop length. F) the V4/V5 loop length G) the 
V3 loop length. The line within each box represents the median value for each group. * 







Previous reports have suggested that a lack of predicted N-linked glycosylation sites at 
positions 6-8 of the V3 loop may be indicative of CXCR4-usage (Coetzer et al. 2006). 
This site was conserved in the clones analyzed in this study, despite the utilization of 
CXCR4 by all the clones. All clones (except those from isolate 01ZADu36_5) contained 
a predicted N-linked glycosylation site at position 6 although they were CXCR4-using. 
This was also observed in a previous study by Johnston and colleagues (Johnston et al. 
2003) where all but one X4 sequence maintained this site. A significant reduction in the 
number of predicted N-linked glycosylation sites within the V3 region of clones 
generated in this study was observed as compared to the R5 sequences from the database 
(Figure 2.5D).  
  
The entire env sequence i.e. gp160 of all CXCR4- and CCR5/CXCR4-using clones were 
compared to determine if any distinguishing features could be identified. Specifically, 
analysis for unique signature patterns such as conversation of amino acids with a specific 
charge or physical property at a particular position, putative N-linked glycosylation sites, 
deletions, insertions or number of amino acids was performed. The 2 clones of RP1 
displaying dualtropism (i.e. clone # 10 and 13) had leucine (L) at position 373 whereas 
the CXCR4-using clones of this isolate (clone # 5; 6; 8) had proline (P) at this position. 
The other isolate that produced clones exhibiting dualtropism was 99ZACM9. No 





Differences in the loop lengths between X4, R5X4 and R5 sequences were next 
analyzed. Most variation was seen in V1 which ranged from 16-27 amino acids. V2 had 
a relatively constant loop length (40-45). The combined V4/V5 loop length ranged from 
37-46. The V1/V2 and V4/V5 loop lengths of the clones produced in this study were 
plotted against R5 sequences from the Los-Alamos database. No significant differences 
were observed between the V1/V2 sequences of clones generated in this study and the 
R5 sequences from the Los Alamos database (Figure 2.5E). However, for the V4/V5 
region, there was a significant difference between the generated clones using the CXCR4 
coreceptor for viral entry and the dual tropic clones (p= 0.015) (Figure 2.5F), with the 
dual tropic clones having an increased V4/V5 loop length. For the V3 loop, all analyzed 
R5 sequences had a loop length of 36 amino acids whereas X4 and R5X4 clones from 
this study showed variability with a range from 35 to 37 amino acids (Figure 2.5G). 
 
2.4. Discussion 
The requirement by HIV-1 for specific cellular interacting factors during the entry step offers 
an opportunity for the development of vaccines and drugs that target this crucial step in the 
virus replication cycle (Dhami et al. 2009; Hunt and Romanelli 2009; Pantophlet and Burton 
2006; Phogat et al. 2007). Coreceptors play an important role in initiating infection at the 
cellular level. Additionally, coreceptor utilization is an important determinant of the rate of 
disease progression. The emerging availability of entry inhibitors such as the CCR5 
antagonists underlines the importance of better characterization of coreceptor utilization and 
cellular tropism by HIV-1 isolates particularly in heavily burdened countries where the drugs 
are likely to be required on a large scale for the clinical management of HIV/AIDS. In this 
study, 35 full-length env clones from seven dual tropic isolates of HIV-1 subtype C was 
generated, in order to determine whether they were a mixture of CCR5 and CXCR4 
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quasispecies or dual tropic viruses at the clonal level. Sequence characteristics of these clones 
were also interrogated in order to better elucidate the genetic determinants of coreceptor 
utilization by HIV-1 subtype C viruses. CXCR4-tropic clones dominated within the dual 
tropic viral isolates quasispecies. A minority proportion of dual tropic clones were also 
identified. Unexpectedly, not a single CCR5-monotropic env clone from the seven primary 
isolates analyzed in this study was found. This is an unusual finding considering that many 
studies have shown that HIV-1 subtype C viruses even in late stages of disease utilize CCR5-
only predominantly for cell entry. Thus a significant proportion of the remnants of these 
viruses among the quasispecies of the dual tropic isolates were expected to be found. Instead, 
all the clones detected in this study used CXCR4 as the coreceptor for cell entry, with a 
minority of these (14.3%) also able to mediate entry via the CCR5 receptor. Results obtained 
may explain why in previous studies of some of the dual tropic isolates described here 
(99ZACM9, 99ZASW20 and 99ZASW30); the isolates could be strongly inhibited by 
CXCR4 inhibitors but only modestly by CCR5 inhibitors (Cilliers et al. 2003). These earlier 
results can now be explained by the observation that although these isolates are dual tropic, 
they are dominated by X4 variant clones.  
 
An alternative explanation of our findings is that these isolates changed their coreceptor 
preference during in vitro passages in PBMC cocultures as has been previously described 
(Voronin et al. 2007). This possible explanation is supported by the finding that isolates 
99ZACM9 and 99ZASW30 displayed remarkably lower CCR5 utilization capacity (Table 
2.1) than was previously described (Cilliers et al. 2003). Another explanation for our 
findings, and possibly a limitation in this study is that the p24 antigen ELISA method was 
employed and not the 50% tissue culture infective dose (TCID50).  The latter is the most 
accurate measure of infectious HIV-1 titers. It involves a limiting dilution-infection assay as 
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and a calculation of the dose required for 50% infectivity of susceptible cells in tissue culture. 
Previous studies have shown that there is a poor relationship between p24 content and 
infectious titre (Marozsan et al. 2004). This may have contributed to a selection bias. It is also 
worth noting that although isolates 96BW17, 99ZASW20 and 01ZADu36_5 showed a 
possible bias towards CCR5 utilization and were clearly dual tropic, all the env molecular 
clones generated from these isolates by bulk PCR amplification were CXCR4-only using. 
This finding strongly suggested that the bulk PCR could be biased towards X4 viruses. 
Limiting endpoint dilution PCR on one dual tropic viral isolate (01ZADu36_5) which was 
biased towards CCR5 utilization was therefore performed (Table 2.1).  Remarkably, of 26 
functional env clones generated by this approach, 24 exhibited dualtropism, one used CXCR4 
exclusively and one used CCR5 exclusively. It can therefore be concluded that dual tropic 
HIV-1 subtype C isolates are dominated by X4 and R5X4 clones with negligible proportion 
of R5 monotropic clones.   
 
It has been recently proposed that coreceptor switching is associated with deleterious 
mutations in env that diminish CCR5-tropism as mutations associated with CXCR4 
utilization accumulate (Coetzer et al. 2008). Although coreceptor binding was not directly 
tested for in this study, results are consistent with the proposal by Coetzer and colleagues and 
with their observation that coreceptor switching is associated with a rapid decrease in the 
ability to use CCR5. Results obtained may suggest that in HIV-1 subtype C, the mutations 
required for adaptation to CXCR4 utilization significantly reduce the ability of env to utilize 
CCR5, thus resulting in reduced fitness of CCR5 utilizing viruses.  This could in turn lead to 
the selection and amplification of clones able to utilize CXCR4. It can be speculated that 
given the low frequency of HIV-1 subtype C CXCR4 utilizing viruses reported in various 
studies, more accumulated mutations are required for switching to CXCR4 utilization for this 
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subtype.  Alternatively, the changes required for a switch to CXCR4 utilization may result in 
a bigger fitness deficit for HIV-1 subtype C CCR5-tropic variants thus leading to selection 
against these viruses once adaptation to CXCR4 utilization has been accomplished.  Further 
studies will be required to carefully investigate the specific localization and nature of 
complementary mutations required for HIV-1 subtype C env coreceptor switch. 
 
The genetic characteristics associated with CXCR4-usage or dualtropism for HIV-1 subtype 
C viruses was also investigated. Results may be limited by founder effects since R5 
sequences from the study isolates could not be generated but HIV-1 subtype C R5 sequences 
were available from the Los Alamos database that facilitated this comparative analysis. As 
described for HIV-1 subtype B, the subtype C third variable loop of gp120 (V3 region) is a 
major determinant of whether CXCR4 or CCR5 will be the accessory protein used by the 
virus for membrane fusion (Cilliers et al. 2003; Coetzer et al. 2007; Coetzer et al. 2006; 
Fouchier et al. 1992; Morris et al. 2007; Ndung'u et al. 2006). Typically, the V3 region 
consists of approximately 35 amino acids in CCR5-tropic viruses (Coetzer et al. 2006). 
Consistent with earlier studies, results show that V3 loop amino acid characteristics are 
important determinants of coreceptor tropism. In most cases, the V3 loop crown of CXCR4-
utilizing clones had basic amino acid substitutions which differed from the canonical GPGQ 
sequence found in CCR5 HIV-1 subtype C viruses to GPGX (where X is any other amino 
acid), GRGH, GPGR or GPRY. X4 variants are more variable than R5 viruses in the V3 
region particularly at positions 11 and 25 which tend to be mostly positively charged amino 
acids, often arginine (R), lysine (K) or histidine (H). The presence of a basic amino acid at 
both or one of these positions for the majority of clones in this study (85%) was observed.  In 
addition, in X4 variants there may be insertions particularly between positions 13 and 14 of 
the V3 loop contributing to an increased length. Amino acid insertions were seen in 71% of 
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clones in this study. X4 variants may also be distinguished from R5 viruses as they usually 
have an increased net V3 charge. Consistent with these observations, 100% of X4-utilizing 
clones had V3 loop amino acid charges of +5 or more. 
 
The V3 region however, is not the exclusive determinant of coreceptor usage and other 
regions within the env gene may also contribute to viral tropism. The V1/V2 and V4/V5 
regions have been implicated in playing a role in determining the biological phenotype of the 
virus. Specifically, the number of N-linked carbohydrate moieties in these variable loops has 
been associated with coreceptor determination (Chohan et al. 2005; Coetzer et al. 2008; 
Masciotra et al. 2002; Pollakis et al. 2001). Here a strong association was found between the 
number of N-linked glycosylation sites and coreceptor utilization with X4 clones having a 
significantly higher number of these sites than R5 clones from the database overall and in the 
V1/V2 or V4/V5 regions (Figure 2.5A-C). In contrast in the V3 region, the number of sites 
was significantly higher in R5 sequences than X4/R5X4 sequences (Figure 2.5D).  A 
previous longitudinal study of HIV-1 env evolution showed no significant changes in N-
linked glycosylation sites of 23 viral isolates from 5 patients followed for 2-4 years (Coetzer 
et al. 2007). Therefore the findings in this study may suggest a rapid accumulation of N-
linked glycosylation sites as coreceptor tropism switches, as opposed to a slow accumulation 
of these sites over time. This is consistent with recent findings of rapid decline in CCR5 
utilization as alternate coreceptor utilization emerges in HIV-1 subtype B infection (Coetzer 
et al. 2008). In both HIV-1 subtypes A and C, shorter V1/V2 loop sequences and fewer 
predicted N-linked glycosylation sites have been correlated with preferential heterosexual 
viral transmission (Chohan et al. 2005; Derdeyn et al. 2004).  No significant differences in 
V1/V2 length between R5 and X4 clones in this study was seen but a trend towards shorter 
V4/V5 for X4 clones was noted (Figure 2.5E-F). Further longitudinal studies will be 
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necessary in order to better understand HIV-1 subtype C transmission, coreceptor switching 
and the env genetic characteristics associated with these processes. Overall, results obtained 
suggest that sequence characteristics in the V3 loop, the V4/V5 loop length as well as the 
number of env predicted N-linked glycosylation sites are the primary genotypic determinants 
for viral tropism in HIV-1 subtype C. 
 
It is worth noting that limiting endpoint dilution of samples in this study except for isolate 
01ZADU36_5 was not performed. Therefore the presence of substantial frequencies of R5-
monotropic viruses in the quasispecies of the isolates where endpoint dilution was not used 
cannot be completely ruled out. However, the absence of these clones in bulk amplified 
clones, in CCR5 only expressing cells and in endpoint diluted 01ZADu36_5 isolate that is 
biased towards CCR5 are all suggestive of absence of such quasispecies or presence at very 
low frequency. Results obtained appear to contradict the recent findings of Irlbeck and 
colleagues (Irlbeck et al. 2008) but it must be emphasized that in that study, samples were 
analyzed directly from plasma and therefore made use of viral RNA. In contrast, this study 
examined in vitro propagated isolates from PBMCs and hence made use of proviral DNA. 
Therefore this could account for the diffrernce observed. Further studies will be needed to 
determine whether env clones directly obtained from patients with dual tropic HIV-1 subtype 
C viruses have a bias towards CCR5 or CXCR4 tropism.     
 
In conclusion, this study shows that dual tropic viral isolates consist of predominantly X4 and 
R5X4 clones. Thirty of 35 env clones analyzed from PBMCs utilized X4 only as the 
coreceptor for entry into cells, whereas 5 of 35 clones tested displayed dualtropism and no 
CCR5-only utilizing clones were identified. R5 monotropic clones could not be detected even 
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when the isolates were cultured in cells expressing CCR5 coreceptor only. A significant 
number of R5 monotropic clones failed to be detected when we changed our approach of 
viral amplification from bulk PCR to limiting endpoint dilution PCR for one dual tropic 
isolate showing bias towards CCR5 tropism.  Viral env sequences from both CXCR4 and 
CCR5-expressing cells were indistinguishable and possessed X4/dual tropic characteristics. 
Furthermore, env sequence characteristics associated with CXCR4 utilization in HIV-1 
subtype C was described.  In addition to sequence changes in the env V3 region, the number 
of N-linked glycosylation sites in the V1/V2, V3 and V4/V5 regions as major determinants of 
coreceptor utilization in HIV-1 subtype C was identified. This study also shows that the 
length of the V4/V5 is a possible determinant of coreceptor utilization. It should be noted that 
results in this study are consistent with recent findings of the rapid loss of fitness of CCR5 
envelope as coreceptor switching emerges and suggest that the sequence characteristics 
associated with coreceptor switch must occur rapidly in vivo. Further studies are needed to 
better characterize coreceptor switching, particularly in the context of HIV-1 subtype C, the 
predominant subtype in the world. Thirty-five full-length CXCR4- or dual tropic clones of 
HIV-1 subtype C have been generated in this study and are important elements that will 
facilitate further functional studies of this globally predominant subtype. Results from this 
study have important implications for coreceptor antagonist design and application, and 









Distinct Patterns of Coreceptor Use by R5X4 HIV-1 Subtype C Clones in Primary 
CD4+ Lymphocytes and Macrophages versus Transformed Cell Lines 
 
3.1. Introduction 
Human immunodeficiency virus type 1 (HIV-1) entry into the cell is initiated when the viral 
envelope (Env) glycoprotein binds to the CD4 receptor, resulting in a conformational change 
in the Env surface subunit (gp120) leading to the exposure of a specific binding site for a 
chemokine receptor most often CCR5 or CXCR4 (Alkhatib et al. 1996a; Choe et al. 1996; 
Deng and Liu 1996; Dragic and Litwen 1996; Feng and Broder 1996; Kwong et al. 1998; 
Lusso 2006; Rizzuto et al. 1998; Wyatt et al. 1995). Thereafter, additional structural changes 
occur allowing the Env transmembrane protein subunit (gp41) to initiate the fusion process 
(Trkola et al. 1996; Wu et al. 1996). 
 
HIV-1 infection of CD4+ lymphocytes and macrophages in vitro and in vivo is thought to be 
mainly mediated by the chemokine receptors CCR5 and CXCR4 (Yi et al. 2005; Zhang et al. 
1998b).  Studies show that the CCR5 chemokine receptor is the most commonly used 
coreceptor for viral transmission (Dean et al. 1996; Liu et al. 1996; Samson et al. 1996).  
Viruses restricted to this receptor (R5 viruses) replicate in primary lymphocytes and 
macrophages, are nonsyncytium-inducing (NSI) and are poorly cytopathic in vitro (Alkhatib 
et al. 1996b; Choe et al. 1996; Deng and Liu 1996; Dragic and Litwen 1996; Fenyo et al. 
1989; Li et al. 1999; Valentin et al. 1994).  These viruses are also classified as macrophage-
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tropic (M-tropic) because of their ability to replicate in macrophages but not in transformed 
CD4+ lymphocyte cell lines (Asjo et al. 1986; Connor et al. 1993; Schuitmaker et al. 1992; 
Zhu et al. 1993).  Conversely, T cell line-tropic (T-tropic) viruses replicate in primary CD4+ 
lymphocytes and CD4+ transformed cell lines but not in macrophages.  These variants, which 
emerge later in infection, use CXCR4 as their principal receptor of entry (X4 viruses), are 
syncytium-inducing (SI) and are highly cytopathic in vitro (Berger 1998; Coetzer et al. 2006; 
Yi et al. 1999).  Dual tropic viruses, which may be intermediate viruses in the evolution from 
R5 to X4 variants, use CCR5 and CXCR4 receptors and infect both macrophages and CD4+ 
T-cell lines as well as primary lymphocytes (Carrington et al. 1997; Follis et al. 1998; Li et 
al. 1999; Naif et al. 2002; Simmons et al. 1998; Yi et al. 1999; Zerhouni et al. 2004). The M 
or T-tropic paradigm was established using lab adapted X4 viruses, and it is now clear that 
many primary X4 variants are able to infect macrophages (Yi et al. 1999). 
 
There have been a number of interesting studies of coreceptor use in primary cells by HIV-1. 
Contrary to earlier beliefs, CXCR4 is expressed on macrophages and some viral isolates use 
this coreceptor to infect macrophages even though T-tropic X4 strains are unable to infect 
these cells (Yi et al. 1999). Other studies have used R5X4 strains previously characterized in 
cell lines to investigate coreceptor usage in primary lymphocytes and macrophages. These 
studies showed that several dual tropic primary and prototype strains used CXCR4 for entry 
and infection in primary lymphocytes even though CCR5 was present (Bleul et al. 1997; Yi et 
al. 2005).  However, in macrophages, these strains used both CCR5 and CXCR4. From these 
observations, it was concluded that although HIV-1 strains were phenotypically characterized 
as R5X4 viruses in transformed cell lines this does not necessarily predict dualtropism in 
primary cells (Yi et al. 2005).  
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Coreceptor usage differences between transformed cell lines and primary cells were observed 
for HIV-1 subtype B strains which is the most widely studied subtype although it is 
responsible for only approximately 12% of infections worldwide (Hemelaar et al. 2006). 
There are no similar studies undertaken for HIV-1 subtype C despite the higher prevalence of 
this subtype globally, and the apparent differences in evolution of coreceptor usage between 
subtypes with  many studies indicating that complete switch to X4 phenotype is very rare for 
subtype C even in isolates obtained from late stages of chronic infection (Bjorndal and 
Sonnerborg 1999; Cecilia et al. 2000; Cilliers et al. 2003; Ndung'u et al. 2006; Tscherning et 
al. 1998).  In this study, CCR5 and CXCR4 coreceptor utilization of functional HIV-1 
subtype C env clones between transformed cell lines and primary cells (CD4+ lymphocytes 
and MDM) that are the main cell HIV-1 targets in vivo was compared. Furthermore it is 
suggested that there may be some important differences and heterogeneity in HIV-1 subtype 
C use of coreceptors in primary cells which is not always predicted or obvious by 
conventional experimental or genotypic analysis approaches. 
 
3.2. Materials and Methods 
3.2.1. Cells and Cell Lines 
CD4+ T cells were isolated by negative selection from whole blood obtained from the 
University of Pennsylvania Centers for AIDS Research Immunology Core. Purified 
lymphocytes were maintained at a concentration of 2x10
6
 cells/ml in RPMI 1640 
containing L-Glutamine with penicillin/streptomycin (50 µg/ml and 50 U/ml) (GIBCO, 
Grand Island, NY) and 10% heat inactivated fetal bovine serum (FBS) and stimulated 
with 5 µg/ml phytohaemagglutinin (PHA) (MP Biomedical, Solon, OH) at 37 
ο
C and 5% 
CO2 for 72 hours in a T-75 flask. They were maintained in 300 U/ml interleukin-2 (IL-2) 
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(Proleukin, Novartis, Basel, Switzerland) thereafter. Monocytes were isolated from 
whole blood from HIV negative volunteers by density gradient centrifugation on Ficoll-
Histopaque (G.E. Healthcare, Piscataway, NJ)  and adherent monocytes were maintained 
in culture at 1x10
6
 cells/ml in RPMI 1640 containing L-Glutamine with 
penicillin/streptomycin (50 µg/ml and 50 U/ml), 10% heat inactivated FBS and 50 ng/ml 
Macrophage Colony Stimulating Factor (M-CSF) (R&D, Minneapolis, MN) in a 100 mm 
x 20 mm tissue culture plate at 37 
ο
C and 5% CO2  for 7 days to allow differentiation into 
monocyte-derived macrophages. 293T cells were obtained from the NIH AIDS Research 
and Reference Reagent Program (Rockville, MD) and were cultured in DMEM 
containing L-Glutamine with penicillin/streptomycin (50 µg/ml and 50 U/ml), 10% heat 
inactivated FBS and kept at 37 °C in 5% CO2. U87.CD4, U87.CD4.CXCR4 and 
U87.CD4.CCR5 cells were obtained from the NIH AIDS Research and Reference 
Reagent Program. U87.CD4 cells were maintained in selective media containing 300 
µg/ml of G418 (Invitrogen, Carsbad, CA) and U87.CD4.CXCR4 and U87.CD4.CCR5 
cells were maintained in selective media containing 1 µg/ml of puromycin (MP 
Biomedical, Solon, OH) and 300 µg/ml of G418 (Invitrogen, Carlsbad, CA).  
 
3.2.2. Transfection 
The 35 envelope molecular clones were generated as described previously (refer to 
2.2.6). One day prior to cotransfection, 6x10
5
 293T cells/well were seeded in a total 
volume of 2 ml per well of a 6-well flat-bottomed plate and incubated at 37 °C in 5% 
CO2. Cotransfection was carried out by first combining 100 µl serum free DMEM with 
12 µl Fugene reagent (Roche Applied Science, Germany) and incubating for 5 minutes at 
room temperature. This was then incubated at room temperature together with 100 µl 
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serum free DMEM and 1.3 µg pNL4-3.Luc.R-E- (Chen et al. 1994; Connor et al. 1995). 
pNL4-3∆env is a full-length HIV plasmid with the env deleted. It contains the reporter 
firefly luciferase gene in the nef ORF. Thereafter 1.3 µg DNA of gp160 env cloned in 
pcDNA3.1D/V5-His-TOPO vector (Invitrogen) was added. The transfection mixture was 
incubated for 30 minutes, and then added to assigned wells of the plate seeded with 293T 
cells and incubated at 37°C and 5% CO2 overnight. The cells were then washed twice 
with DMEM containing L-Glutamine with penicillin/streptomycin (50 µg/ml), 10% heat 
inactivated FBS and replaced with 2 ml fresh media. This was incubated at 37°C and 5% 
CO2 overnight. Viral supernatants were then harvested. Supernatants were aliquotted into 
15 ml tubes and centrifuged at 1,200 x g for 5 minutes. Supernatants were then removed 
and aliquotted into a 15 ml tube containing 100% Sucrose (final concentration of 5% 
sucrose) (Sigma, St. Louis, MO). Single aliquots were then stored frozen at -80°C. The 
titre of each of the pseudoviruses was determined by p24 antigen ELISA. 
 
3.2.3. Infections 
Infections of various cells and cell lines were performed as follows. U87.CD4, 
U87.CD4.CXCR4 and U87.CD4.CCR5 cells were seeded 0.15x10
5
 cells/well in a 96-
well plate respectively 1 day prior to infection and maintained in DMEM containing L-
Glutamine with penicillin/streptomycin, 10% heat inactivated FBS.  For blocking 
experiments, cells were pre-treated with 5 µg/ml of the CXCR4 inhibitor AMD3100 
(Sigma-Aldrich, St. Louis, MO), 5 µM CCR5 inhibitor maraviroc (Pfizer Inc., New York 
City, NY) or a combination of  both inhibitors (Loftin et al. 2010).  For resistance testing 
on the U87 cells, an additional concentration of 15 µg/ml AMD3100 was included.  
Infection was done by spinnoculation at 1,200 x g for 2 hours with the HIV-1 
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pseudoviruses using an equivalent amount of virus (approximately 8 ng) as determined 
by p24 measurements.  Following infection, cells were cultured at 37°C and 5% CO2 for 
3 days.  Infection of monocyte derived macrophages was performed similarly, except 
cells were plated at 0.5x10
5 
cells/well in 96 well plates one day before infection. CD4+ T 
lymphocytes were plated at 2x10
5
 cells/well in 96 well plates in the presence of 10 U/ml 
of IL-2 and cultured at 37°C and 5% CO2 for 4 days after infection.  An R5, X4 and 
R5X4 control was included in all experiments. Successful infection of target cells was 
determined by luciferase activity measured by removing cell supernatant and lysing the 
cells in PBS containing 0.1% Triton X-100. 50 µl cell lysate was combined with 50 µl 
luciferase assay substrate (Luciferase Assay System; Promega, Madison, WI) and the 
luciferase relative light units (RLUs) were measured using a Dynex technologies 
microtiter plate luminometer (Figure 3.1). All experiments were done in duplicate. 
Furthermore because primary T cells and macrophages from different donors differ in 





Figure 3.1: Coreceptor usage using the Spinnoculation method of infection 
48 hours following tranfection infection was performed using the spinnoculation method. 
Transfection supernatants were centrifuged at 1200 x g gor 2 hours before the luciferase 
assay was carried out. 
 
3.2.4. Genotypic Analysis 








3.3.1. Transformed Cell Line Coreceptor Usage  
Thirty five envelope clones, five each from seven dual tropic isolates were generated 
from each isolate, transfected into 293T cells to produce pseudoviruses and then tested 
for coreceptor utilization in transformed U87 cells expressing CD4 and either CCR5 or 
CXCR4, with coreceptor negative cells as a control. Previously coreceptor usage was 
performed and infection was carried out using the DEAE-dextran method (refer to 2.2.8). 
All 35 clones were able to infect cells expressing CXCR4. Five of 35 (14.3%) clones 
were also able to mediate entry via CCR5, indicating that they were dual tropic. 
Surprisingly, no CCR5 monotropic clones were detected from the dual tropic isolates 
(refer to 2.3.3). Here coreceptor usage was performed and infection was carried out using 
a spinnoculation method (O'Doherty et al. 2000). All 35 env clones-derived 
pseudoviruses were able to efficiently infect cells expressing CXCR4. Twenty of 35 
clones (57%) tested were also able to mediate entry via the CCR5 receptor, indicating 
that they were R5X4 although usage of CXCR4 was higher for most. Most clones from 
the same isolate showed a similar coreceptor utilization profile. All clones from isolate 
96BW17 were dual tropic except for 96BW17 #15 which used only CXCR4. All clones 
of 99ZATM1B displayed exclusive CXCR4 usage. All clones from isolate RP1 except 
for clone #13 used CXCR4 exclusively. RP1 #13 showed both CCR5 and CXCR4 usage. 
Pseudovirus clones from the RP1 isolate were generally poorly infectious as indicated by 
the low luciferase activity observed in target cell lines. All clones from 99ZASW20 and 
99ZASW30 were R5X4 while all but one clone (#16) from 99ZACM9 also used both 
CCR5 and CXCR4. The 99ZACM9 #16 clone showed poor infection in cells expressing 
CCR5 and was therefore classified as exclusively X4. Only 1 clone (# 9) from 
01ZADu36_5 used both CCR5 and CXCR4 while the remaining 4 clones used CXCR4. 
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Overall, although both coreceptors were used by some pseudoviruses, CXCR4 was the 
preferred coreceptor. These results also indicated that the spinnoculation method was 
better at facilitating infection of U87.CD4.CCR5 by R5X4 clones compared to the 
DEAE-dextran method (Table 3.1, Figure 3.2). As previously noted, there were no R5-
only clones detected and the spinnoculation method confirmed this finding.    
 
Table 3.1: Comparison of the DEAE-dextran method and Spinnoculation method of 
infection 
               DEAE-Dextran               Spinnoculation 
Clone   U87.CD4.CCR5 U87.CD4.CXCR4  U87.CD4.CCR5   U87.CD4. CXCR4 
 
96BW17 #2             -          +++            +           +++ 
96BW17 #3              -          +++           ++           +++ 
96BW17 #6             -          +++            +           +++ 
96BW17 #7             -          +++            +           +++ 
96BW17 #15             -          +++            -           +++ 
99ZATM1B #3             -          +++            -           +++ 
99ZATM1B #5             -          +++            -           +++ 
99ZATM1B #6              -           ++            -           +++ 
99ZATM1B #8 -            ++            -           +++ 
99ZATM1B #13             -           ++            -           +++ 
RP1 #5             -           ++            -            ++ 
RP1 #6             -           ++            -            ++ 
RP1 #8             -           ++            -            ++ 
RP1 #10            ++           ++            -            ++ 
RP1 #13            ++           ++           ++            ++ 
99ZASW20 # 2             -           ++            +            ++ 
99ZASW20 #3             -           ++            +            ++ 
99ZASW20 #11             -           ++          +++           +++ 
99ZASW20 #14             -          +++          +++           +++ 
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99ZASW20 #15             -           ++          +++           +++ 
99ZASW30 #1             -           ++           ++           +++ 
99ZASW30 #2             -          +++           ++           +++ 
99ZASW30 #3             -          +++           ++           +++ 
99ZASW30 #6              -          +++           ++           +++ 
99ZASW30 #9             -          +++           ++           +++ 
99ZACM9 #1            ++          +++           ++           +++ 
99ZACM9 #2            ++          +++           ++           +++ 
99ZACM9 #16             -          +++             -            ++ 
99ZACM9 #18             -          +++           ++           +++ 
99ZACM9 #21            +          +++            +            ++ 
01ZADu36_5 #2             -          +++             -           +++ 
01ZADu36_5 #7             -          +++             -           +++ 
01ZADu36_5 #8             -           ++             -            ++ 
01ZADu36_5 #9             -           ++            +           +++ 
01ZADu36_5 #10             -           ++             -           +++ 
 
Note: +; ++ and +++ indicate the degree of coreceptor usage per clone with + being 
utilization and +++ representing strong interaction as measured by luminescence units. For 
the DEAE-dextran method, a positive result was considered to be 2 × the average relative 
luminescence units (RLUs) of the negative control wells+standard deviation. RLUs above 
this but less than 3 × this cut off value are indicated by “+”, values 3 × to 10 × above cut off 
are shown as “++” and values above 10 × the cut off are indicated as “+++”. For the 
spinnoculation method, + indicates a value of 100 obtained on the log scale with 1 000-
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Figure 3.2: Coreceptor usage in transformed cell lines 
Figure 3.2 indicates the coreceptor usage characterization of each of the clones of the dual 
tropic viral isolates. Majority of the clones (57%) exhibit dualtropism whereas 43% show 
exclusive usage of CXCR4. No R5 monotropic clones were observed. The results are 
expressed in relative light units (RLU) and represent means +/- standard error (SEM) for 
experiments performed in duplicate. RLU of 100 was used as the cut-off value. Values 
greater than 100 RLU was regarded as infectious. A-G represent the coreceptor usage of 
clones of each isolate i.e the clones of each isolate are represented separately in each figure. 
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3.3.2. Coreceptor Usage in CD4+ T Lymphocytes and Monocyte Derived 
Macrophages 
Transformed cell systems are conventionally used to establish virus coreceptor utilization 
profiles, however, the major targets of HIV infection in vivo are primary CD4+ 
lymphocytes and macrophages (Yi et al. 2005). Therefore, coreceptor usage of the 
previously characterized HIV-1 subtype C env clones in CD4+ T lymphocytes and 
monocyte derived macrophages was investigated.  To determine the pathways utilized on 
primary cells, the CXCR4 antagonist AMD3100, the CCR5 antagonist maraviroc and a 
combination of these two inhibitors was used. For each inhibition assay experiment, not 
only the pathways of infection used but also the coreceptor utilization preference of the 
pseudoviruses as calculated relative to the entry of cells not blocked by antagonists was 
examined. The pathways of infection used by the 35 clones in CD4+ T lymphocytes and 
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Figure 3.3: Viral infection of CD4+ T cells 
The panel on the left indicates the pathways of infection used by the respective virus i.e. the 
coreceptor pathways used for cell entry. Data are means +/- SEM of duplicate wells and 
representative of 2 separate experiments using lymphocytes from different donors.  Results 
shown for each virus are presented in RLU where a RLU of 100 was used as the cut-off 
value. Values greater than 100 RLU was regarded as infectious. The panel on the right shows 
the coreceptor pathway preference of the particular virus as calculated relative to the entry of 
untreated cells i.e. as a percentage of the RLU seen in the absence of coreceptor blockers. 
Those that were not infectious were excluded from the graphs illustrating coreceptor 
preference (right panel). A-G represent the infection of clones of each isolate i.e the clones of 
each isolate are represented separately in each figure. U – cells that are untreated, A – cells 
that are treated with AMD3100, M – cells that are treated with maraviroc and A+M – cells 
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Figure 3.4:  Viral infection of monocyte derived macrophages 
The panel on the left indicates the pathways of infection used by the respective virus i.e. the 
coreceptor pathways used for cell entry. Data are means +/- SEM of duplicate wells and 
representative of 2 separate experiments using monocyte derived macrophages from different 
donors.  Results shown for each virus are presented in RLU where a RLU of 100 was used as 
the cut-off value. Values greater than 100 RLU was regarded as infectious. The panel on the 
right shows the coreceptor pathway preference of the particular virus as calculated relative to 
the entry of untreated cells i.e. as a percentage of the RLU seen in the absence of coreceptor 
blockers. Those that were not infectious were excluded from the graphs illustrating 
coreceptor preference (right panel). A-G represent the infection of clones of each isolate i.e 
the clones of each isolate are represented separately in each figure. U – cells that are 
untreated, A – cells that are treated with AMD3100, M – cells that are treated with maraviroc 
and A+M – cells that are treated with a combination of AMD3100 and maraviroc. 
 
As shown in Figure 3.3, most clones from each dual tropic viral isolate showed a similar 
pattern of CD4+ T lymphocyte infection. The panel on the left hand side shows the 
extent of CD4+ T lymphocyte infection in the absence of coreceptors antagonists, in the 
presence of AMD3100, maraviroc and both coreceptor inhibitors combined in order to 
decipher the coreceptor pathway(s) used for cell entry. AMD3100 is a CXCR4 
antagonist and blocks CXCR4 entry into cells. Maraviroc is a CCR5 antagonist thereby 
preventing entry of CCR5 into cells. The panel on the right hand side displays coreceptor 
preference as calculated by determination the relative amount of luciferase in cells with 
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and without the coreceptor antagonist. Four of 5 clones from 96BW17 used both CCR5 
and CXCR4 with a preference for CXCR4 whereas 96BW17 #2 was not infectious in 
CD4+ T lymphocytes. All clones from 99ZATM1B used only CXCR4 for entry into 
CD4+ T lymphocytes. Clones # 5, 6, 10 and 13 from RP1 were infectious in CD4+ T 
lymphocytes. Blockade with either of the coreceptor antagonists significantly reduced 
infectivity for clones 5 and 6 suggesting co-dependency on both coreceptors.  Clones 
RP1 # 10 and 13 were X4. All clones of 99ZASW20 used both CCR5 and CXCR4 
equally while clones of 99ZASW30 were R5X4 although CXCR4 preference was 
observed for all of them. Clones from 99ZACM9 were R5X4 with clones # 1 and 16 
using both coreceptors equally with the remaining 3 displaying preferential CXCR4 
utilization. Two clones of 01ZADu36_5 were noninfectious in CD4+ T lymphocytes 
while the remaining 3 used CXCR4 only. Figure 3.3 (right panel) shows that CXCR4 is 
the preferred pathway used by clones from most isolates (96BW17, 99ZATM1B, RP1, 
99ZASW30 and 01ZADu36_5) in CD4+ T lymphocytes as blocking with maraviroc 
(CCR5 antagonist) did not significantly impact the degree of cell entry, whereas blocking 
with the CXCR4 antagonist AMD3100 did relative to unblocked cells.  For clones from 
some isolates, CXCR4 use predominates with little contribution coming from CCR5 
mediated infection (96BW17, 99ZASW30).  Two clones from one isolate (99ZACM9 # 
2 and 21) exhibit a preference for CXCR4, but CCR5 use by these clones also noticeably 
contributes to CD4+ T cell infection.  Only two isolates (99ZASW20 and 99ZACM9 # 1 
and 16) had clones with approximately equal preference for both CCR5 and CXCR4. 
 
Overall the majority of clones infected CD4+ T cells using both the CXCR4 and CCR5 
pathways, however CXCR4 was typically used more efficiently than CCR5.  In contrast, 
clones from 2 isolates displayed nearly equal CCR5 and CXCR4 usage. Additionally, 
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some clones infected CD4+ lymphocytes exclusively using CXCR4, while a number of 
clones were very poorly infectious or did not infect CD4+ T cells at all. As expected, 
viruses that were X4 on the U87 cell line (99ZATM1B, RP1 and clones # 2 and 7 from 
01ZADu36_5) used CXCR4 exclusively on primary CD4+ lymphocytes. Surprisingly, 
when a combination of inhibitors was used, cell entry was still observed in clones from 
isolates 99ZACM9 and 01ZADu36_5 indicating that the use of both antagonists 
concurrently did not efficiently inhibit viral entry. Similar to the results obtained on U87 
cells, no virus displayed exclusive CCR5 mediated entry and infection in CD4+ T 
lymphocytes.  
 
Most clones from each dual tropic viral isolate showed a similar pattern of infection in 
monocyte derived macrophages (MDM) (Figure 3.4).  All but one clone (#2) from 
96BW17 displayed the R5X4 phenotype with a preference for CXCR4. 96BW17 # 2 was 
exclusively X4. All clones from 99ZATM1B displayed exclusive CXCR4-utilization. 
Majority of clones from RP1 were noninfectious in macrophages except for clone #13 
which showed some CXCR4 usage. All clones from 99ZASW20 were R5X4 in 
macrophages with a preference for CCR5. Three clones from 99ZASW30 (clones #3, 6, 
9) used only CXCR4 while 2 (clones #1 and 2) used both CCR5 and CXCR4 with more 
efficient CXCR4 usage. Three clones from 99ZACM9 (clones #2, 16, 21) used both 
CCR5 and CXCR4 with a preference for CXCR4 while 2 (clones #1 and 18) clones used 
only CXCR4. One clone of 01ZADu36_5 (clone #8) was not infectious in macrophages 
while the remaining 4 were CXCR4-utilizing. Overall, the majority of clones infected 
macrophages using both CXCR4 and CCR5.  CXCR4 usage by many of these clones 
was more efficient than CCR5 use (96BW17 # 3, 6, 7 and 15, 99ZASW30 # 1 and 2 and 
99ZACM9 # 2, 16 and 21). Additionally, a number of clones from five isolates 
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(99ZATM1B and 01ZADu36_5 and clones 96BW17 # 2, 99ZASW30 # 3, 6 and 9, 
99ZACM9 # 1 and 18, RP1 # 13) show no contribution of CCR5-usage to macrophage 
entry. In contrast to the results for CD4+ T lymphocytes where no clones showed more 
efficient entry through CCR5 compared to CXCR4, clones from one isolate 
(99ZASW20) displayed more efficient CCR5 utilization on macrophages.  This was in 
contrast to the coreceptor phenotype for this isolate on CD4+ T lymphocytes where both 
pathways were used approximately equally. 
 
In a similar divergence, clones from two isolates used CXCR4 exclusively on 
macrophages although these clones infect CD4+ T lymphocytes using both coreceptors 
(99ZASW30 # 3, 6 and 9 and 99ZACM9 # 1 and 18), while another CXCR4 using clone 
was noninfectious on lymphocytes (96BW17 # 2).  Again, clones that were X4 using on 
U87 cells (99ZATM1B, RP1 and 01ZADu36_5) used CXCR4 exclusively on 
macrophages as well.  With the exception of one clone (RP1 #13), viruses that were 
minimally infectious or noninfectious on CD4+ lymphocytes (RP1 # 5, 6 and 8  and 
01ZADu36_5 # 8) were also not infectious in MDM. Exclusive CCR5 usage was not 
observed in MDM similar to the observation in CD4+ T lymphocytes. 
 
Interesting patterns emerged when infection in the presence of both antagonists on CD4+ 
lymphocytes and macrophages was compared.  When a combination of inhibitors was 
used, entry into macrophages was reduced for all clones of 99ZACM9, 99ZASW30, 
01ZADu36_5 #2, 99ZASW20 #11, 14 and 15.  Clones from isolate 99ZACM9 displayed 
a similar pattern of apparent resistance in both cell types however, for the clones from 
the other isolates poor inhibition seen in the presence of both antagonists was cell type 
88 
 
dependent.  All clones of isolate 01ZADu36_5 appeared to be resistant to inhibition on 
CD4+ lymphocytes, but only clone # 2 had a similar phenotype on macrophages.  
Alternatively, clones from isolates 99ZASW20 and 99ZASW30 were inhibited in CD4+ 
T lymphocytes when both antagonists were used, yet complete inhibition was not 
observed in monocyte derived macrophages. 
 
Recent reports have shown that some primary isolates are naturally resistant to 
AMD3100 (Harrison et al. 2008), and in the experiments carried out there were clones 
that were not completely inhibited in the presence of AMD3100 and maraviroc, which 
led to the hypothesis that these viruses may be resistant to these coreceptor antagonists.  
An alternative explanation is that these clones that appear resistant to CXCR4 and CCR5 
antagonists use alternate coreceptors in primary cells. In order to determine whether 
these pseudovirus clones were resistant to the coreceptor antagonists as observed in 
primary cells, we performed inhibition assays (as done in 3.2.3)  in the U87.CD4 cell line 
expressing either CCR5 or CXCR4. For this experiment, a virus that appeared to be 
resistant to AMD3100 (01ZADu36_5 # 10) as well as one clone each from the other 
isolates that displayed incomplete inhibition (99ZASW20 #14, 99ZASW30 #1 and 
99ZACM9 #16) was selected. Also included were the remaining clones derived from 
01ZADu36_5 as well as a virus that appeared to be sensitive to inhibition by the 
antagonists (96BW17 # 15). An R5 control JRFL and X4 control TYBE (Collman et al. 
1992; Yi et al. 2003) were used in parallel. Those viruses that exhibited partial or 
complete resistance in the primary cell lines also exhibited a similar resistance profile in 
the transformed cell lines, and the virus that was inhibited was also blocked on 
U87.CD4.CXCR4 cells. Furthermore, the pattern of infection was the same irrespective 
of the concentration of the drug used (Figure 3.5A). These observations indicate that 
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some of these viruses truly exhibit resistance to AMD3100. Three viruses that were 
R5X4-using in transformed cell lines (01ZADu36_5 #9, 99ZASW30 #1 and 99ZASW20 
#14) were also tested for resistance to maraviroc in the U87.CD4.CCR5 cell line. 
01ZADu36_5 #9 displayed resistance to inhibition by maraviroc (Figure 3.5B). 
 
 
Figure 3.5: Viral infection of U87.CD4.CXCR4 cells in the presence of AMD3100 and 
U87.CD4.CCR5 cells in the presence of maraviroc 
A) Nine virus clones were selected and tested for resistance to CXCR4 antagonist AMD3100. 
U87.CD4 cells expressing CXCR4 were infected in the presence of two different 
concentrations of AMD3100 (5 and 15 µg/ml). B) Three R5X4-using virus clones were 
selected and tested for resistance to CCR5 antagonist maraviroc. U87.CD4 cells expressing 
CCR5 were infected in the presence of maraviroc (5 µM).  Results shown for each virus are 
presented in RLU where a RLU of 100 was used as the cut-off value. Values greater than 100 
RLU was regarded as infectious. U – cells that are untreated, A (5 and 15 µg/ml) – cells that 
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are treated with 5 and 15 µg/ml AMD3100 respectively, M (5 µM)– cells that are treated with 
5 µM maraviroc. 
 
3.3.3. Genotypic Analysis 
Full-length env sequences of all the clones analyzed here were previously reported (2.3.3). 
Here it was investigated whether coreceptor usage in primary cells was associated with 
specific env sequence characteristics. Since the V3 loop region has been shown to be an 
important determinant of coreceptor usage we first focused on this region. There were no 
obvious env V3 loop sequence characteristics that distinguished between clones with 
differential capability to mediate entry into primary cells. The full env sequence was also 
analyzed to determine if any patterns that correlated with preferential coreceptor usage in 
primary cells or primary cell infectivity could be observed. There were no obvious amino 
acid differences that correlated with preferential coreceptor utilization or infectivity in 
primary cells for clones from isolates 96BW17, 99ZATM1B, 99ZASW20, 99ZASW30 and 
99ZACM9. However, there were numerous amino acid sequence changes throughout the env 
noted in 01ZADu36_5 #8, the only clone of isolate 01ZADu36_5 that was noninfectious in 
both primary cell types although the number of these amino acid differences made it difficult 
to pinpoint residues responsible for the unique phenotype of clone #8 in primary cells.. RP1 
#13 was the only clone of isolate RP1 displaying CXCR4-usage in both CD4+ T 
lymphocytes and MDM. In contrast, RP1 #10 was CXCR4-using in CD4+ T lymphocytes 
and noninfectious in MDM whereas clones #5, 6 and 8 were noninfectious in both cell types. 
Differences in amino acid residues at various positions were observed for RP1 #10 which had 
threonine (T) at position 591, proline (P) at position 612 and asparagine (N) at position 618 
whereas all other clones of this isolate had methionine (M) at position 591 and serine (S) at 






 591                                       612         618     
RP1 
Consensus  
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 31 34        44    238       248    332      443      
99ZASW20 
consensus  
MGNLWVTVYYGVPVWT  NNKTFNGTGPCHNVST  IGDVRQ  PPIAGN  
99ZASW30 
consensus  
VGLWVTVYYGVPVWRE  NVSTVQCTHGIKPVVS  EKDWNK  TSNITG  
99ZACM9 
consensus  
NLWVTVYYGVPVWKEA  FNGTGPCNNVSTVQCT  AHCNIS  GNITCT  
01ZADu36_5 
#2,7 & 9  
NLWVTVYYGVPVWKEA  NVSTVQCTHGIKPVVS  PDWNET  GGTTNG   
01ZADu36_5 
#8  
GGNLWVTVYYGVPVWK  CTNVSTVQCTHGIKPV  SPPDWN  TRDGGN  
01ZADu36_5 
#10  





Figure 3.6: Genotypic analysis 
A and B) Differences in amino acids at various positions are represented with the HxB2 positions 














































*** 0.3 1 
96BW17#3 -----------M--GIGRGQ----M-R---------- 5 8 1 
96BW17# 6 -----------M--GIGRGQ----M-R---------- 6 14 1 
96BW17#7 -----------M--GIGRGQ----M-R---------- 1 3 1 
96BW17#15 -----------M--GIGRGQ----M-R---------- 3 15 1 
99ZATM1B#3 ----------NV--GIGRGQ----N-----N------ 0.5 0.2 1 
99ZATM1B#5  ----------NV--GIGRGQ----N-----N------ 0.8 0.2 1 
99ZATM1B#6 ----------NV--GIGRGQ----M-R---N------ 0.4 0.8 1 
99ZATM1B#8 ----------NV--GIGRGQ----N-----N------ 0.4 0.3 1 
99ZATM1B# 13 ----------NV--GIGRGQ----N-----N------ 0.5 0.1 1 
RP1# 5 -I--G-----RV-LGIGPGQ------RV-R------- 4 NI
*** 1 
RP1# 6 -I--G-----RV-LGIGPGQ------RV-R------- 7 NI
*** 1 
RP1#8 -I--G-----RV-LGIGPGQ------RV-R------- NI
*** NI*** 1 
RP1# 10 -I--G-----RV-LGIGPGQ------RV-R------- 2 NI
*** 1 
RP1# 13 -I--G-----RV-LGIGPGQ------RV-R------- 0.05 0.1 1 
99ZASW20#2 -------------TGIGRGQ------Q---V-----  30 42 1 
99ZASW20#3 -------------TGIGRGQ------Q---V-----  72 60 1 
99ZASW20# 11 -------------TGIGRGQ------Q---V-----  48 75 1 
99ZASW20# 14 -------------TGIGRGQ------Q---V-----  43 75 1 
99ZASW20# 15 -----------V-IGIGRGHA--T—KV--N------- 42 80 1 
99ZASW30#1 -----------V--GIGRGHA--T-GKV--N------ 1 28 1 
99ZASW30#2 -----------V--GIGRGHA--T-GKV--N------ 2 53 1 
99ZASW30#3 -----------V--GIGRGHA--T-GKV--N------ 2 12 1 




99ZASW30#9 -----------V--GIGRGHA--T-GKV--N------ 2 3 1 
99ZACM9 #1 -A--G---I-R---..GPRYA---KET---------- 49 21 1 
99ZACM9 #2 -A--G---I-R---..GPRYA---KET---------- 50 25 1 
99ZACM9#16 -A--G---I-R---..GPRYA---KET---------- 49 23 1 
99ZACM9#18 -A--G---I-R---..GPRYA---KET---------- 56 19 1 
99ZACM9#21 -A--G---I-R---..GPRYA---KET---------- 52 23 1 
01ZADu36_5#2 ----D-KINMKRIKI.GPGRA-V--KG-R---R--Y- 12 0.3 1 




*** NI*** 1 
01ZADu36_5#9 ----D-KINMKRIKI.GPGRA-V--KG-R---R--Y- NI*** 17 1 
01ZADu36_5# 
10 
----D-KINMKRIKI.GPGRA-V--KG-R---R--Y-  41 4 1 
 
Figure 3.6: Genotypic analysis 
C) V3 sequence alignment and viral phenotype prediction. * Percentage of total entry in the 
presence of CXCR4 blocking. ** Predicted coreceptor phenotype based on R5X4 PSSM 
algorithm.  0=R5, 1=X4 or R5X4. ***NI=Non-infectious. 
 
 
Full env sequence analysis revealed that no major amino acid changes were observed in 
clones 99ZASW20 #3, 11, 12 and 15 and clones from 99ZASW30 where drug resistance in 
macrophages was seen. These clones all had amino acid valine (V) at position 248 and 
aspartic acid (D) at position 332. Valine was also present at position 248 in 01ZADu36_5 #2 
and 9 which also showed resistance to inhibition in macrophages. The same amino acid 
substitution was present in 01ZADu36_5 #7 which showed resistance in CD4+ T 
lymphocytes. Aspartic acid was also located at position 332 in 01ZADu36_5 # 10, where 
resistance to inhibition was seen in CD4+ T lymphocytes. However, clones from 99ZACM9 
displayed resistance to inhibition in macrophages but did not possess the above mentioned 
amino acids at the respective positions, suggesting a complex and subtle basis for resistance. 
94 
 
It was also investigated whether any similarities could be found between clones from 
99ZACM9, 99ZASW20 and 99ZASW30 in which resistance to inhibition by a combination 
of antagonists was observed in macrophages. Amino acid threonine (T) at position 238 was a 
common feature of all these clones. This was also observed in 01ZADu36_5 # 2 and 9 which 
showed resistance in macrophages and #7 where resistance was seen in CD4+ T 
lymphocytes. Clones from 99ZACM9 and clones 01ZADu36_5 #2, 7 and 10 all displayed 
resistance to inhibition in CD4+ T lymphocytes. All of these clones have shared unique 
amino acids of leucine (L) at position 31, threonine (T) at position 34, glutamic acid (E) at 
position 44 and threonine (T) at position 443. Clone #8 of 01ZADu36_5 which was 
noninfectious in both cell types and all other clones did not have these amino acids located at 
these respective positions (Figure 3.6B). 
 
The relationship between V3 sequences and CD4+ lymphocyte and monocyte derived 
macrophage coreceptor preference was further investigated (Figure 3.6C).  A substantial 
percentage of CCR5-usage was seen in both primary cell types despite C-PSSM prediction 
being X4/R5X4 for clones of 99ZASW20 and 99ZACM9. Significant CCR5 usage was also 
noted for 99ZASW30 #1 and 2 and 01ZADu36_5 #10 in monocyte derived macrophages, 
despite a C-PSSM score predictive of X4/R5X4 phenotype. For most clones a C-PSSM score 
of 1 indicating X4/R5X4-usage correlated with the calculated percentage of CCR5-use in 







Chemokine receptors play an important role in the initiation of HIV-1 infection at the cellular 
level. Chemokine receptor utilization is also an important determinant of the rate of disease 
progression. Due to the emerging availability of entry inhibitors such as the CCR5 
antagonists for the clinical management of HIV-1 infection, it has become increasingly 
important to better characterize coreceptor utilization and cellular tropism by HIV-1 isolates 
as well as to understand the mechanisms underlying coreceptor switch and evolution in the 
course of infection particularly in regions heavily affected by HIV/AIDS. Previously, 35 full-
length env clones from seven dual tropic isolates of HIV-1 subtype C were generated. It was 
found that in transformed cell lines that express either CXCR4 or CCR5, most of the 
pseudovirus clones from these isolates were CXCR4 utilizing (85.7%), with a minority of 
R5X4 clones (14.3%) and virtually no R5 clones detected (refer to 2.3.3). Here, the 
coreceptor utilization profile of these clones using the spinnoculation method of cell infection 
was re-evaluated and based on this approach, 57% of the clones were R5X4 and 43% were 
X4. However, even dual tropic clones generally preferred CXCR4 usage. Nevertheless, both 
approaches confirmed the absence of R5-only pseudovirus clones from the 35 clones 
generated from the 7 dual tropic isolates. For a significant majority of clones, results were 
exactly the same in spite of the methodology used for infection. The finding that the 
spinnoculation method resulted in higher infectivity of U87.CD4.CCR5 cells is consistent 
with the observation by O’Doherty and colleagues (O'Doherty et al. 2000) where it was noted 
that the spinnoculation method which involves allowing cell/virus contact by centrifugation 
at 1,200 x g for 2 hours is better at facilitating productive cell infection.  This study shows 
that differences in coreceptor usage classification can be obtained from using different 
methodologies to infect target cells and highlight the need for caution in interpreting and 
comparing data across studies that use varied infection protocols. 
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It is generally assumed that virus coreceptor usage determination in transformed cells predicts 
coreceptor preference in vivo where the main target cells of HIV-1 are primary lymphocytes 
and macrophages although significant differences have previously been reported (Yi et al. 
2005). In addition, genotypic methods do not always predict coreceptor usage especially in 
distinguishing X4 and R5X4 viruses (Garrido et al. 2008; Low et al. 2007). Data on 
coreceptor usage in primary cells and genotypic prediction algorithms is particularly lacking 
for HIV-1 subtype C which is the predominant subtype globally and which appears to be 
unique in coreceptor evolution. 
 
 In the current study therefore, the coreceptor utilization profile of HIV-1 subtype C clones in 
transformed cell lines was compared to the coreceptor utilization profile in primary CD4+ T 
lymphocytes and monocyte derived macrophages. HIV-1 subtype C Env clones determined to 
be R5X4 or X4 in transformed cell lines used either both the CCR5 and CXCR4 or 
exclusively the CXCR4 pathway for entry. The coreceptor utilization profiles were the same 
in transformed cell lines and in both primary cell types, CD4+ T lymphocytes and MDM for 
20 of 35 (57%) clones. One clone (2.9%) was dual tropic (R5X4) in transformed cell lines but 
CXCR4-only using in both primary cell types. One clone (2.9%) was X4 in U87 cells and 
CD4+ T lymphocytes but was not infectious in MDM. Five clones (14.3%) were R5X4 in 
U87 cells and CD4+ T lymphocytes but used only CXCR4 in MDM. Two clones (5.7%) 
were CXCR4-using in transformed cell lines but were R5X4 in both primary cell types. Two 
clones (5.7%) that were R5X4 in U87 cells used CXCR4 only in MDM but were not 
infectious in CD4+ T lymphocytes. The remaining four (11.4%) of 35 clones showed CXCR4 
usage in transformed cell lines but were non-infectious in both primary cell types. Thus while 
results showed that in a majority of cases (57%) there is a concurrence in coreceptor 
utilization profile between transformed and primary cells, there was discordance between 
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results obtained in transformed versus primary cells in 43% of cases. These results underline 
the need to further study the determinants of coreceptor usage in primary cells since 
coreceptor antagonists will need to prevent infection of target cells in vivo.        
 
When both the CCR5 and CXCR4 pathways were utilized for entry there was a striking bias 
towards CXCR4 preference in both CD4+ T lymphocytes and MDM for the majority of the 
pseudoviruses as was the case in transformed cell lines. This observation, combined with the 
observation that X4 and dual tropic but nor R5 clones were predominant among dual tropic 
isolates are consistent with the suggestion that CCR5 coreceptor utilization is rapidly lost as 
dual tropic isolates emerge during HIV-1 infection (Coetzer et al. 2008). However, it is worth 
noting that clones from isolate 99ZASW20 used both CCR5 and CXCR4 almost equally in 
CD4+ T lymphocytes and were biased towards CCR5 in MDM. Two clones derived from 
isolate 99ZACM9 (# 1 and 16) used both CCR5 and CXCR4 with similar levels of efficiency 
in CD4+ T lymphocytes but clone #1 was exclusively CXCR4-using in macrophages and 
clone #16 preferred using CXCR4 in macrophages. Further studies will be needed to address 
whether such dual tropic clones with preferential CCR5 utilization represent earlier phases in 
virus coreceptor evolution, suggesting a sequential shift and adaptation where CCR5 usage is 
progressively lost as CXCR4 usage emerges as opposed to a sudden shift to X4 phenotype. 
 
The results on the ability of dual tropic strains to use both CCR5 and CXCR4 on primary 
cells, albeit with a high degree of heterogeneity in efficiency of utilization are consistent with 
the findings of Ghezzi and colleagues who reported similar diverse dual tropic HIV-1 subtype 
B Env phenotypes in primary cells (Ghezzi et al. 2001).  However, results on HIV-1 subtype 
C viruses are somewhat in contrast to the findings of Yi et al. who showed that while several 
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subtype B R5X4 primary and prototype strains used both CCR5 and CXCR4 for infection of 
MDM, they were restricted to usage of CXCR4 only for entry and infection in peripheral 
blood lymphocytes even though CCR5 was present and could be utilized by R5-using strains 
(Yi et. al., 2005). A possible explanation for these differences could be the particular virus 
strains studied. In turn, these virus strain differences could be associated with the specific 
timing or phase of coreceptor evolution. Longitudinal studies in patients undergoing 
coreceptor usage switch will be needed to further understand these differences.  
 
Most clones in this study were sensitive to coreceptor inhibitors but some appeared to be 
resistant as they did not exhibit complete inhibition in both primary cell types even when a 
combination of antagonists was used. This was observed for some clones of isolates 
99ZASW20, 99ZASW30, 99ZACM9 and 01ZADu36_5. It is noteworthy that although 
clones from isolates 99ZASW20 and 99ZASW30 were inhibited in CD4+ T lymphocytes, 
complete inhibition was not observed in MDM. Clones from isolates 99ZACM9 and 
01ZADu36_5 displayed a similar pattern of inhibition in both cell types.  This led to the 
investigation of whether these viruses were truly resistant to the inhibitors. Results from 
transformed cell line infections confirmed that some of the env clones had a natural resistance 
to the CXCR4 inhibitor AMD3100. Results obtained suggest that it is unlikely that alternate 
coreceptors played a role since experiments in U87.CD4 cells confirmed the pattern observed 
in primary cells. It can therefore be concluded that some HIV-1 subtype C envelope proteins 
display natural resistance to chemokine receptor antagonists. Further studies will be needed 




Genotypic analysis of env clones in this study suggested that subtle or complex amino acid 
patterns likely contribute to the phenotype differences observed between transformed cell 
lines and primary cells since no obvious amino acid changes or patterns were noted. A 
limitation of this study is that primary cells from diverse donors may differ in expression 
levels and cell surface configuration of coreceptors, making it difficult to assess the extent to 
which the results obtained in this study can be generalized. However, it is noteworthy that for 
PBMCs from 2 different donors used in this study, results were comparable suggesting that 
the Env properties described here are unlikely to have been influenced by the donor 
phenotype.    
 
This is the first study to examine correlation of coreceptor usage between transformed cell 
lines and primary T cells for HIV-1 subtype C envelope clones. It can be concluded that 
while coreceptor usage assessment in reporter cell lines accurately predicts coreceptor usage 
in a majority of cases, important differences exist in a minor but significant proportion of 
cases. In addition, as shown in this study most HIV-1 subtype C dual tropic env clones are 
capable of using both CCR5 and CXCR4 in both CD4+ T lymphocytes and MDM. However, 
a diverse repertoire of phenotypes existed, with most clones displaying a bias for the CXCR4 
coreceptor over CCR5, although there were also notable exceptions. Finally, it is also noted 
that there are several HIV-1 subtype C Env clones with apparent natural resistance to 
coreceptor antagonists. Further studies to address genetic basis for biased coreceptor 








Drug Resistance and Viral Tropism in HIV-1 Subtype C-Infected Patients in KwaZulu-
Natal, South Africa:  Implications for Future Treatment Options 
 
4.1. Introduction 
South Africa has the highest number of HIV infections worldwide and the province of 
KwaZulu-Natal accounts for the highest estimated percentage (39%) of infections among 
women attending antenatal clinics in the country (UNAIDS 2007).  The most frequently 
encountered HIV-1 genetic strain in South Africa and in KwaZulu-Natal is HIV-1 subtype C 
(HIV-1C) and this subtype accounts for more than half of the global infections (Esparza 
2005; Hemelaar et al. 2006; Visawapoka et al. 2006). Access to HAART in South Africa has 
increased  dramatically since the launch of the Operational Plan for Comprehensive HIV and 
AIDS Care and Treatment for South Africa in 2003 
(http://www.info.gov.za/otherdocs/2003/aidsplan/report.pdf.). As a consequence of this 
uptake, South Africa now has the largest antiretroviral therapy programme in the world 
although the proportion of people on HAART to those needing treatment remains low with 
only an  estimated 28% of infected people receiving HAART by the end of 2007 
(www.doh.gov.za).  
 
It is important to note that even in the presence of HAART and undetectable viremia in 
chronic HIV-1 infection, viral transcriptional activity persists, suggesting that there is 
ongoing low-level replication or transcriptionally active latent infection (Furtado et al. 1999; 
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Tobin et al. 2005). This ongoing viral replication can lead to emergence and persistence of 
drug resistance, which poses a significant public health threat. Drug resistance is of particular 
concern in resource-poor countries, because intense Virologyogical monitoring is not always 
affordable or feasible resulting in the use of clinical or immunological algorithms to guide the 
use of HAART (WHO guidelines, 2006). The use of these algorithms may inadvertently lead 
to a delay in the switching of failing HAART regimens. The delay in the switch of failing 
HAART regimens in the developing world, where WHO guidelines recommend the use of 2 
nucleoside reverse-transcriptase inhibitors (NRTIs) and one non-nucleoside reverse-
transcriptase inhibitor (NNRTI) as first line therapy may in turn result in the unintended 
consequences of the accumulation of thymidine analog mutations (TAMs) which are 
associated with broad cross resistance and may therefore severely limit the options available 
for second line therapy. A recent study from Malawi has highlighted this emerging problem 
although it remains unclear how widespread the problem is and there exists data to suggest 
that the accumulation of TAMs in resource-poor settings is lower than would have been 
anticipated under current guidelines and practices (Cozzi-Lepri et al. 2009; Hosseinipour et 
al. 2009). 
 
In addition to concerns regarding the emergence of TAMs in resource-poor settings, there is 
inconclusive evidence that individuals failing HAART may have a higher proportion of 
chemokine receptor CXCR4-utilizing viruses compared to antiretroviral naïve patients (Hunt 
et al. 2006; Johnston et al. 2003; Marconi et al. 2008).  During the early stages of HIV-1 
infection, CCR5-utilizing viruses (R5 viruses) predominate whereas X4 and R5X4 variants, 
which are associated with rapid disease progression, emerge in the late chronic phase of 
disease in a significant proportion of patients (Connor et al. 1997; Scarlatti et al. 1997). 
Several studies have shown that although all subtypes can undergo the switch from the 
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utilization of CCR5 to CXCR4, this is less frequently observed in HIV-1C infections even in 
late stages of disease (Bjorndal and Sonnerborg 1999; Cecilia et al. 2000; Cilliers et al. 2003; 
Ndung'u et al. 2006; Tscherning et al. 1998). The predominant utilization of CCR5 by HIV-
1C could be interpreted to suggest that CCR5 antagonists would be more efficacious in this 
setting as salvage therapy in patients failing the current classes of drugs. However, in a study 
in Zimbabwe, where HIV-1 subtype C predominates, Johnston and coworkers found a high 
frequency (50%) of CXCR4-tropic viruses in patients failing partially suppressive ARV 
therapy while no such viruses were found in ARV-naïve patients although the CD4 cell 
counts were comparable between the two groups (Johnston et al. 2003). This study suggested 
that ARV therapy may be selecting for the more virulent X4 strains in subtype C infection. A 
higher proportion (41%) of dual/mixed or X4-tropic viruses was also encountered in HIV-1 
subtype B treated individuals as compared to 18% of treatment-naïve individuals (Hunt et al. 
2006). Due to the emergence of drug resistance to NRTIs, NNRTIs and PIs, CCR5 entry 
inhibitors may represent an important salvage option but only if individuals failing treatment 
harbor exclusively R5 viruses (Heera et al. 2009; Vandekerckhove et al. 2009). Alternatively, 
if duration of infection or HAART facilitates the emergence of X4 viruses, CCR5 inhibitors 
may have to be applied as part of first-line/early regimens for maximum benefit. Maraviroc, a 
CCR5 inhibitor has been approved by the  Food and Drug Administration (FDA) as long as 
the tropism assay has been performed prior to its use 
(http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivitie
s/ucm124198.htm). Hoever, since the tropism assay is an expensive procedure it is not 
feasible to perform this assay on all patients in South Africa.             
 
Here the prevalence and patterns of drug resistance mutations in individuals failing 
antiretroviral therapy in a resource-poor setting where HIV-1 subtype C predominates was 
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studied. The drug resistance mutational pathways and factors associated with failure of first-
line HAART in an area where monitoring relies mainly on clinical and immunological 
algorithms was sought to be understood. Furthermore, coreceptor utilization profiles of HIV-
1C viruses from individuals initiating or failing HAART was determined to assess the 
usefulness of CCR5 antagonists either as first-line or salvage therapy in this setting. The 
accuracy of env sequence based genotypic predictive algorithms in assessing the prevalence 
of R5 and X4 viruses in patients initiating or failing HAART was also explored.    
 
4.2. Materials and methods 
4.2.1. Study Participants:  
Study participants were recruited from the Sinikithemba outpatient HIV/AIDS clinic at 
McCord hospital in Durban, KwaZulu-Natal, South Africa.  Patients were included in the 
ARV-naïve cohort if they were at least 18 years of age, were HIV positive and had no 
prior history of ARV therapy (the use of single dose nevirapine for the prevention of 
mother to child HIV transmission was not an exclusion criteria). Patients who met these 
criteria as well as had a CD4+ T-cell count of ≤ 200 cell/µl or displayed AIDS defining 
clinical features according to WHO staging irrespective of CD4 counts or viral loads 
were recruited into this study. Patients were included in the ARV-failing arm if they 
were at least 18 years of age, had a known HIV infection, an HIV-1 RNA of ≥5,000 
copies/ml, a CD4 cell count of <200/µl and had at least 6 months of uninterrupted ARV 
therapy. HAART-failing patients were also recruited into the study if they clinically 
assessed to be failing therapy irrespective of CD4+ T-cell counts. A total of 45 HAART-
failing and 45 HAART-naive patients were recruited. All study participants gave written 
informed consent and the study was approved by the Biomedical Research Ethics 
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Committee (BREC), UKZN. Following consent to participate in the study, further 
clinical and demographic data were collected and these are summarized in Table 4.1. 
 
Table 4.1: Patient information 
Patient Characteristic ARV-Experienced 
Patients failing 
Treatment (n=45)  
ARV-Naïve Patients (n=45) p-value 
Age, median years  
(Q1-Q3) 
36 (24-51) 36 (20-78) 0.65 
Gender: Female 28 (65%) 27 (60%)  
Black race 45 (100%) 45 (100%)  




   
Current 174  (9-718) 123 (8-660) 0.036 
Nadir 57 (3-197)          
 
 0.0004 







WHO stage at visit  
  I 
  II 
  III 
  IV 
 
29 (64 %) 
3 (7 %) 
0 (0 %) 








Current treatment regimen:  
  Regimen 1A  
      (d4T, 3TC, EFV) 
  Regimen 1B  
      (d4T, 3TC, NVP) 
ZDV/AZT, d4T, ddI, NVP 
ZDV/AZT, d4T, 3TC, EFV 














Change in ARVs from initial 
regimen 
27 (60%)   
Duration of ARV therapy, 
median months 
29 (7-100)   
 
4.2.2. Sample collection, Viral Load and CD4 Measurement  
Thirty-five milliliters of blood was obtained in an ethylene-diaminetetraacetic acid 
(EDTA) vacutainer or acid citrate dextrose (ACD) tubes for viral load quantification, 
CD4 cell counts, genotypic resistance testing and viral tropism studies. CD4 + T cell 
counts were determined from fresh blood from all HIV-infected participants using the 
FACS MultiSET System and analyzed on the four-colour FACS Calibur flow cytometer 
(Becton-Dickinson, Franklin Lakes, NJ, USA) according to the manufacturer’s 
instructions. Plasma viral load measurements were done using the quantitative COBAS 
AmpliPrep/COBAS Amplicor HIV-1 Monitor Test, version 1.5 (Roche Diagnostics, 
Rotkruez, Switzerland). 
 
4.2.3. Genotypic resistance testing 
Vacutainer tubes containing approximately 10 ml blood were gently inverted to ensure 
that the blood was properly mixed. The tubes were then centrifuged at 2,200 rpm for 10 
minutes (Jouan C412) and the plasma aliquotted and stored for genotypic resistance 
testing using the Viroseq HIV-1 Genotyping System (Celera Diagnostics, CA, USA) as 





4.2.4. Phenotypic coreceptor analysis 
Coreceptor usage of viruses from patient plasma samples was determined using the 
Trofile Coreceptor Tropism Assay (Monogram Biosciences, San Francisco, California, 
USA). The Trofile assay is a commercial, standardized cell-based approach which assists 
in determining coreceptor tropism by testing all determinants of tropism in the gp160 
coding region of the envelope protein (Coakley et al. 2005; Westby et al. 2006).    
 
4.2.5. cDNA synthesis, envelope amplification and cloning 
PBMCs were separated from whole blood by density-gradient centrifugation on Ficoll-
Paque (Amersham Biosciences, Uppsala, Sweden). The plasma layer was removed and 
used for RNA extraction using the QIA-amp Viral RNA Kit (Qiagen, Germany) and 
cDNA was synthesised using the Superscript III Reverse Transcriptase Kit (Invitrogen 
Carisbad, CA). The following components were pipetted into a 0.5 ml RNase-free tube: 
8.75 µl water, 1.25 µl 20 µM primer (OMF19 - 
5’GCACTCAAGGCAAGCTTTATTGAGGCTTA3’), 5µl dNTP mix (10 mM) and 50 
µl RNA template. This mixture was placed at 65ºC for 3-5 minutes and then cooled on 
ice for 1 minute. The following components were then combined in a second tube: 20 µl 
5 x buffer, 5 µl DTT (100 mM), 5 µl RNaseOUT (40 u/µl) and 5 µl SSIII RT (200 u/µl). 
These ingredients were then added to the original tube, mixed and incubated at 50ºC for 
one hour and the temperature then increased to 55ºC for one hour. SSIII RT was then 
inactivated by heating at 70ºC for 15 minutes. Thereafter, 1 µl RNase H was added to the 




The 3 kb env gene was amplified by a nested polymerase chain reaction (PCR) using the 
Platinum Taq High Fidelity System (Invitrogen, Carisbad, CA) and the following 
primers in the first round: OMF19 -5’GCACTCAAGGCAAGCTTTATTGAGGCTTA3’ 
and VIF1 – 5’GGGTTTATTACAGGGACAGCAGAG3’. Cycling conditions were as 
follows: a 4 minute denaturation at 94°C, followed by 35 cycles of 15 seconds at 94°C, 
30 seconds at 55°C, and 4 minutes at 68°C. The final extension was at 68°C for 20 
minutes.  For the second round PCR, 5 µl of first round template was then amplified 
using the Phusion Phusion Hot Start High-Fidelity DNA Polymerase kit (Finnzymes, 
Finland) together with the following primers: Env1A 5’-
CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3’ and EnvM 5’-
TAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3’. The forward primer Env1A was 
designed to include the 4 base pair sequences (CACC) necessary for directional cloning 
on the 5’ end. Cycling conditions were as follows: a 5 minute denaturation at 94°C, 
followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 55°C, and 4 minutes at 72°C. 
The final extension was at 72°C for 10 minutes (as in 2.2.5). The amplified product was 
then run on a 1% agarose gel and gel purified using the Qiaquick gel extraction kit 
(Qiagen, Germany).  
 
Once the DNA was purified, one env from 20 ARV-failing patients and 20 ARV-naïve 
patients was cloned into the pcDNA3.1D/V5-His-TOPO vector (Invitrogen, Carisbad, 





4.2.6. Envelope sequencing and sequence analysis  
After cloning, the env gene was sequenced using the ABI PRISM Big Dye Terminator 
Cycle Sequencing Ready Reaction kit version 3.1 (Applied Biosystems, CA, USA). 
Sequences were assembled and edited using Sequencher 4.8 and aligned with Mega 4. 
To evaluate the clustering of these sequences with each other and with subtype 
references, phylogenetic trees were constructed in Paup 4.0 and visualized using 
Treeview 1.6.6. Coreceptor utilization was predicted using the web-based subtype C-
specific position specific scoring matrix (C-PSSM) programme 
(http://indra.mullins.microbiol.washington.edu/pssm/), a bioinformatics tool that reliably 
predicts coreceptor phenotype using V3 loop sequences (Jensen et al. 2006). Predicted 
N-linked glycosylation sites were examined using the web-based programme N-
GLYCOSITE (www.hiv.lanl.gov).  
 
4.2.7. Statistical Analysis 
All statistical analysis was done using Graph Pad Prism 5. Factors associated with 
tropism were assessed using unpaired t tests and Fisher’s exact tests. 
 
4.3. Results 
4.3.1. Patient Demographics 
Forty five HAART-naïve and 45 HAART-failing patients were recruited for this study. 
Table 4.1 shows patient information as well as drug regimens, viral loads and CD4+ T-
cell counts at the time of recruitment. For patients failing therapy, nadir CD4 counts are 
also represented. All patients were Black African. The median age for both groups was 
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36 years.  Majority of patients in both groups were female - 60% of HAART-naïve 
patients and 65% HAART-failing patients. The median CD4+ T-cell count at the time of 
recruitment was 123 cells/mm
3
 for HAART-naïve patients and 174 cells/mm
3
 for 
HAART-failing patients, a significant difference between the two groups (p=0.036). 
CD4+ T cell counts at recruitment were also significantly different between the two 
groups, with HAART-naïve individuals having a median of 123 cells/µl compared to 
HAART-failing patients with a median of 174 cells/µl (p=0.0004). The median nadir 
CD4+ T cell count for HAART-failing study subjects was 57 cells/µl. HAART-naïve 
patients had significantly higher median plasma viral load of 44,042 copies/ml compared 
to 6,653 copies/ml for HAART-experienced participants (p=0.001). For patients failing 
treatment, the median duration on therapy was 29 months. Drug regimens at the time of 
sampling are listed in Table 4.1.  
 
4.3.2. Genotypic Drug Resistance Typing 
Drug resistance results were obtained for 43 of the 45 HAART-failing patients. 
Resistance testing was also performed for ten HAART-naïve patients. The only major 
drug resistance mutation observed in the HAART-naïve individuals was in one patient 
with the NNRTI-associated E138A mutation. Three HAART-naive patients had minor 
protease inhibitor (PI) resistance mutations, one patient with mutations L10L/V and 
T74S/T, another had mutation A71T and the third patient had the T74S/T mutation. Of 
the 45 HAART-failing patients, 51.1% were on South African national treatment 
guidelines Regimen 1A (d4T, 3TC and EFV); 4.4% were on Regimen 1B (d4T, 3TC and 
NVP), 29% were on ZDV/AZT/ZDV 3TC and EFV; 8.9% were on ZDV/AZT/ZDV, 
3TC and NVP; 2.2% were on ZDV/AZT/ZDV, d4T, ddI and NVP and 4.4% were on 
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ZDV/AZT/ZDV, d4T, 3TC and EFV. Twenty seven (60%) of the patients were on 
previous ARV therapy. Of this, 11/27 (40.8%) had previous history of Regimen 1A. 2/27 
(7.4%) had a previous history of d4T, 3TC, NVP and EFV; 2/27 (7.4%) had a previous 
history of d4T and NVP and 1/27 (3.7%) each had previous history of the following: 
ZDV/AZT, d4T, 3TC, ddI, EFV; d4T, NVP, EFV; ZDV/AZT, 3TC, NVP, 
Lopinivir/Ritonivir; ZDV/AZT, d4T, EFV; ZDV/AZT, 3TC, Lopinivir/Ritonivir; 
ZDV/AZT, d4T, 3TC, NVP; d4T, 3TC; ZDV/AZT, d4T, NVP; 3TC, ddI, EFV; 
ZDV/AZT, 3TC, EFV; d4T, 3TC, ddI, EFV;  and ZDV/AZT, 3TC,ddI (Table 4.1). 
The specific drug resistance amino acid substitutions detected, mutation frequency and 
pathways in HAART-failing patients are shown in Figure 4.1. Mutations to all three 
major classes of drugs were noted. The prevalence of mutations and mutational pathways 
are summarized in Figure 4.1.  Forty one of the 43 (95%) ARV-failing patients possessed 
at least one drug resistance mutation. Ninety one percent of patients had at least one drug 
resistance mutation against 2 classes of drugs (nucleoside reverse transcriptase inhibitors 
(NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). Nineteen percent 
had at least one resistance mutation against all 3 classes of drugs (NRTI, NNRTI and PI). 
For PI, only one minor mutation (T74S) was present in 9 of the HAART-failing patients 
(20%). M184V/I, present in 87% of HAART-failing patients was the most common 
NRTI mutation detected. Thymidine analog resistance mutations (TAMs) were detected 
in 55% of patients. The TAM1 pathway NRTI mutations M41L and T215Y, associated 
with intermediate to high level resistance to ZDV/AZT and d4T and low level resistance 
to ddI, ABC and TDF (Whitcomb et al. 2003)  were present in approximately 9% of 
patients. Neither an insertion at codon 69 nor the L210W mutation, both also indicative 
of the TAM1 pathway was noted. The TAM2 pathway mutations present were D67N, 
K70R, T215F and K219EQR. Forty four percent of patients had TAM2 pathway 
111 
 
mutations. Seven percent of patients possessed both TAM1 and TAM2 mutations and 
16% had three or more TAMs. Approximately 91% of patients had high level resistance 
to 3TC and FTC, 19% had high or intermediate level resistance to ZDV/AZT. Fourteen 
percent had high or intermediate level resistance to d4T while 9% had high level 
resistance or intermediate resistance to ddI. High or intermediate level resistance to ABC 
was noted in 28% of patients, while only 7% displayed high or intermediate level 
resistance to TDF (Figure 4.1A). 
 






























































































































































































Figure 4.1: Frequency of drug resistance mutations and thymidine analog 
resistance mutations (TAMs) 
A) shows the frequency of NRTI resistance mutations, thymidine analogue mutation 
frequencies and number of patients displaying high and intermediate level resistance to 
specific NRTIs and B) shows the frequency of NNRTI resistance mutations and the number 
of patients showing resistance to specific NNRTIs. C) shows the frequency of TAMs 







higher percentage of TAM2 than the other two studies, and there is a sharp increase in 
proportion of patients with TAMs in patients failing therapy in this study compared to the and 
earlier study (Marconi et al, 2008) from the same health setting. 
 
 
NNRTI mutations noted are summarized in Figure 4.1B. The most common NNRTI 
resistance mutation was V106M, found in 49% of HAART-failing participants. The 
K103N (40%) and G190A (27%) mutations were also relatively common but no G190S 
mutations were present in any of the patients. V106M and K103N both cause high-level 
resistance to 3 of the 4 NNRTI: nevirapine (NVP), delavirdine (DLV) and efavirenz 
(EFV) but has no effect on etravirine (ETR). G190A causes high level resistance to NVP, 
intermediate resistance to EFV and low level resistance to ETR. This mutation also 
increases susceptibility to DLV (http://hivdb.stanford.edu). Ninety-five percent of 
patients had mutations associated with high level resistance to NVP, 93% had 
high/intermediate level EFV resistance mutations. Ninety three percent displayed high or 
intermediate level resistance to DLV, with 49% displaying high/intermediate level 
resistance to ETR (Figure 4.1B).     
 
Recent studies in southern Africa have highlighted the growing problem of thymidine 
analog mutations in patients receiving the World Health Organization (WHO) or national 
antiretroviral programmes recommended first-line therapy (Hosseinipour et al. 2009; 
Marconi et al. 2008; Novitsky et al. 2007).  The prevalence of these mutations may be 
increasing as antiretroviral roll-out accelerates, accompanied by mainly clinical and 
immunological based monitoring of treatment.  The proportion and patterns of TAM 
mutations observed in this study was therefore compared to data reported from earlier 
studies from similar geographic and social-economic background. Fifty-five percent of 
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individuals failing therapy had TAM mutations compared to 32% and 74% reported from 
the South Africa and Botswana respectively (Marconi et al. 2008; Novitsky et al. 2007) 
(Figure 4.1C).  Patients in the current study were recruited from the same healthcare 
facility as those analyzed in the study by Marconi and colleagues and generally followed 
the same treatment guidelines and overall clinical care. In the Botswana study, patients 
were predominantly on a regimen containing ZDV/AZT and ddI. In all three studies, 
there were higher proportions of TAM2 compared to TAM1 mutations, with 
substantially higher percentage of mixed TAM1 and TAM2 noted in the Botswana study. 
It was further investigated whether the duration of treatment was associated with the 
development of TAMs. A non-significant trend between the presence of TAMs and the 
duration of treatment (p=0.08) was obtained.   
 
4.3.3. Coreceptor utilization  
4.3.3.1. Phenotypic Coreceptor Analysis 
The Trofile coreceptor tropism assay was used to determine viral tropism of plasma 
derived viruses. Only 75 samples (32 from ARV-experienced patients failing treatment 
and 43 from ARV-naive patients) yielded reportable data. Overall, 31/75 (41%) were 
dual/mixed viruses, 43/75 (57%) were CCR5-using, and only 1 (1%) was CXCR4-
utilizing. Of the 43 ARV-naive patients, 30 (70%) possessed R5 viruses compared to 13 
(30%) with dual/mixed viruses. No ARV-naive patients exhibited exclusive X4 viruses 
in this assay. Of the 32 ARV-experienced patients failing treatment, 13 (41%) possessed 
R5 viruses, 18 (56%) had dual/mixed infections while one patient (3%) had X4-only 
viruses (Figure 4.2A, Table 4.2). Thus patients failing treatment had a higher percentage 
(59%) of X4/dual/mixed viruses compared to ARV-naive patients with  30% and 
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conversely, ARV-naive patients had higher proportion of R5 viruses (70%) compared to 


































































































































































































Figure 4.2: Relationship of viral tropism of ARV-naive and ARV-failing patients 
A) Frequency of X4/dual/mixed- and R5-utilizing viruses in patients failing treatment and 
treatment-naive individuals. Bar graph indicating results from the trofile assay. A significant 
p value of p<0.02 was obtained. B) CD4 counts and coreceptor usage in HAART-naive 
patients and HAART-failing patients. Dot graph indicating results from trofile assay. ARV-
naive patients with X4/D/M viruses had a lower CD4 count than ARV-naive patients with R5 
viruses (p=0.014). ARV-failing patients with X4/D/M viruses had a lower CD4 count than 
ARV-failing patients with R5 viruses (p=0.02). For ARV-failing patients nadir CD4 counts 
are respresented C) Viral loads and coreceptor usage in HAART-naive patients and HAART-
failing patients. Dot graph indicating results from trofile assay. ARV-naive patients with R5 
viruses had a higher viral load than ARV-failing patients with R5 viruses (p=0.04).  D) 
Association of TAMs in X4/D/M viruses. Bar graph indicating trofile assay results. D/M 














704MC001F R5X4-using 704MC001N CCR5-using 
704MC002F R5X4-using 704MC002N CCR5-using 
704MC003F CCR5-using 704MC003N CCR5-using 
704MC004F CCR5-using 704MC004N CCR5-using 
704MC005F R5X4-using 704MC005N R5X4-using 
704MC006F Non-reportable 704MC006N R5X4-using 
704MC007F  Non-reportable 704MC007N R5X4-using 
704MC008F CCR5-using 704MC008N CCR5-using 
704MC009F R5X4-using 704MC009N CCR5-using 
704MC010F Non-reportable 704MC010N R5X4-using 
704MC011F CCR5-using 704MC011N R5X4-using 
704MC012F Non-reportable 704MC012N CCR5-using 
704MC013F Non-reportable 704MC013N CCR5-using 
704MC014F R5X4-using 704MC014N CCR5-using 
704MC015F CCR5-using 704MC015N CCR5-using 
704MC016F R5X4-using 704MC016N R5X4-using 
704MC017F R5X4-using 704MC017N CCR5-using 
704MC018F CCR5-using 704MC018N R5X4-using 
704MC019F Non-reportable 704MC019N CCR5-using 
704MC020F CXCR4-using 704MC020N CCR5-using 
704MC021F CCR5-using 704MC021N CCR5-using 
704MC022F  R5X4-using 704MC022N Non-reportable 
704MC023F Non-reportable 704MC023N R5X4-using 
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704MC024F  Non-reportable 704MC024N CCR5-using 
704MC025F R5X4-using 704MC025N CCR5-using 
704MC026F CCR5-using 704MC026N CCR5-using 
704MC027F R5X4-using 704MC027N R5X4-using 
704MC028F Non-reportable 704MC028N R5X4-using 
704MC029F CCR5-using 704MC029N CCR5-using 
704MC030F CCR5-using 704MC030N CCR5-using 
704MC031F CCR5-using 704MC031N CCR5-using 
704MC032F R5X4-using 704MC032N CCR5-using 
704MC033F CCR5-using 704MC033N CCR5-using 
704MC034F Non-reportable 704MC034N CCR5-using 
704MC035F R5X4-using 704MC035N CCR5-using 
704MC036F R5X4-using 704MC036N CCR5-using 
704MC037F R5X4-using 704MC037N R5X4-using 
704MC038F R5X4-using 704MC038N CCR5-using 
704MC039F R5X4-using 704MC039N Non-reportable 
704MC040F Non-reportable 704MC040N CCR5-using 
704MC041F Non-reportable 704MC041N CCR5-using 
704MC042F R5X4-using 704MC042N CCR5-using 
704MC043F Non-reportable 704MC043N R5X4-using 
704MC044F R5X4-using 704MC044N CCR5-using 
704MC045F CCR5-using 704MC045N R5X4-using 
 
It was then sought to determine if there was a relationship between CD4 counts, viral 
loads and viral tropism. Using the nadir CD4 count for patients failing treatment, it was 
found that patients with X4/dual/mixed viruses had significantly lower CD4+ T cell 
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counts compared to those with R5 viruses in both the ART-naive and ART-failing 
groups with significant p values of 0.014 and 0.002 respectively, whereas no significant 
differences were found between failures and naives with R5 viruses (p=0.07) and 
X4/dual/mixed viruses (p=0.06). ART-naive patients harbouring R5 viruses had a 
significantly higher viral load than patients failing treatment (p=0.04) (Figure 4.2C). 
Studies have suggested that the emergence of CXCR4-using viruses is a consequence of 
duration of infection. Thus it was next investigated whether the presence of 
dual/mixed/X4 viruses was associated with age in this cohort of patients. No significant 
correlation (p=0.29) was observed. It was then sought to determine if the length of 
treatment was associated with the presence of dual/mixed/X4 viruses, but no such 
relationship (p=0.95) was observed.  It was also investigated whether patients with 
TAMs were more likely to harbor dual/mixed/X4 viruses. Eleven of 16 (69%) HAART-
failing patients with TAMs had X4/dual/mixed viruses and 5 (31%) had CCR5-using 
viruses, compared to the respective proportions of 50% dual/mixed/X4 versus 50% R5 
among patients without TAMs (p=0.47) (Figure 4.2D).  
   
4.3.3.2. Genotypic Analysis of the env gene 
HIV-1 envelope sequence determines coreceptor utilization (Briggs et al. 2000; Cann et 
al. 1992; Fouchier et al. 1992; Rizzuto et al. 1998; Wu et al. 2006). Envelope sequence 
based genotypic coreceptor prediction algorithms offer a simpler and less expensive 
means of analyzing viral tropism in patients and could facilitate easier determination of 
whether a patient can be treated with CCR5 antagonists or not, particularly in resource-
limited settings where phenotypic assays are too expensive and not readily available. The 
extent to which viral tropism could be predicted by env sequence characteristics was next 
assessed. Randomly 20 Virologyogically failing and 20 ARV-naïve patients were 
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selected and analyzed full-length env sequences for predictive coreceptor utilization 
profiles.  
 
All 40 full-length env clones generated in this study phylogenetically clustered with 
HIV-1 subtype C references with a high degree of confidence (Figure 4.3A). 
Phylogenetic analysis of the pol region also showed that all patients with the exception of 
one participant (704MC012F) were infected with HIV-1 subtype C. Patient 704MC012F 
was infected with subtype G as identified by a web-based Rega HIV Subtyping tool 




























Figure 4.3: Neighbour-Joining phylogenetic trees 
A) Neighbour-Joining phylogenetic tree constructed from the env gene sequences. All clones 
highlighted in red cluster closely with subtype C. B) Neighbour-Joining phylogenetic tree 
constructed from the pol gene sequences.  All patient samples highlighted in red cluster 
together with the subtype C reference with the exception of 704MC012F which clusters with 





The env V3 loop sequences were first analyzed because this region is an important 
determinant of coreceptor usage (Figure 4.4 and Table 4.3). The overall V3 consensus 
sequence generated for ARV-naive patients had 2 more amino acids than the consensus 
sequence generated for ARV-failing patients. Amino acid substitutions in the crown 
motif, a conserved tetrapeptide located at the tip of the V3 loop may influence coreceptor 
utilization. The conventional V3 loop crown motif sequence in R5 HIV-1 subtype C 
sequences is GPGQ whereas in CXCR4-tropic sequences the crown motif may change 
from the conventional GPGQ to GPGX where X is any other amino acid (Coetzer et al. 
2006). Thus CXCR4 utilization in HIV-1 subtype C is commonly associated with a basic 
amino acid substitution in the V3 loop. The crown motifs for most clones generated were 
GPGQ. Thirty-three (83%) clones produced this crown motif, 16 of which were from 
patients failing therapy and 17 were from ARV naïve individuals. Of the 16 clones from 
ARV-failing patients displaying the GPGQ crown motifs, 8 were predicted to be CCR5-
usage only. Of the 17 ARV-naïve clones displaying the GPGQ crown motifs, all except 1 
(704MC020N) showed CCR5-usage only. Crown motifs for the clones from the 
remaining failures were GPGR (704MC009F; 704MC020F; 704MC028F and 
704MC034F) all of which showed CXCR4-usage or dual tropism according to C-PSSM. 
Clone from patient 704MC012F and possessed crown motifs that read GRGQ and 
showed CXCR4-usage or dual tropism. From the clones produced from the ARV-naïve 
individuals, 2 had crown motifs that read GPGR and both of these showed CXCR4-usage 
or dual tropism according to C-PSSM. One clone (704MC027N) had a crown motif that 
read GGPG and showed X4-usage or dual tropism. In the study by Johnston and 
colleagues where 50% of the patients were X4-using, crown motifs of GPGQ 
predominated followed by GPGR as in our study (Johnston et al. 2003). One clone 
(704MC035N) had a V3 sequence identical to the subtype C consensus.      
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007F  -V-------T----..GPGQ-----NG------E---  
008F  ----G----R–V--..GPGQ-----------------  
009F  -S-GQ–KRR.STRI..GPGRQI—GRS–RT---GK–Y-  
011F  -I—G---------...GPGQ---.–NK----------  
012F  ---------R–M—.GIGRGQ----M–R----------  
013F  ----GDHRKRI---..GPGQA–H–RDN------K–Y-  
017F  ----G----R---V..GPGQSI---NR------K–Y-  
018F  -I—G------V--...GPGQ------EV---------  
019F  -L—G---------...GPGQ------A----------  
020F  -------ITTR–ISI.GPGRP--TKNIGRDIK---Y-  
021F  ----G----R---V..GPGQSI---NR------K–Y-  
022F  -------R–R–M--..GPGQV-----A---N----Y-  
23F  ----G----R----..GPGQ-------------K---  
024F  ----G----RG---..GPGQ--F--RT--N-------  
028F  -------K–RR–K-..GPGRA–VTNN---N-----Y-  
031F  ----G----Q----..GPGQ-------------K---  
033F  -----------V--..GPGQ-----N---------Y-  
034F  ---------R----..GPGR--FT----....-----  
037F  ----G--I--R-G-..GPGQA–R--SG---N----Q-  
























001N  ----G---------..GPGQ----NN-----------  
003N -I--G------V--..GPGQ----N.-------K---  
004N ---------Q--GF..GPGQA----------------  
005N  -I--G---------..GPGQ-----------------  
008N  ----G------V--..GPGQ----------NT-----  
010N  -----I–K–QR---..GPGRA–V–I–K------K---  
013N ----S------VG-..GPGQ–I---------------  
016N -----------V--..GPGQA-----G--------Y-  
017N ---VG------V--..GPGQA----N-----------  
018N  -I--G---------..GPGQA---H–E---N------  
019N  ----G------V--..GPGQ----------N------  
020N ----G--I------..GPGQA–FT-----------Y-  
021N --------------..GPGQA----E-----------  
024N -----------V–L..GPGQ-------------E---  
027N ------TR–TR---GPGGPGHAFY–NTV-----K–Y-  
028N  -I---SH--QEGVRI.GPGRA--VR–K------K–Y-  
029N  ----G----T----..GPGQ------AVT--------  
030N  ----G---------..GPGQ----------N------  
034N  ----G----------.GPGQ–L–TN.-------K–Y-  
035N  --------------..GPGQ-----------------  
 
 
Figure 4.4: Alignment of V3 sequences of clones of ARV-failing and ARV-naïve patients 
The crown motif for each sequence is indicated in red. All sequences from viruses 








Table 4.3: Summary table of V3 characteristics of clones ARV-failing and ARV-naïve patients 











Prediction based on the 3 
rules**  
R-5 only virus 
96BWM01_5 
35 4 4 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC007F  35 3 3 Ser(S)/Gly(G) GPGQ CCR5-using only CCR5-using 
704MC008F 35 4 4 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC009F 36 7 7 Ser(S)/Asp(D) GPGR CXCR4-using CXCR4-using 
704MC011F 34 6 6 Ser(S)/Lys(K) GPGQ CXCR4-using CXCR4-using 
704MC012F 37 7 7 Ser(S)/Arg(R) GRGQ CXCR4-using CXCR4-using 
704MC013F 35 7 7 Iso(I)/Asn(N) GPGQ CXCR4-using CXCR4-using 
704MC017F 35 6 6 Ser(S)/Arg(R) GPGQ CXCR4-using CXCR4-using 
704MC018F 35 4 4 Ser(S)/Glu(E) GPGQ CCR5-using only CCR5-using 
704MC019F 35 5 5 Ser(S)/Ala(A) GPGQ CCR5-using only CCR5-using 
704MC020F 35 5 5 Iso(I)/Asn(N) GPGR CXCR4-using CXCR4-using 
704MC021F 35 6 6 Ser(S)/Arg(R) GRGQ CXCR4-using CXCR4-using 
704MC022F  35 5 5 Ser(S)/Ala(A) GPGQ CXCR4-using CXCR4-using 
704MC023F 35 5 5 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC024F  34 7 7 Gly(G)/- GPGQ CXCR4-using CXCR4-using 
704MC028F 34 8 8 Arg(R)/Asn(N) GPGR CXCR4-using CXCR4-using 
704MC031F 35 4 4 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC033F 34 4 4 Ser(S)/Asn(N) GPGQ CCR5-using only CCR5-using 
704MC034F 31 6 6 Ser(S)/- GPGR CXCR4-using CXCR4-using 
704MC037F 35 6 6 Arg (R)/Gly(G) GPGQ CXCR4-using CXCR4-using 
704MC045F 35 4 4 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
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*C-PSSM cannot distinguish between CXCR4-using and dual tropic and classifies these as CXCR4-using. 
**The 3 rules include the overall net V3 charge, the amino acids at positions 11 and/or 25 and C-PSSM 
prediction. 
 
Another feature of the env V3 loop associated with coreceptor usage and tropism 
determination is the property of amino acids at positions 11 and/or 25 (Fouchier et al. 
1992). Of the 20 failures 6 clones had a negative amino acid at either one of these 
704MC001N 35 4 4 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC003N 35 5 5 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC004N 35 2 2 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC005N 35 4 4 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC008N 35 5 5 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC010N 35 9 9 Arg (R)/Lys(K) GPGR CXCR4-using CXCR4-using 
704MC013N 35 3 3 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC016N 35 4 4 Ser(S)/Gly(G) GPGQ CCR5-using only CCR5-using 
704MC017N 35 4 4 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC018N 35 6 6 Ser (S)/Glu(E) GPGQ CCR5-using only CCR5-using 
704MC019N 35 5 5 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC020N 35 3 3 Ser(S)/Asp(D) GPGQ CXCR4-using CCR5-using 
704MC021N 35 3 3 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC024N 35 3 3 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC027N 37 7 7 Arg(R)/The(T) GGPG CXCR4-using CXCR4-using 
704MC028N 36 7 7 Gly(G)/Lys(K) GPGR CXCR4-using CXCR4-using 
704MC029N 35 4 4 Ser (S)/Ala(A) GPGQ CCR5-using only CCR5-using 
704MC030N 35 5 5 Ser(S)/Asp(D) GPGQ CCR5-using only CCR5-using 
704MC034N 34 4 4 Ser(S)/Asp(D GPGQ CCR5-using only CCR5-using 
704MC035N 35 4 4 Ser(S)/Asp(D GPGQ CCR5-using only CCR5-using 
128 
 
positions with a neutral amino acid at the other. Five of these clones showed CCR5-
usage according to C-PSSM. Six clones had a positive amino acid at either one of the 
positions with a neutral amino acid at the other. All 6 clones showed CXCR4-usage or 
dual tropism according to C-PSSM. The remaining 8 clones all had neutral amino acids 
at both positions. Five of these showed X4-usage or dual tropism and 3 showed R5-usage 
according to C-PSSM. Majority (15) of the naïve clones had a negative amino acid at 
either position 11 or 25 and a neutral charge at the other. All but one (704MC020N) 
showed CCR5-usage according to C-PSSM. Two (704MC027N and 704MC028N) had a 
positive amino acid at either one of these positions with a neutral amino acid at the other. 
Both exhibited CXCR4-usage or dual tropism. Clone from 704MC010N had positive 
amino acids at both positions 11 and 25 and both showed X4-usage or dual tropism. 
704MC016N and 704MC029N had neutral amino acids at both positions and showed 
R5-usage according to C-PSSM (Table 4.3).  
 
The number of amino acids in the V3 loop can also be indicative of tropism. The typical 
V3 loop from CCR5 tropic viruses has 35 amino acids. Thirty of the 40 V3 clonal 
sequences had an amino acid of 35. Thirteen (43%) of these belonged to the group failing 
therapy. Majority of the clones in the ARV-naïve group (17; 57%) had a V3 length of 35 
amino acids. Five clones had an amino acid length of 34. Four of the 5 belonged to the 
ARV-failing group. Two clones had 36 amino acids, one from each group of patients and 
two clones had 37 amino acids – again, one from each group of patients. One clone 
(704MC034F) had only 31 amino acids within the V3 region (Table 4.3). 
 
Amino acid insertions in the V3 loop, particularly at positions 13 and 14 are features 
consistent with CXCR4 usage as previously described (Coetzer et al. 2006). This was 
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found this in three of the four clones that had a V3 length of greater than 35 
(704MC012F, 704MC027N, 704MC028N). All of these show CXCR4-using or dual 
tropic according to C-PSSM. The fourth clone (704MC009F) shows an insertion at 
position 19 and was also indicated as CXCR4-using or dual tropic by C-PSSM.  
  
The V3 region was also analyzed by manually calculating the overall net amino acid 
charge, another indicator of env coreceptor utilization (Table 4.3). C-PSSM was also 
used. Both manual and C-PSSM calculations were comparable for all clones. A higher 
overall net V3 charge is associated with X4-usage. As a general rule a charge less than 
+4.5 is regarded as R5-using and charges greater than +4.5 are regarded as X4-using 
(Coetzer et al. 2006; Fouchier et al. 1995; Fouchier et al. 1992; Kuiken et al. 1992). 
When we looked at the charge obtained to the C-PSSM coreceptor prediction, we saw 
this in 32 cases (80%). The remaining 9 showed discrepancies to this rule. However, 6 of 
these (704MC019F, 704MC023F, 704MC003N, 704MC008N, 704MC019N and 
704MC030N) had charges of (+5) and showed CCR5-usage, only slightly above +4.5. 
Clone 704MC018N had a charge of +6 and displayed X4-usage or dual tropism and 
704MC020N had a charge of 3 even though C-PSSM predication was CXCR4-using or 
dual tropic.  
 
Therefore, based on the multiple V3 loop sequence-based algorithms available for 
phenotype prediction, the clones generated suggest that there are discrepancies among 
the various methods in terms of predictability when using C-PSSM as not all results 
indicated the same coreceptor prediction. Such observations have also been recorded 
previously (Johnston et al. 2003), where in one case a R5 virus showed X4 
characteristics. For the purpose of comparing the predictive coreceptor usage obtained 
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for the cloned samples in this study as well as the drug resistance mutations, a series of 
predictors of coreceptor usage was employed. These included the 11/25 rule, the overall 
net V3 charge and C-PSSM. A combined algorithm which made use of all 3 predictive 
rules was used and was calculated taking into account 2 correlating predictions from the 
3 rules.  
 
Using the combined algorithm, the V1/V2, V3 and V4/V5 regions of the env gene was 
further analyzed as these regions have been implicated in playing a role in coreceptor 
utilization. Sequence features in these regions that may influence viral tropism are the 
amino acid length and the number of predicted N-linked glycosylation sites (Chohan et 
al. 2005; Coetzer et al. 2007; Coetzer et al. 2008; Masciotra et al. 2002; Pollakis et al. 
2001). The total number of predicted N-linked glycosylation sites in clones from this 
study varied from 24 to 37. Various groups were compared and the predicted R5-using 
failures had a significantly greater amount of predicted N-linked glycosylation sites 
within the env (p=0.0123).  No other significant findings with regard to predicted N-
linked glycosylation sites within the specific regions i.e. the V1/V2, V3 and V4/V5 




Figure 4.5: Box plots of predicted N-linked glycosylation sites (PNLGS) 
A) shows the total number of PNLGS within the env. B) the number of PNGLS within the 
V1/V2 region  C) the number of PNGLS within the V3 region D) the number of PNLGS 





Previous reports have suggested that a lack of predicted N-linked glycosylation sites at 
positions 6-8 of the V3 loop may be indicative of CXCR4-utilization (Coetzer et al. 
2006). Seven generated clones had a lack of this site in our study (704MC009F, 
704MC018F, 704MC022F, 704MC028F, 704MC010N, 704MC020N and 704MC028N). 
Of these majority (5) were predicted to be CXCR4-using.  
 
Differences in the loop lengths between R5, X4 and R5X4 sequences were next 
analyzed. The overall V1/V2 length ranged from 48-90 amino acids and the combined 
V4/V5 loop length ranged from 34-47. The V3 loop length ranged from 31-37 amino 





















































































































































































































































































































































































Figure 4.6: Box plots of env variable loop lengths. 
A) the V1/V2 loop length. B) the V3loop length C) the V4/V5 loop length. The line within 







Using the combined algorithm method for coreceptor prediction, it was then investigated 
whether those patients failing treatment had a higher percentage of predicted CXCR4 
usage. With the entire group of patients from which sequence data has been generated it 
was found that 60% of failures were predicted to be CXCR4-using and of the ARV-naïve 
patients 85% were predicted to be CCR5-using (p=0.0079). This also produced a 
significant result in our functional assay.  No significant association between CD4 counts 
and X4-usage was observed (p=0.65). However, when X4/dual/mixed-usage in failures 
verses naive patients were examined, patients failing treatment harboured a significantly 
higher amount of X4/dual/mixed viruses (p=0.0028) as compared to R5 viruses where no 
significance was obtained (p=0.49). It was also investigated whether predicted CXCR4-
usage was associated with older patients. No significant result (p=0.41) was obtained. It 
was then further investigated if the length of treatment could possibly be a driving force 
towards predicted CXCR4-usage but once again no significant result was obtained for 
this (p=0.88).  It was next investigated whether those patients with TAMs were mostly 
predicted to have CXCR4-using viruses. Five (56%) of failures with TAMs were 
predicted to use CXCR4 and 4 (44%) were predicted to use CCR5. Although TAMs 
were found in more patients that harboured X4/dual/mixed viruses no significance was 
reported (p=0.31). It is noteworthy that for the predicted results a much smaller group of 
patients were analyzed.      
 
The various predictive algorithms were also assessed in their ability to correctly predict 
sequences. Functional results for 32 of the 40 patients were obtained and on which 
predictive analysis was done using the Trofile Coreceptor Tropism Assay. Twenty-seven 
samples (84%) produced comparable results when the predictive data using the 
combined algorithm and the functional data were analyzed. Only 5 samples (16%) 
135 
 
produced results that did not correlate between the two methods. Overall the combined 
algorithm predicted 84% of sequences correctly followed by C-PSSM (81%), 11/25 rule 
(78%) and overall net V3 charge (75%) (Table 4.4). Both the combined algorithm and 
the 11/25 rule produced the highest percentage (90%) of R5 sequences correctly 
predicted with C-PSSM being 85% and overall net V3 charge of 71%. This was in 
contrast for X4/dual/mixed sequences where the overall net V3 charge displayed the 
highest percentage (81%) of correct prediction followed by the combined algorithm and 
C-PSSM (72%) and then the 11/25 rule (55%). In summary these predictive methods 
have proved to be reliable as analysis of results from both the functional assay as well as 
the predicted coreceptor utilization method were comparable.  
     
 Table 4.4: V3 loop-based methods for coreceptor usage prediction 
 
*The combined algorithm makes use of all 3 predictive rules i.e. the amino acids at positions 11 and/or 
25, the overall net V3 charge and C-PSSM prediction. For the combined algorithm, results were 





Method % of sequences correctly 
predicted 
% of R5 sequences 
correctly predicted 
% of X4/D/M sequences 
correctly predicted 
11/25 78 90 55 
Overall net V3 charge  75 71 81 
C-PSSM 81 85 72 




Highly active antiretroviral therapy has saved lives and improved the quality of lives for 
millions of people living with HIV/AIDS worldwide. However, the emergence and spread of 
drug resistance could limit and reverse some of the gains experienced so far in the clinical 
management of HIV/AIDS, particularly in the developing world where the options of 
affordable and easily accessible antiretroviral drugs are limited. Monitoring the patterns of 
antiretroviral drug use and emerging drug resistance is therefore crucial for the success and 
sustainability of treatment programmes.  Moreover, as new drugs become available, there is a 
growing need to better characterize viruses from both drug naïve and Virologyogically failing 
patients in order to better understand the suitability of these new drugs either as part of the 
current regimens or as salvage therapy options. This study investigated the prevalence and 
pattern of drug resistance mutations in a cohort of HIV-1 subtype C-infected individuals 
failing therapy. In addition, since it has been previously reported that suboptimal 
antiretroviral treatment or certain classes of drugs  may select for the more virulent X4 virus 
variants (Johnston et al. 2003), and in an attempt to better understand coreceptor usage 
evolution for HIV-1 subtype C viruses, the determinants of viral tropism in antiretroviral 
therapy-naïve and therapy experienced Virologyogically failing patients were analyzed. 
 
Results show that in a South African setting where patients are receiving antiretroviral 
therapy according to national and WHO guidelines, 95% of patients failing therapy had at 
least one drug resistance mutation. More than half of the patients had a previous history of 
ARV therapy and majority of the patients were on Regimen 1A (d4T, 3TC, EFV). The most 
common NRTI mutation noted was M184V/I in 87% of patients, consistent with other recent 
subtype C studies (Marconi et al. 2008), although the percentage of patients with this 
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mutation was higher in this cohort. V106M was the commonest NNRTI resistance mutation, 
occurring in 49% of Virologyogically patients and at a much higher frequency compared to 
the V106A (2%) mutation. This pattern is also consistent with reports from previous HIV-1C 
studies (Brenner et al. 2003; Kantor et al. 2005; Loemba et al. 2002; Marconi et al. 2008). 
The K103N mutation was also relatively common at (40%), and unsurprisingly, there were 
hardly any protease inhibitor mutations since none of the patients were on protease inhibitors. 
Data from this study also revealed that 55% of patients failing therapy had thymidine analog 
mutations (TAMs) compared to 32% of patients studied from the same city in 2005-2006 
(Marconi et al. 2008). A recent study in Malawi also reported a similar high percentage 
(56%) of TAMs in persons failing therapy under the public sector antiretroviral programme 
(Hosseinipour et al. 2009), and these data are in contrast to earlier studies where lower levels 
of TAMs were reported (Marconi et al, 2008 and Novitsky et al, 2007).  There was  a higher 
percentage of TAM2 pathway mutations (44%) in this cohort compared to the Marconi 
cohort from the same population (19%) whereas in the studies by Novitsky et al. and Cozzi-
Lepri et al., 35% and 52%  of the TAM2 pathway mutations were identified respectively 
(Cozzi-Lepri et al. 2009; Marconi et al. 2008; Novitsky et al. 2007). A higher TAM2 versus 
TAM1 percentage  similar to previous studies was observed (Marconi et al. 2008; Novitsky et 
al. 2007) but very low when compared to Cozzi-Lepri et al. where 65% of TAM1 pathway 
mutations were seen but this is explained by the longer treatment period in this study (Cozzi-
Lepri et al. 2009) as compared to the other studies.  From these findings, we see that TAM 
mutations appear to be occurring at high frequencies particularly in patients following 
government/national/WHO guidelines in resource-poor settings, which may be severely 
limiting in terms of switch regimes. In addition, the same mutations are seen in other subtype 
C studies, and TAM2 is more common despite different regimens. This is in contrast to 
subtype B.  This may require further studies. Overall, it can be concluded that there is a high 
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level of mutations in ART-experienced patients failing therapy suggesting the development 
of drug resistance rather than non-adherence whereas no significant mutations in ART-naïve 
individuals were identified (although sample size is small).  
 
Numerous studies have previously reported that X4 viruses are rare in HIV-1C infections. 
The data obtained here appear to be consistent with these previous studies as only one sample 
contained X4 only variants. However, it has recently been shown that X4 clones dominate in 
dual tropic primary HIV-1C isolates propagated in peripheral blood mononuclear cells (Singh 
et al. 2009) , while in contrast others have described that R5 viruses predominate in plasma 
from X4/dual/mixed subtype B (Irlbeck et al. 2008) . Therefore, further studies will be 
needed to address which envelope clones dominate in plasma from the X4/dual/mixed 
phenotypes identified in this study. However, it can be concluded that in most HIV-1C 
infections, there is residual CCR5 utilization by HIV-1 despite evolution to CXCR4 usage, 
and this is in contrast to HIV-1 subtype B where complete switch to CXCR4 usage is 
commonly observed (Bjorndal and Sonnerborg 1999; Cecilia et al. 2000; Cilliers et al. 2003; 
Ndung'u et al. 2006; Tscherning et al. 1998). It was also investigated whether HAART-
failing HIV-1C-infected patients had higher proportion of X4/dual/mixed viruses compared 
to HAART-naïve patients. Although this was found to be the case, the patients failing 
HAART had lower median (nadir) CD4+ counts compared to HAART-naïve patients, and as 
shown in Figure 4.2B, individuals possessing X4/dual/mixed viruses had significantly lower 
CD4+ T cell counts compared to those with R5-only viruses, in both the HAART-naïve and 
HAART-failing arms of this study. These data therefore suggest that CD4+ T cell counts (and 
perhaps length of infection), rather than HAART is the possible main cause of X4/dual/mixed 
viruses, consistent with data from HIV-1 subtype B studies (Briz et al. 2008; Hunt et al. 
2006).  However, only a longitudinal study can decisively determine whether there is higher 
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proportion of emergence of X4/dual/mixed viruses in treated versus HAART-naïve patients 
with similar CD4 T cell counts.  This study underlines the importance of introducing CCR5 
inhibitors relatively early in the course of HIV-1 subtype C infection for possible maximum 
benefit and to preserve other drugs for later use. Clinical trials are needed to determine the 
equivalence or superiority of CCR5 inhibitors as part of first line or early regimens, rather 
than as salvage therapy in HIV-1 subtype C settings.         
 
Finally, the availability of virus phenotype and genotype data allowed us to assess the utility 
of V3 loop sequenced based methods for predicting viral tropism. Data shows that while 
genotypic methods are reliable for a majority of cases, they failed to correctly predict tropism 
in 10 to 45% of cases. It was also noteworthy that sequence based algorithms were better at 
predicting R5 compared to X4/dual/mixed phenotypes. There remains an urgent need to 
further investigate and develop better predictive algorithms, perhaps taking into account 
sequences outside of the V3 and more detailed analysis of V3 loop sequences using newer 
technologies able to better characterize V3 loop quasispecies diversity.    
 
In summary, this study examines coreceptor tropism directly in patients failing currently 
recommended regimens, and compares this with ARV-naïve patients in a HIV-1 subtype C 
setting. The presence of high proportions of patients with TAMs suggests that these 
mutations may be accumulating over time in this population as a result of inadequate viral 
suppression, most likely as a consequence of immunological and clinically driven 
monitoring. These results may suggests that in situations where Virologic monitoring is not 
possible, measures need to be put in place to improve adherence and to develop new 
monitoring tools. Comparison of the prevalence of CXCR4-utilizing viruses between ARV-
140 
 
naive prior to initiating ART with the prevalence among treated patients revealed that there 
was a high prevalence of X4/dual/mixed utilizing viruses in patients failing treatment, 
possibly due to lower nadir CD4 counts in these patients, underlining the need for 
investigating the possible earlier use of CCR5 inhibitors before the development of 
X4/dual/mixed viruses. Data also highlights the usefulness and limitations of genotypic 
coreceptor prediction methods in assessing whether HIV-1C infected patients can be put on 
regimens that include CCR5 inhibitors. Longitudinal studies on viral coreceptor evolution in 


















Discussion and Conclusion 
 
Infection with human immunodeficiency virus type 1 (HIV-1) is characterized by high 
genomic diversity of the virus. Because of this diversity several distinct groups of the virus 
each with its own unique DNA sequence characteristics have emerged. HIV-1 is divided into 
three groups – M (major) which accounts for 90% of infections, O (outlyier) and N (new or 
non-O, non-M) (Lihana et al. 2009; Penn et al. 2008; Simon et al. 1998; Wainberg 2004). The 
major group is further subdivided into 9 subtypes (Peeters and Sharp 2000; Thomson et al. 
2002) and 43 circulating recombinant forms (CRFs) 
(http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). Particular viral subtypes 
predominate in specific geographical regions with subtype C, the focus of this study, 
accounting for more than half of all new infections worldwide and being the most 
predominant circulating subtype in southern Africa (Hemelaar et al. 2006; Penn et al. 2008). 
Viral entry into cells is mediated by binding of the viral envelope (Env) gp120 with a CD4 
receptor and a chemokine receptor most often CCR5 and CXCR4 (Alkhatib et al. 1996a; 
Choe et al. 1996; Deng and Liu 1996; Dragic and Litwen 1996; Feng and Broder 1996; 
Kwong et al. 1998; Lusso 2006; Rizzuto et al. 1998; Wyatt et al. 1995). HIV-1 viral isolates 
are differentiated based on their ability to use these coreceptors – R5 viruses use CCR5, X4 
viruses use CXCR4 and R5X4 (dual tropic) viruses use both CCR5 and CXCR4. According 
to various published studies HIV-1 subtype C has a unique viral coreceptor evolution pattern 
in that a switch from the predominant CCR5 (R5) to CXCR4 (X4) phenotype is less common 
for this subtype compared to other subtypes. However, although rare, dual tropic HIV-1C 
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isolates have been described previously. Furthermore, reports have suggested that certain 
highly active antiretroviral drugs (HAART) may select for X4 viral variants. Therefore, this 
study was undertaken to better understand the functional and genotypic characteristics of dual 
tropic HIV-1C isolates, and to characterize drug resistance and coreceptor usage patterns in 
HAART-naïve versus HAART-failing HIV-1C infected patients. 
 
Coreceptor utilization has been characterized extensively in previous studies. However, most 
previous studies have focused on viral isolates, although HIV-1 exists as distinct quasispecies 
within isolates (Coetzer et al. 2006; Ping et al. 1999; Yi et al. 1999; Yi et al. 2005).  Since 
most previous studies have shown that HIV-1 subtype C maintains preferential CCR5 
utilization even in late stages of clinical AIDS, it is hypothesized that R5 clones would 
dominate in dual tropic HIV-1 subtype C isolates. In order to test this hypothesis and further 
determine whether dual tropic HIV-1 subtype C isolates exist as a mixture of CCR5- and 
CXCR4- tropic quasispecies,  truly dual tropic viruses or both at the clonal level, 35 
functional HIV-1 full-length env clones derived from seven dual tropic HIV-1C strains were 
first generated. The coreceptor usage of the clones in transformed cell lines was characterized 
using two different phenotypic methods of transfection and infection. The sequence 
characteristics of these clones were also examined in order to better elucidate the genetic 
determinants of coreceptor utilization by HIV-1 subtype C viruses. Using the DEAE-dextran 
method of infection, 30 of 35 (85.7%) clones were CXCR4-tropic clones, thus demonstrating 
that X4 clones dominated within the dual tropic viral isolates quasispecies. A minority 
proportion of dual tropic clones (14.3%) were also identified. However, when the approach of 
coreceptor utilization was changed to a spinnoculation method of infection, 20 of 35 (57%) of 
the clones were dual tropic with 43% exhibiting exclusive X4 phenotype. Therefore the 
method of infection used may result in significant differences in phenotypic determination of 
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viral coreceptor usage, and this finding has important implications for the comparison of data 
across different studies that use different methods.  However, surprisingly and importantly, 
using both methods of infection, there was not a single CCR5-monotropic env clone 
identified from the seven primary isolates analyzed. This result was unusual considering that 
previous studies have shown that HIV-1 subtype C viruses utilize CCR5-only predominantly 
for cell entry, even in late stages of disease. Predominance or at least a significant proportion 
of the CCR5 clones among the quasispecies of the dual tropic isolates was therefore expected 
to be found. Instead, majority of the clones were CXCR4-utilizing with a substantial 
percentage being able to mediate cell entry via the CXCR4 receptor exclusively.  
 
The finding that X4 clones dominated in these dual tropic strains was further confirmed by 
analysis of sequences from both transformed cell lines (U87.CD4 cells expressing both 
CXCR4 and CCR5) and peripheral blood mononuclear cells were examined. All of these 
sequences were classified as X4/dual tropic, including clones generated from the U87.CD4 
cell line expressing CCR5 that were classified as dual tropic. Single genome amplification of 
clones from one dual tropic isolate also produced sequences that were predominantly X4/dual 
tropic.     
 
Phenotypic analysis is expensive and not practical to carry out in heavily burdened 
populations, particularly in a poor resource setting. Genotypic sequence analysis would 
mitigate some of the cost and feasibility concerns. However, it has been shown that genotypic 
methods may not always be reliable as they do not always predict coreceptor usage especially 
in distinguishing X4 and R5X4 viruses (Garrido et al. 2008; Low et al. 2007), so there is a 
continuing need to develop better sequence based genotypic algorithms. The next aim 
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therefore was to establish how consistent these currently available genotypic methods for 
HIV-1 subtype C are by comparing the phenotypic data obtained to genotypic data analysis. 
Coreceptor utilization is genetically determined by sequence characteristics within the env 
gene. These include specific amino acid changes particularly within the V3 variable loop as 
well as the number and pattern of predicted N-linked glycosylation sites. The V3 region is 
critical for coreceptor binding and is the major determinant of which chemokine receptor 
(CCR5 or CXCR4) will be the accessory protein used by the virus for membrane fusion 
(Cilliers et al. 2003; Coetzer et al. 2007; Coetzer et al. 2006; Fouchier et al. 1992; Huang et 
al. 2005; Morris et al. 2007; Ndung'u et al. 2006). This region typically consists of 
approximately 35 amino acids in CCR5-tropic viruses (Coetzer et al. 2006; Mefford et al. 
2008) and variations such as variations in the length, the amino acids at positions 11 and 25, 
changes within the crown motif and the overall net charge may all contribute to coreceptor 
usage (Coetzer et al. 2007; Coetzer et al. 2006; Jensen et al. 2006; Jensen et al. 2003; Renjifo 
et al. 1999). A web based programme C-PSSM 
(http://indra.mullins.microbiol.washington.edu/pssm/) which also assists in determining viral 
phenotype was used. PSSM is a bioinformatic tool used for predicting HIV-1 coreceptor 
usage from the amino acid sequence of the V3 loop. PSSM is in most part highly accurate but 
there have been studies where not all results were completely accurate particularly when 
clonal samples were studied (Jensen et al. 2003; Low et al. 2007). 
 
Other sequence characteristics outside of the V3 loop may also assist in coreceptor 
utilization. These include specific amino acid changes within the remaining variable regions 
V1/V2, V3, V4/V5 as well as the pattern and number of predicted N-linked glycosylation 
sites.  All of these genotypic methods of analysis proved to be reliable in this study and there 
was a strong correlation between the phenotypic and genotypic methods used, although 
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limitations were noted. Hence it is suggested from these observations that the genotypic 
methods investigated in this study were consistent. 
 
The findings from this study have many implications on HIV-1 subtype C pathogenesis 
particularly on coreceptor evolution. It was found that at the clonal level, dual tropic strains 
appear to be dominated by X4 virus variants. Further, a substantial number  (57%) of subtype 
C-infected patients investigated in this study harbored dual tropic viruses. CCR5 inhibitors 
would not be suitable for managing such individuals with dual tropic HIV-1 subtype C 
infection. The initial hypothesis was that in a subtype C setting R5 viruses would dominate in 
these strains but observations from this study overwhelmingly refutes that hypothesis and 
clearly suggests that CCR5 antagonists are unsuitable even as salvage therapy in dual tropic 
HIV-1 subtype C. All of these observations impact on coreceptor evolution and may imply 
that a rapid loss of CCR5 tropism is occurring as CXCR4 usage emerges. This is consistent 
with recent findings of rapid decline in CCR5 utilization as alternate coreceptor utilization 
emerges in HIV-1 subtype B infection (Coetzer et al. 2008). However one would question 
that if viruses had been cloned directly from plasma rather than using primary isolates 
cultured in peripheral blood mononuclear cells, would X4 viruses still dominate? This may be 
a question for further study especially since a previous study has shown that R5 viruses 
predominated in dual tropic HIV derived from plasma samples (Irlbeck et al. 2008).    
 
Most studies on viral coreceptor usage have been done using stably transfected reporter cell 
lines. However, transfected cell systems may differ from coreceptor utilization in vivo where 
the main target cells of infection are primary lymphocytes and macrophages (Yi et al. 2005). 
The ability of the HIV-1C env clones to facilitate infection of lymphocytes and macrophages 
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was next investigated and their coreceptor utilization profiles in primary CD4+ T 
lymphocytes and monocyte-derived macrophages characterized. Clones generated from dual 
tropic isolates irrespective of whether they were CXCR4- or R5X4-using in transformed cell 
lines used either both the CCR5 and CXCR4 pathways of entry or exclusively the CXCR4 
pathway of entry. When both pathways were utilized there was a striking bias towards 
CXCR4-usage in both CD4+ T lymphocytes and monocyte derived macrophages for majority 
of the viruses. A few viruses displayed comparable CCR5 and CXCR4 usage and clones from 
one virus isolate preferred CCR5 usage in macrophages. It is noteworthy that some viruses 
particularly those that show lower levels of infection in transformed cell lines were not 
infectious in primary cells. Thus although in most instances (57%) coreceptor usage in 
primary cells was consistent with coreceptor utilization in transformed cell lines, a few cases  
(43%) showed that coreceptor phenotyping in transformed cell lines does not always predict 
usage in primary cells. It should also be noted that pseudoviruses were used for transfection 
and then infection. Perhaps infection  with primary viruses may produce a different outcome. 
  
Finally, the patterns of drug resistance mutations and coreceptor usage among HAART-naïve 
and HAART-failing HIV-1C infected patients were studied and analyzed. At least one drug 
resistance mutation was observed in 95% of HAART-failing patients with thymidine analog 
resistance mutations (TAMs) being present in 55% of patients. A high percentage of patients 
had mutations from the TAM2 pathway (44%) whereas 9% of patients had mutations from 
the TAM1 pathway. Overall the level of TAMs in patients from this study was high 
particularly when this study is compared to the study by Marconi et al., (32%) which used 
patients from the same population. However the duration of treatment in each study may 
provide an explanation for this as patients from the Marconi study had a mean duration of 
treatment of 11 months (Marconi et al. 2008) versus this study of 29 months. Hence, shorter 
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exposure to failing regimens may reduce the opportunity for the accumulation of TAMs. 
Also, because more than half of the patients were receiving thymidine analogs (stavudine and 
zidovudine) and majority of patients were previously on a regimen containing either one or 
both of these drugs, it is an indication that these mutations were highly favoured. The fact 
that most patients failing HAART had drug resistance mutations shows that these patients are 
truly failing therapy and the problem is not that patients are being non-compliant.  
 
In addition a high percentage of patients had high level resistance to 3TC and FTC followed 
by ABC. This is consistent with the fact that the M184VI mutation occurred most frequently 
and this is associated with high level resistance to 3TC and FTC (http://hivdb.stanford.edu).  
NNRTI mutations V106M and K103N also occurred at high frequency. These are associated 
with high level resistance to NVP, DLV, EFV and ETR (http://hivdb.stanford.edu) all of 
which showed a substantial percentage of high level resistance. 
 
HAART-failing patients had significantly higher prevalence (59%) of X4/dual/mixed-
utilizing viruses compared to HAART-naïve patients (30%) using the Trofile coreceptor 
tropism assay while 41% of HAART-failing patients harbored viruses that used CCR5 and 
70% of HAART-naïve patients used CCR5. This is in keeping with previous studies where 
X4/dual tropic viruses dominated in patients failing treatment (Hunt et al. 2006; Johnston et 
al. 2003). This suggests that ARVs may be creating an environment for the emergence of 
X4/dual/mixed-utilizing viruses. However, patients failing treatment had lower nadir CD4 
counts so it may be suggested that X4/dual/mixed viruses occurred at high frequency because 
these patients had lower CD4 counts. Only a longitudinal study can decisively determine 
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whether there is higher proportion of emergence of X4/dual/mixed viruses in treated versus 
HAART-naïve patients with similar CD4 T cell counts. As most of these virus variants were 
dual/mixed variants and only 1 exclusive CXCR4-utilizing virus was found, it can be 
suggested that coreceptor evolution clearly occurs but also that X4-only viruses are rare. 
However, as the presence of exclusive CCR5-using viruses has not been observed in this 
study, it is suggested that CCR5 inhibitors may not be appropriate for a significant proportion 
of HIV-1 subtype C infected people with low CD4 counts. There is therefore a need for 
clinical trials to test coreceptor antagonists in early phases of infection before X4 viruses 
emerge. This study suggests that maximum benefit is more likely to be achieved when drugs 
such as maraviroc are used early in infection rather than waiting to use these drugs as salvage 
therapy. This study also shows that coreceptor testing will be necessary for HIV-1 subtype C 
infections before coreceptor antagonists can be used. This however, is currently expensive 
and may not be feasible. 
 
The correlation of phenotypic and genotypic methods was further investigated for patient 
plasma derived viruses that had not been cultured. There was an 84% correlation between the 
functional assay and the combined predictive algorithm method. This method correctly 
predicted 90% of R5 sequences and 72% of X4 sequences. C-PSSM predicted 81% of 
sequences correctly with 85% of R5 sequences and 72% of X4 sequences being correctly 
predicted. The 11/25 rule predicted 78% of sequences correctly with 90% of R5 sequences 
and 55% of X4 sequences being correctly predicted. The overall net V3 charge predicted 
75% of sequences correctly with 71% of R5 sequences and 81% of X4 sequences being 
correctly predicted. It should be noted that there is a clear pattern that R5 sequences were 
better predicted than X4/dual/mixed sequences.  However from these observations it is 
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suggested that although there were discrepancies, the genotypic methods investigated in this 
study were in most part consistent.  
In summary, while X4 variants arose, R5 and dual/mixed viruses still dominated in both the 
naïve and treated patients. Further studies will be needed to address whether X4 clones 
dominated in the plasma of the patients studied here as the results do appear to suggest there 
are some differences between viruses derived from plasma and primary isolates cultured in 
peripheral blood mononuclear cells. Perhaps the culturing of primary isolates in peripheral 
blood mononuclear cells creates an environment that favors/selects for X4-virus variants 
thereby accounting for the high prevalence of CXCR4-utilizing viruses derived from 
peripheral blood mononuclear cells. From these observations, the following model had been 
hypothesized. For subtype B infection, an evolutionary shift suggests that these dual/mixed-
utilizing viruses are in the intermediate stage of viral switching before CXCR4-usage 
associated with advanced disease progression and AIDS emerges and dominates (Figure 
5.1A). Subtype C behaves differently where dual/mixed-utilizing viruses begin to emerge 
during the intermediate stage of infection although R5 viruses dominate during this stage. In 
the late stage of infection these dual/mixed viruses dominate possibly with the emergence of 
some X4-using viruses (Figure 5.1B). However, culturing of primary viral isolates in 
peripheral blood mononuclear cells may introduce some bias in somehow selecting for 
CXCR4-utilizing viruses (Figure 5.1A and B). This proposed model contributes to the 
existing knowledge of the HIV-1 epidemic but further investigation is required.       
 
This study enhances our understanding of HIV-1 subtype C pathogenesis and the results have 
important implications for the use of coreceptor antagonists for the clinical management of 







Figure 5.1: Viral evolution of HIV-1 subtype B and C 
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It is widely documented that a complete switch from the predominant CCR5 (R5) to CXCR4 (X4) phenotype
is less common for HIV-1 subtype C (HIV-1C) compared to other major subtypes. We investigated whether
dualtropic HIV-1C isolates represented dualtropic, mixed R5 and X4 clones or both. Thirty of 35 functional
HIV-1 env clones generated by bulk PCR amplification from peripheral blood mononuclear cells (PBMCs)
infected with seven dualtropic HIV-1C isolates utilized CXCR4 exclusively. Five of 35 clones displayed
dualtropism. Endpoint dilution of one isolate did not yield a substantial proportion of R5-monotropic env
clones. Sequence-based predictive algorithms showed that env sequences from PBMCs, CXCR4 or CCR5-
expressing cell lines were indistinguishable and all possessed X4/dualtropic characteristics. We describe
HIV-1C CXCR4-tropic env sequence features. Our results suggest a dramatic loss of CCR5 monotropism as
dualtropism emerges in HIV-1C which has important implications for the use of coreceptor antagonists in
therapeutic strategies for this subtype.
© 2009 Elsevier Inc. All rights reserved.
Introduction
HIV/AIDS is the most serious infectious disease challenging the
public health sector in sub-Saharan Africa. The disease remains the
leading cause of death in the region and in 2007 alone, 76% of deaths
were as a result of HIV/AIDS, with 68% of all new HIV infections
occurring in this region. Southern Africa is the most seriously affected
sub-region and in 2007 accounted for 32% of all new infections and
AIDS-related deaths worldwide. South Africa constitutes the highest
number of HIV infections globally (UNAIDS, 2007). The main
circulating HIV-1 subtype in South Africa is HIV-1 subtype C (HIV-
1C), which accounts for approximately 56% of infections worldwide
(Esparza, 2005; Hemelaar et al., 2006; Visawapoka et al., 2006).
Subtype groupings are based on sequence variations that occur within
all gene and non-protein coding regulatory regions, but the most
dramatic differences are found in the envelope (env) gene (Gao et al.,
1998). The envelope is an important target of humoral immune
responses and is a crucial determinant of overall viral fitness (Ball et
al., 2003; Marozsan et al., 2005). The env gene plays an important role
in viral transmission by determining which coreceptor the virus uses
to mediate entry. During transmission and subsequent to infection,
viral fitness and target cell tropism properties are thought to be
important determinants of infectivity and the rate of disease
progression (Troyer et al., 2005). The importance of the envelope as
a major target of humoral immunity, its contribution to overall fitness
during transmission, and its role in the rate of disease progression
make it a particularly attractive target for vaccine and drug
development. However, progress towards these goals has been
greatly hindered by the extreme genetic variability of the env gene.
HIV-1 utilize members of the seven transmembrane chemokine
receptor family as coreceptors for entry into target cells (de Roda
Husman et al., 1999; Oppermann, 2004; Ross and Cullen, 1998; Vila-
Coro et al., 2000; Xiao et al., 1999). The virus gp120 envelope
glycoprotein first binds to the primary CD4 receptor on target cells,
which induces conformational changes on the envelope exposing the
coreceptor binding site (Rizzuto et al., 1998; Wyatt et al., 1995). The
two main coreceptors that the HIV-1 envelope binds to subsequent to
the conformational change are CCR5 or CXCR4 (Alkhatib et al., 1996;
Choe et al., 1996; Deng and Liu, 1996; Doranz et al., 1996; Dragic and
Litwen, 1996; Feng and Broder, 1996). HIV-1 strains can be classified
based on their coreceptor utilization, with CCR5 tropic viruses termed
R5, CXCR4 tropic viruses termed X4 and viruses that use both
coreceptors (dualtropic viruses) termed R5X4 (Berger, 1998; Berger,
Murphy, and Farber, 1999). R5 viruses predominate in the early stages
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of HIV-1 infection, whereas dualtropic and X4 variants, which are
associated with rapid disease progression, emerge in the late chronic
phase of disease in a significant proportion of patients (Connor et al.,
1997; Scarlatti et al., 1997). It is well established that while all
subtypes are capable of undergoing coreceptor utilization switch
from CCR5 to CXCR4, this is less frequently encountered in HIV-1
subtype C infections, even in late stages of disease (Bjorndal and
Sonnerborg, 1999; Cecilia et al., 2000; Cilliers et al., 2003; Ndung'u
et al., 2006; Tscherning et al., 1998). Furthermore, expanded
coreceptor usage beyond CCR5 and CXCR4 has also been occasion-
ally reported but its significance for HIV-1 replication in vivo and
disease progression is unclear (Aasa-Chapman et al., 2006; Cilliers
et al., 2005; Dash et al., 2008).
Coreceptor utilization is genetically determined by sequence
characteristics within the env gene, primarily specific amino acid
changes within three of the five hypervariable regions namely the V1/
V2 and V3 loops, as well as the number and pattern of predicted N-
linked glycosylation sites (Fouchier et al., 1992; Pastore and Nedellec,
2006; Pollakis et al., 2001). Additional sequence changes within the
env gene have also been implicated in coreceptor determination or
the coreceptor switching process (Aasa-Chapman et al., 2006; Coetzer
et al., 2008).
In several instances where HIV-1 subtype C isolates able to
mediate cell entry via CXCR4 have been described, dualtropic (R5X4)
strains that utilize both CCR5 and CXCR4 have been more frequently
encountered compared to X4 monotropic viruses (Cilliers et al., 2003;
Coetzer et al., 2006; Dash et al., 2008; Johnston et al., 2003; Ndung'u et
al., 2006; van Rensburg et al., 2002). However, despite the occasional
isolation of dualtropic HIV-1C viruses, such viruses have rarely been
extensively characterized at both the functional and genetic clonal
level. It is therefore largely unknown whether dualtropic HIV-1C
strains represent a mixture of R5 and X4 viruses or truly dualtropic
strains (or both) at the clonal level. Furthermore, genetic determi-
nants associated with change in coreceptor usage have rarely been
described for HIV-1 subtype C, particularly those that may reside
outside of the V3 loop region. In this study we investigated whether
dualtropic HIV-1C primary isolates represented truly dualtropic
viruses at the clonal level, or mixed R5 and X4 clones. We describe
the generation of functional envelope clones from dualtropic HIV-1C
isolates and the sequence characteristics in the HIV-1C env gene, both
within and outside of the V3 region that are associated with
coreceptor utilization phenotype.
Results
Viral infection of stimulated PBMCs
Seven HIV-1 subtype C dualtropic isolates from individuals in
South Africa (Cilliers et al., 2003) and Botswana (Ndung'u et al., 2006)
were selected for this study. In addition, a well-characterized CCR5-
only utilizing HIV-1 subtype C isolate, BWM01_5 was used as a
positive control (Ndung'u et al., 2006). Infection of the stimulated
PBMCswas assessed by HIV-1 p24 antigen ELISA over a 14-day culture
period. As shown in Fig. 1, p24 antigen concentration increased in
culture supernatant for all the isolates. The isolates replicated to
different levels and with different replication kinetics. On day 14,
culture supernatants were removed and genomic DNA was extracted
from the cells for env gene amplification.
Confirmation of dualtropism of primary viral isolates
We first analyzed the seven primary viral isolates propagated in
PBMCs for their ability to use multiple coreceptors on cell lines.
Specifically, we analyzed for ability to mediate cell entry via CCR5 or
CXCR4 because these are the main coreceptors previously described
for a significant proportion of HIV-1 primary isolates. In order to
assess the ability of the isolates to utilize these coreceptors, virus
equivalent to 2 ng of p24 antigen each was used to infect U87.CD4
glioma cell lines with or without the co-expression of the coreceptors.
Table 1 shows the highest amounts of p24 antigen reached by the
primary isolates over a 10-day period in culture. All 7 primary viral
isolates replicated in cells expressing CXCR4 and CCR5. It was
noteworthy that while all the isolates replicated efficiently in CXCR4
expressing cells, 3 isolates (RP1, SW30 and CM9) replicated to
relatively low titers in cells expressing CCR5. Isolates CM9 and SW30
were previously shown to replicate efficiently in both CCR5 and
CXCR4 expressing cell lines (Cilliers et al., 2003) and therefore our
results could indicate that in vitro passages of the isolates is selecting
against CCR5 utilization.
Determination of coreceptor usage by env clones
The env gene (approximately 3 kb) was then amplified from
PBMC genomic DNA by PCR, gel purified and cloned into a
mammalian cell expression plasmid vector (pcDNA3.1D/V5-His-
Fig. 1. Viral infection of PBMCs. 5000 pg p24 antigen equivalent of virus was used to infect stimulated PBMCs. Virus growth was monitored by p24 antigen concentration increased
over a 14-day period. BWM01_5 is an R5 monotropic viral isolate and was used as a positive control. All isolates and clones are referred to by their shorter names within the text
(BW17, TM1B, RP1, SW20, SW30, Du36_5, CM9 and BWMO1_5).
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TOPO). Five clones for each patient isolate were generated.
Pseudoviruses were prepared by cotransfecting 293T cells with
each of the 35 env plasmid clones with the pNL4-3.Luc.R-E-
construct (Connor et al., 1995; He et al., 1995). This construct
contains the infectious NL4-3 provirus backbone but is env and vpr
deleted and nef has been replaced by the firefly luciferase gene.
Virus supernatant from the transfected 293T cells equivalent to 2 ng
p24 antigen was then used to infect U87 cells expressing the
chemokine receptors CCR5 or CXCR4. A previously characterized
dualtropic env clone Du179 (Coetzer et al., 2006) was used in
parallel as a positive control. Productive entry of target cells was
determined by measurement of firefly luciferase activity in cell
lysates of infected U87 cells. All 35 env clones were able to
efficiently infect cells expressing CXCR4 (Table 2). Five of 35 (14.3%)
clones tested were also able to mediate entry via the CCR5 receptor,
indicating that they were dualtropic. Two of the clones able to
utilize CCR5 were from isolate RP1 while the other three were from
isolate CM9. Surprisingly, there were no CCR5 monotropic clones
detected from the bulk PCR envelope analysis of dualtropic isolates
in this study.
We then reasoned that there were two possibilities to explain
these results; one is that CCR5 monotropic envelopes are present at
very low frequencies and therefore are virtually undetectable as
clones from amongst the primary isolate viral quasispecies or that the
CXCR4 viruses may be more fit and outcompeting CCR5 clones when
propagated in PBMCs. In order to differentiate between these two
possibilities, we infected U87.CD4.CCR5 cells with each of the primary
viral isolates, with the objective of amplifying or favoring the CCR5-
tropic clones in CCR5-only expressing cells. RNA was then extracted
from the viral supernatant from U87.CD4.CCR5 cells, functional env
clones generated and coreceptor usage determined as described for
the PBMC-derived clones. All clones generated from U87.CD4.CCR5
cell supernatants showed dualtropism (data not shown). This result
suggests that env clones using CCR5 only were virtually absent or
present at very low frequencies within the quasispecies of the 7
primary isolates analyzed here.
Limiting endpoint dilution PCR
We also considered the possibility that bulk PCR env amplification
and cloning could result in resampling bias and explain the absence of
CCR5-only env clones. We thus used a single genome amplification
approach to generate diverse clones from isolateDu36_5. This clonewas
selected for this analysis because it showed a bias towards CCR5
utilization and yet we had failed to identify CCR5-only tropic clones
from this isolate. Thirty clones of DU36_5were amplified and cloned by
this limiting endpoint dilution PCR approach. These clones were then
tested for coreceptor usage in the U87.CD4.CCR5 and U87.CD4.CXCR4
cell lines. Of the 26 functional clones, 24were dualtropic, one clone used
CXCR4 exclusively and one clone showed exclusive R5-usage.
Genotypic analysis of the env gene
All 35 env full-length clones generated in this study by bulk PCR
were sequenced to investigate phylogenetic relationships and to
correlate coreceptor usage phenotype to genotype data. Phyloge-
netic analysis showed that all clones clustered with subtype C
references with a high degree of confidence (Fig. 2). Furthermore,
the clones from each primary viral isolate clustered together. As
described above, sequences were also generated from U87.CD4.
CCR5 and U87.CD4.CXCR4 cells infected with each of the primary
isolates. These clones utilized both CCR5 and CXCR4, and their
sequences were virtually phylogenetically indistinguishable from
those obtained from PBMC cultures. Results obtained by using
position-specific scoring matrix for HIV-1 subtype C (C-PSSM), a
phenotype predictive tool based on HIV-1 subtype C sequences
(Jensen et al., 2006) indicated CXCR4 or dualtropic phenotype and
high net V3 charges (data not shown).
Table 1





Highest p24 antigen (pg/ml) reached by
primary isolates over 10-day period in culture
U87.CD4 U87.CD4.CCR5 U87.CD4.CXCR4
96BW17 NA NA (19) 630 (25) 707,297 (10) 209,119
99ZATM1B NA 190,000 (13) 610 (151) 32,012 (126) 98,654
RP1 7 178,830 (0.9) 610 (1.2) 2120 (646) 961,835
99ZASW20 2 43,595 (0.2) 0 (0.2) 160,683 (1.5) 47,787
99ZASW30 2 73,860 (0.8) 1 (0.8) 2141 (1.0) 158,623
99ZACM9 24 NA (1.1) 2 (1.2) 2201 (1.1) 11,979
01ZADu36_5 25 54,944 (1.3) 1 (2.1) 1,658,728 (1.0) 46,525
96BWM01_5 NA NA – – –
Du179 279 2640 – – –
NA—not available. All patients were ART naive.
2000 pg of p24 viral supernatants from PBMC co-cultures was used to infect U87.CD4
cells expressing different coreceptors i.e. CCR5 or CXCR4 coreceptors. The U87.CD4 cell
line was used as a control cell line. We used 2000 pg of HIV-1 p24 equivalent of virus to
infect and cells were washed 3 times after overnight incubation with infecting stock.
Virus growth above 2000 pg (amount used to infect) was considered productive
infection of target cells. All italicized figures in brackets indicate background level i.e.
the p24 antigen (pg/ml) on day 0.
Table 2
Coreceptor usage characterization of the HIV-1C env clones.
Clone U87.CD4.CCR5 U87.CD4.CXCR4 Accession number
96BW17 #2 − +++ FJ846633
96BW17 #3 − +++ FJ846634
96BW17 #6 − +++ FJ846635
96BW17 #7 − +++ FJ846636
96BW17 #15 − +++ FJ846637
99ZATM1B #3 − +++ FJ846653
99ZATM1B #5 − +++ FJ846654
99ZATM1B #6 − ++ FJ846655
99ZATM1B #8 − ++ FJ846656
99ZATM1B #13 − ++ FJ846657
RP1 #5 − ++ FJ846658
RP1 #6 − ++ FJ846659
RP1 #8 − ++ FJ846660
RP1 #10 ++ ++ FJ846661
RP1 #13 ++ ++ FJ846662
99ZASW20 #2 − ++ FJ846643
99ZASW20 #3 − ++ FJ846644
99ZASW20 #11 − ++ FJ846645
99ZASW20 #14 − +++ FJ846646
99ZASW20 #15 − ++ FJ846647
99ZASW30 #1 − ++ FJ846648
99ZASW30 #2 − +++ FJ846649
99ZASW30 #3 − +++ FJ846650
99ZASW30 #6 − +++ FJ846651
99ZASW30 #9 − +++ FJ846652
01ZADu36_5 #2 − +++ FJ846628
01ZADu36_5 #7 − +++ FJ846629
01ZADu36_5 #8 − ++ FJ846630
01ZADu36_5 #9 − +++ FJ846631
01ZADu36_5 #10 − ++ FJ846632
99ZACM9 #1 ++ +++ FJ846638
99ZACM9 #2 ++ +++ FJ846639
99ZACM9 #16 − +++ FJ846640
99ZACM9 #18 − +++ FJ846641





For each experiment, a positive result was considered to be 2 × the average relative
luminescenceunits (RLUs)of thenegative controlwells+standarddeviation. RLUsabove
this but less than 3× this cutoff value are indicatedby “+”, values 3× to10×above cut off
are shown as “++” and values above 10 × the cut off are indicated as “+++”.
a 96BWM01_5 is an R5-only control, 96BW17#10 is an X4-only control and Du179 is
an R5X4 contol. pNL4-3.Luc.R-E- is the negative control.
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Fig. 3. Alignment of V3 sequences of clones of primary viral isolates. The crown motif for each sequence is indicated in blue and dualtropic clone sequences are indicated in green.
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The envelope V3 loop is an important determinant of coreceptor
utilization (Briggs et al., 2000; Cann et al., 1992; Fouchier et al., 1992;
Rizzuto et al., 1998; Wu et al., 2006). Therefore, we further analyzed
the V3 loop of the functionally characterized env clones in order to
identify and describe sequences associated with dualtropism and
CXCR4 utilization (Fig. 3 and Table 3). Of particular interest was the
crownmotif, a conserved tetrapeptide located at the tip of the V3 loop.
Changes within this region may influence coreceptor usage. The
consensus crown motif for clones from isolate RP1 was GPGQ, which
is the conventional V3 loop crown sequence observed in CCR5-tropic
subtype C sequences. The crown motifs for clones generated from
Du36_5 and CM9 were GPGR and GPRY respectively, sequence
substitutions that are indicative of CXCR4 tropism (Coetzer et al.,
2006). Clones from BW17, TM1B and SW20 each displayed consensus
crown motif sequences that read GRGQ. The consensus crown motifs
of SW30, Du36_5 and CM9 read GRGH, GPGR and GPRY respectively.
Thus CXCR4 utilization in HIV-1 subtype C is commonly associated
with a basic amino acid substitution in the V3 tetrapeptide although
this is not an absolute requirement.
Another feature of the env V3 loop associated with tropism
determination is the property of amino acids at positions 11 and/or
25 (Fouchier et al., 1992). The consensus sequences for all isolates
with the exception of SW20 showed a positively charged amino acid
substitution at one or both of these positions. BW17 has serine (S)
(neutral charge) and arginine (R) (positively charged); TM1B has
asparagine (N) (neutral) and arginine, SW20 has serine and
glutamine (Q) both of which carry neutral charges, SW30 has serine
and lysine (K), Du36_5 has arginine and glycine (G) and CM9 has
arginine and threonine (T) at positions 11 and 25 respectively. RP1
has arginine at both positions. The number of amino acids in the V3
loop can also be indicative of coreceptor usage. The typical V3 loop
from CCR5 tropic viruses has 35 amino acids. Clones from CM9 were
35 amino acids long in the V3 loop, whereas clones from Du36_5
were 36 amino acids long. Clones from isolates TM1B, SW30 and
BW17 had 2-amino acid insertions, increasing the length of the V3
loop to 37 amino acids. The insertions occurred at positions 13 and
14 of the V3 loop for clones from isolates RP1 and SW20 and at
positions 6 and 7 for clones from Du36_5. Clones from TM1B, SW30
and BW17 had insertions between positions 15 and 16. Amino acid
insertions in the V3 loop, particularly at positions 13 and 14 are
features consistent with CXCR4 utilization as previously described
(Coetzer et al., 2006). None of the insertions observed in the V3 loop
of the clones from this study was noted in HIV-1 subtype C R5
sequences downloaded from the Los Alamos database (www.hiv.lanl.
gov) (data not shown). The V3 region was also analyzed by manually
calculating the overall net amino acid charge, another indicator of
env coreceptor tropism (Table 3). C-PSSM, a web-based bioinformatic
tool used for predicting HIV-1C coreceptor usage from the amino acid
sequences of the V3 loop (Jensen et al., 2006) was also used. Both
manual and C-PSSM calculations were comparable except for the
clones from SW30 where calculated scores were slightly higher than
C-PSSM generated scores. Higher overall net V3 charges are
associated with X4-usage. A charge less than +4.5 is regarded as
R5-using and charges above +4.5 are regarded as X4-using (Coetzer
et al., 2006; Fouchier et al., 1995; Fouchier et al., 1992; Kuiken et al.,
1992). Therefore, based on the multiple V3 loop sequence based
algorithms available for phenotype prediction, all clones generated in
this study were either only CXCR4-using or dualtropic, consistent
with the functional data.
We next analyzed the V1/V2 and V4/V5 regions of the env gene as
these regions have also been implicated in playing a role in viral
tropism. Sequence features in these regions that may influence
coreceptor utilization are the amino acid length and the number of
predicted N-linked glycosylation sites (Chohan et al., 2005; Coetzer et
al., 2007; Coetzer et al., 2008; Masciotra et al., 2002; Pollakis et al.,
2001). The number of predicted N-linked glycosylation sites in clones
from this study varied from 23 to 33. Clones for RP1, SW20 and SW30
all had 30 predicted N-linked glycosylation sites. Within the V1/V2
and V3 regions, the N-linked glycosylation sites varied between
isolates but occurred at the same positions for all clones of the same
isolate irrespective of whether they were X4-using or dualtropic
except for one clone from TM1B which had 2 predicted N-linked
glycosylation sites in the V2 region whereas the other 4 clones of this
isolate had 3. The sites within the V4/V5 regions for all clones of all
isolates showed slight variations in position. However, all clones from
Du36_5 exhibited CXCR4-usage and showed variation in the positions
of the sites in all five hypervariable regions. The positions of N-linked
glycosylation sites varied from clone to clone and based on these
positions no pattern emerged that could distinguish CXCR4-using
clones from those that used both CCR5 and CXCR4.
When the total number of predicted N-linked glycosylation sites
within the env as well as within the V1/V2 and V4/V5 regions was
analyzed, no significant difference was observed between the CXCR4-
using clones and dualtropic clones. However, the median number of
N-linked glycosylation sites for X4/X4R5 clones from this study was
significantly higher at (30) compared to (21) for R5 clones (30
sequences downloaded from the Los Alamos HIV-1 database)
(p b0.0001) (Figs. 4A–C). R5 sequences showed a lower number of
predicted N-linked glycosylation sites within the entire env as well as
within the V1/V2 and V4/V5 regions when compared to R5X4/X4
clonal sequences.
Previous reports have suggested that a lack of predicted N-linked
glycosylation sites at positions 6–8 of the V3 loop may be indicative of
CXCR4-usage (Coetzer et al., 2006).We found this site to be conserved
in the clones analyzed in this study, despite the utilization of CXCR4
by all the clones. All clones (except those from isolate Du36_5)
contained a predicted N-linked glycosylation site at position 6
although they were CXCR4-using. This was also observed in a
previous study by Johnston et al. (2003) where all but one X4
sequence maintained this site. We found a significant reduction in the
number of predicted N-linked glycosylation sites within the V3 region
of clones generated in this study as compared to the R5 sequences
from the database (Fig. 4D).
The entire env sequence i.e. gp160 of all CXCR4- and CCR5/CXCR4-
using clones were compared to determine if any distinguishing
features could be identified. Specifically, we analyzed for unique
Table 3
Summary table of V3 characteristics of clones of primary viral isolates.
Clone A.A length Calc V3 net charge PSSM V3 net charge Amino acid (11/25) Crown motif PSSM coreceptor usage Phenotype prediction
R-5 only virus 96BWM01_5 35 4 4 Ser (S)/Asp (D) GPGQ CCR5-using only CCR5-using
96BW17 #2; 3; 6; 7; 15 37 7 7 Ser (S)/Arg(R) GRGQ CXCR4-using CXCR4-using or dt
99ZATM1B #3; 5; 6; 8; 13 37 8 8 Asp(N)/Arg(R) GRGQ CXCR4-using CXCR4-using or dt
P1 #5; 6; 8; 10; 13 37 8 8 Arg(R)/Arg(R) GPGQ CXCR4-using CXCR4-using or dt
99ZASW20; #2; 3; 11; 14; 15 37 6 6 Ser(S)/Glut(Q) GRGQ CXCR4-using CXCR4-using or dt
99ZASW30 #1; 2; 3; 6; 9 37 9 8 Ser(S)/Lys(K) GRGH CXCR4-using CXCR4-using or dt
01ZADu36_5 #2; 9 36 8 8 Arg(R)/Gly(G) GPGR CXCR4-using CXCR4-using or dt
01ZADu36_5 #7; 8; 10 36 7 7 Arg(R)/Gly(G) GPGR CXCR4-using CXCR4-using or dt
99ZACM9 #1; 2; 16; 18; 21 35 6 6 Thr(T)/Arg(R) GPRY CXCR4-using CXCR4-using or dt
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Fig. 4. Box plots of putative N-linked glycosylation sites (PNLGS) and env variable loop lengths. (A) Shows the total number of PNLGSwithin the env. (B) The number of PNGLS within
the V1/V2 region. (C) The number of PNGLS within the V4/V5 region. (D) The number of PNLGS within the V3 region. (E) The V1/V2 loop length. (F) The V4/V5 loop length. (G) The
V3 loop length. The line within each box represents the median value for each group. ⁎Indicates R5 sequences downloaded from the Los Alamos database (www.hiv.lanl.gov).
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signature patterns such as conservation of amino acids with a specific
charge or physical property at a particular position, putative N-linked
glycosylation sites, deletions, insertions or number of amino acids.
The 2 clones of RP1 displaying dualtropism (i.e. clones #10 and 13)
had leucine (L) at position 373 whereas the CXCR4-using clones of
this isolate (clones #5; 6; 8) had proline (P) at this position (data not
shown). The other isolate that produced clones exhibiting dualtrop-
ism was CM9. No distinguishing signature sequences were noted that
could differentiate between X4 and X4R5 sequences.
We next analyzed for differences in the loop lengths between X4,
X4R5 and R5 sequences. Most variation was seen in V1 which ranged
from 16 to 27 amino acids. V2 had a relatively constant loop length
(40–45). The combined V4/V5 loop length ranged from 37 to 46. The
V1/V2 and V4/V5 loop lengths of the clones produced in this study
were plotted against R5 sequences from the Los Alamos database. No
significant differences were observed between the V1/V2 sequences
of clones generated in this study and the R5 sequences from the Los
Alamos database (Fig. 4E). However, for the V4/V5 region, there was a
significant difference between the generated clones using the CXCR4
coreceptor for viral entry and the dualtropic clones (p=0.015) (Fig.
4F), with the dualtropic clones having an increased V4/V5 loop length.
For the V3 loop, all analyzed R5 sequences had a loop length of 36
amino acids whereas X4 and R5X4 clones from this study showed
variability with a range from 35 to 37 amino acids (Fig. 4G).
Discussion
The requirement by HIV-1 for specific cellular interacting factors
during the entry step offers an opportunity for the development of
vaccines and drugs that target this crucial step in the virus
replication cycle (Dhami et al., 2009; Hunt and Romanelli, 2009;
Pantophlet and Burton, 2006; Phogat et al., 2007). Coreceptors play
an important role in initiating infection at the cellular level.
Additionally, coreceptor utilization is an important determinant of
the rate of disease progression. The emerging availability of entry
inhibitors such as the CCR5 antagonists underlines the importance
of better characterization of coreceptor utilization and cellular
tropism by HIV-1 isolates particularly in heavily burdened countries
where the drugs are likely to be required on a large scale for the
clinical management of HIV/AIDS. In this study, we generated 35
full-length env clones from seven dualtropic isolates of HIV-1
subtype C, in order to determine whether they were a mixture of
CCR5 and CXCR4 quasispecies or dualtropic viruses at the clonal
level. We also interrogated the sequence characteristics of these
clones in order to better elucidate the genetic determinants of
coreceptor utilization by HIV-1 subtype C viruses. We found that
CXCR4-tropic clones dominated within the dualtropic viral isolates
quasispecies. A minority proportion of dualtropic clones were also
identified. Unexpectedly, we found that there was not a single
CCR5-monotropic env clone from the seven primary isolates
analyzed in this study. This is an unusual finding considering that
many studies have shown that HIV-1 subtype C viruses even in late
stages of disease utilize CCR5-only predominantly for cell entry. We
thus expected to find a significant proportion of the remnants of
these viruses among the quasispecies of the dualtropic isolates.
Instead, all the clones detected in this study used CXCR4 as the
coreceptor for cell entry, with a minority of these (14.3%) also able
to mediate entry via the CCR5 receptor. Our results may explain
why in previous studies of some of the dualtropic isolates described
here (CM9, SW20 and SW30); the isolates could be strongly
inhibited by CXCR4 inhibitors but only modestly by CCR5 inhibitors
(Cilliers et al., 2003). These earlier results can now be explained by
the observation that although these isolates are dualtropic, they are
dominated by X4 variant clones.
An alternative explanation of our findings is that these isolates
changed their coreceptor preference during in vitro passages in PBMC
co-cultures as has been previously described (Voronin et al., 2007).
This possible explanation is supported by the finding that isolates
CM9 and SW30 displayed remarkably lower CCR5 utilization capacity
(Table 1) than was previously described (Cilliers et al., 2003). It is also
worth noting that although isolates BW17, SW20 and Du36_5 showed
a possible bias towards CCR5 utilization and were clearly dualtropic,
all the envmolecular clones generated from these isolates by bulk PCR
amplification were CXCR4-only using. This finding strongly suggested
that the bulk PCR could be biased towards X4 viruses. We therefore
performed limiting endpoint dilution PCR on one dualtropic viral
isolate (Du36_5) which was biased towards CCR5 utilization (Table
1). Remarkably, of 26 functional env clones generated by this
approach, 24 exhibited dualtropism, one used CXCR4 exclusively
and one used CCR5 exclusively. We therefore conclude that dualtropic
HIV-1 subtype C isolates are dominated by X4 and X4R5 clones with
negligible proportion of R5 monotropic clones.
It has been recently proposed that coreceptor switching is
associated with deleterious mutations in env that diminish CCR5-
tropism as mutations associated with CXCR4 utilization accumulate
(Coetzer et al., 2008). Although we did not directly test for coreceptor
binding in this study, our results are consistent with the proposal by
Coetzer et al. and with their observation that coreceptor switching is
associated with a rapid decrease in the ability to use CCR5. Our results
may suggest that in HIV-1 subtype C, the mutations required for
adaptation to CXCR4 utilization significantly reduce the ability of env
to utilize CCR5, thus resulting in reduced fitness of CCR5 utilizing
viruses. This could in turn lead to the selection and amplification of
clones able to utilize CXCR4. We can speculate that given the low
frequency of HIV-1 subtype C CXCR4 utilizing viruses reported in
various studies, more accumulated mutations are required for
switching to CXCR4 utilization for this subtype. Alternatively, the
changes required for a switch to CXCR4 utilization may result in a
bigger fitness deficit for HIV-1 subtype C CCR5-tropic variants thus
leading to selection against these viruses once adaptation to CXCR4
utilization has been accomplished. Further studies will be required to
carefully investigate the specific localization and nature of comple-
mentary mutations required for HIV-1 subtype C env coreceptor
switch.
We also investigated the genetic characteristics associated with
CXCR4-usage or dualtropism for HIV-1 subtype C viruses. Our results
may be limited by founder effects since we could not generate R5
sequences from the study isolates but we nevertheless had HIV-1
subtype C R5 sequences available from the Los Alamos database that
facilitated this comparative analysis. As described for HIV-1 subtype B,
the subtype C third variable loop of gp120 (V3 region) is a major
determinant of whether CXCR4 or CCR5 will be the accessory protein
used by the virus for membrane fusion (Cilliers et al., 2003; Coetzer et
al., 2007; Coetzer et al., 2006; Fouchier et al., 1992; Morris et al., 2007;
Ndung'u et al., 2006). Typically, the V3 region consists of approxi-
mately 35 amino acids in CCR5-tropic viruses (Coetzer et al., 2006).
Consistent with earlier studies, we found that V3 loop amino acid
characteristics are important determinants of coreceptor tropism. In
most cases, we found that the V3 loop crown of CXCR4-utilizing
clones had basic amino acid substitutions which differed from the
canonical GPGQ sequence found in CCR5 HIV-1 subtype C viruses to
GPGX (where X is any other amino acid), GRGH, GPGR or GPRY. X4
variants are more variable than R5 viruses in the V3 region
particularly at positions 11 and 25 which tend to be mostly positively
charged amino acids, often arginine (R), lysine (K) or histidine (H).
We found the presence of a basic amino acid at both or one of these
positions for the majority of clones in this study (85%). In addition, in
X4 variants there may be insertions particularly between positions 13
and 14 of the V3 loop contributing to an increased length. We found
amino acid insertions in 71% of clones in this study. X4 variants may
also be distinguished from R5 viruses as they usually have an
increased net V3 charge. Consistent with these observations, we
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found that 100% of X4-utilizing clones had V3 loop amino acid charges
of +5 or more.
The V3 region however, is not the exclusive determinant of
coreceptor usage and other regions within the env gene may also
contribute to viral tropism. The V1/V2 and V4/V5 regions have been
implicated in playing a role in determining the biological phenotype
of the virus. Specifically, the number of N-linked carbohydrate
moieties in these variable loops has been associated with coreceptor
determination (Chohan et al., 2005; Coetzer et al., 2008; Masciotra et
al., 2002; Pollakis et al., 2001). Here we found a strong association
between the number of N-linked glycosylation sites and coreceptor
utilization with X4 clones having a significantly higher number of
these sites than R5 clones from the database overall and in the V1/V2
or V4/V5 regions (Figs. 4A–C). In contrast in the V3 region, the number
of sites was significantly higher in R5 sequences than X4/X4R5
sequences (Fig. 4D). A previous longitudinal study of HIV-1 env
evolution showed no significant changes in N-linked glycosylation
sites of 23 viral isolates from 5 patients followed for 2–4 years
(Coetzer et al., 2007). Therefore our findings may suggest a rapid
accumulation of N-linked glycosylation sites as coreceptor tropism
switches, as opposed to a slow accumulation of these sites over time.
This is consistent with recent findings of rapid decline in CCR5
utilization as alternate coreceptor utilization emerges in HIV-1
subtype B infection (Coetzer et al., 2008). In both HIV-1 subtypes A
and C, shorter V1/V2 loop sequences and fewer predicted N-linked
glycosylation sites have been correlated with preferential heterosex-
ual viral transmission (Chohan et al., 2005; Derdeyn et al., 2004). We
did not find significant differences in V1/V2 length between R5 and X4
clones in this study but a trend towards shorter V4/V5 for X4 clones
was noted (Figs. 4E–F). Further longitudinal studies will be necessary
in order to better understand HIV-1 subtype C transmission,
coreceptor switching and the env genetic characteristics associated
with these processes. Overall, our results suggest that sequence
characteristics in the V3 loop, the V4/V5 loop length as well as the
number of env predicted N-linked glycosylation sites are the primary
genotypic determinants for viral tropism in HIV-1 subtype C.
It is worth noting that we did not perform limiting endpoint
dilution of samples in this study except for isolate Du36_5. Therefore
we cannot completely rule out the presence of substantial frequencies
of R5-monotropic viruses in the quasispecies of the isolates where
endpoint dilution was not used. However, the absence of these clones
in bulk amplified clones, in CCR5 only expressing cells and in endpoint
diluted Du36_5 isolate that is biased towards CCR5 is all suggestive of
absence of such quasispecies or presence at very low frequency. Our
results appear to contradict the recent findings of Irlbeck et al. (2008)
but it must be emphasized that in that study, samples were analyzed
directly from plasma in contrast to our study in whichwe examined in
vitro propagated isolates. Further studies will be needed to determine
whether env clones directly obtained from patients with dualtropic
HIV-1 subtype C viruses have a bias towards CCR5 or CXCR4 tropism.
In conclusion, we show in this study that dualtropic viral isolates
consist of predominantly X4 and X4R5 clones. Thirty of 35 env clones
analyzed from PBMCs utilized X4 only as the coreceptor for entry into
cells, whereas 5 of 35 clones tested displayed dualtropism and no
CCR5-only utilizing clones were identified. R5 monotropic clones
could not be detected even when the isolates were cultured in cells
expressing CCR5 coreceptor only. We also failed to detect a significant
number of R5 monotropic clones when we changed our approach of
viral amplification from bulk PCR to limiting endpoint dilution PCR for
one dualtropic isolate showing bias towards CCR5 tropism. Viral env
sequences from both CXCR4 and CCR5-expressing cells were
indistinguishable and possessed X4/dualtropic characteristics. Fur-
thermore, we describe env sequence characteristics associated with
CXCR4 utilization in HIV-1 subtype C. In addition to sequence changes
in the env V3 region, we identify the number of N-linked glycosylation
sites in the V1/V2, V3 and V4/V5 regions as major determinants of
coreceptor utilization in HIV-1 subtype C. We also show that the
length of the V4/V5 is a possible determinant of coreceptor utilization.
We note that our results are consistent with recent findings of the
rapid loss of fitness of CCR5 envelope as coreceptor switching emerges
and suggest that the sequence characteristics associated with
coreceptor switch must occur rapidly in vivo. Further studies are
needed to better characterize coreceptor switching, particularly in the
context of HIV-1 subtype C, the predominant subtype in the world.
We have generated 35 full-length CXCR4- or dualtropic clones of HIV-
1 subtype C, important reagents that will facilitate further functional
studies of this globally predominant subtype. Our results have
important implications for coreceptor antagonist design and applica-




Seven primary viral isolates were analyzed in this study. BW17 is a
dualtropic HIV-1C virus isolated in 1996 from an infected person with
acquired immunodeficiency syndrome (AIDS) in Botswana (Ndung'u
et al., 2006). TM1B; RP1; SW20; SW30; CM9 and Du36_5 were
obtained from the AIDS Virus Research Unit, National Institute for
Communicable Diseases, Johannesburg, South Africa and were from
patients at various disease stages: acute infection (Du36_5), slow
progressor (TM1B), rapid progressor (RP1) and AIDS (SW20; SW30;
CM9) (Choge et al., 2006; Cilliers et al., 2003; Coetzer et al., 2006).
Cells and cell lines
U87.CD4 cells with or without the expression of the chemokine
receptors CCR5 or CXCR4 were obtained from the NIH AIDS Research
and Reference Reagent Program (Rockville, MD). U87.CD4 cells
without chemokine receptors were cultured in Dulbecco's modified
eagles medium (DMEM) containing L-glutamine (Gibco, NY, USA)
supplemented with 15% heat inactivated fetal bovine serum (FBS)
(Gibco, NY, USA), 300 μg/ml G418 (Sigma, Germany) and 50 μg/ml
penicillin–streptomycin (Gibco, NY, USA). U87.CD4 cells expressing
CCR5 or CXCR4were propagated in the samemedium but additionally
supplemented with 1 μg/ml puromycin (Sigma, Germany). 0.5×106
cells were cultured in 6-well flat-bottomed plates in a total of 2 ml
culture medium at 37 °C and 5% CO2.
293T cells were obtained from the NIH AIDS Research and
Reference Reagent Program (Rockville, MD) and were cultured in
DMEM containing L-glutamine supplemented with 10% heat inacti-
vated FBS and 50 μg/ml gentamicin (Sigma, Germany). 50,000 293T
cells per well were seeded in a total volume of 0.3 ml per well of a 48-
well flat-bottomed plate. These cells were incubated at 37 °C in 5% CO2
overnight before transfection.
Viral isolates propagation and DNA extraction
PBMCs from anonymous low risk HIV-negative volunteers were
separated by density-gradient centrifugation on Ficoll-Paque (Amer-
sham Biosciences, Uppsala, Sweden). We confirmed that the samples
were HIV-negative by performing HIV RNA testing on the plasma
(Ampliscreen v1.5, Roche Diagnostics, Rotkreuz, Switzerland). 5×106
PBMCs from 2 donors were combined and stimulated by culturing in
RPMI 1640 with penicillin–streptomycin (50 μg/ml and 50 U/ml), 10%
heat inactivated FBS, 5 μg/ml phytohaemagglutinin (PHA) (Sigma,
Germany) and 20 U/ml interleukin-2 (IL-2) (Roche Applied Science,
Germany) at 37 °C and 5% CO2 for 72 h in a T-25 flask. For infection of
the stimulated PBMCs, 5 ng p24 antigen equivalent of virus was used.
On days 1, 4, 7, and 10, 50% of the media was removed and replaced
with fresh medium. Aliquoted supernatant was retained for
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quantification of p24 antigen as previously described. On day 14,
supernatant was removed and preserved for p24 antigen quantifica-
tion. Cells were harvested and resuspended in 200 μl PBS. DNA was
then extracted using the QiaAmp DNA Blood Mini kit (Qiagen,
Germany).
Confirmation of dualtropism of primary viral isolates
PBMC-grown virus corresponding to 2 ng of p24 HIV-1 antigen
was used for infection of U87.CD4 cells expressing either CCR5 or
CXCR4. On days 0, 4, 7 and 10 half of the media was removed and
replaced with fresh medium. The removed supernatant was retained
for quantification of p24 antigen using the Vironostika HIV-1 Antigen
Microelisa system (Biomerieux, Boxtel, Netherlands). Previously well-
characterized dualtropic (Du179) and CCR5-tropic (BWM01_5)
primary isolates were used as positive controls.
Amplification of envelope (env) gene
The 3 kb env gene was amplified by polymerase chain reaction
(PCR) using Phusion Hot Start High-Fidelity DNA Polymerase
(Finnzymes, Finland) with the following primers: Env1Adir 5′-
CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3′ and EnvM 5′-
TAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3′. The forward primer Env1A-
dir was designed to include the 4 base pair sequence (CACC)
necessary for directional cloning on the 5′ end. Cycling conditions
were as follows: a 5 minute denaturation at 94 °C, followed by
35 cycles of 30 s at 94 °C, 30 s at 55 °C, and 4 min at 72 °C. The final
extension was at 72 °C for 10 min . The amplified product was then
run on a 1% agarose gel and gel purified using the Qiaquick gel
extraction kit (Qiagen, Germany).
Cloning
Once the DNA was purified, the env of each primary viral isolate
was cloned into the pcDNA3.1D/V5-His-TOPO vector (Invitrogen,
Carlsbad, CA). For the transformation procedure, Stratagene XL-10
Gold Ultracompetent cells (Stratagene, USA) were used. Molecular
clones were screened as follows. A colony PCR was performed after
the colony was incubated for 1.5 h at 37 °C with continuous shaking
(225 rpm) in a 96-well plate containing 100 μl Luria Bertani (LB)
media (Sigma, Germany) and ampicillin (100 μg/ml) (Calibiochem,
Darmstadt, Germany) to determine positivity of the cloned insert. This
is a directional env insert-specific PCR as it uses the forward primer T7
(5′ TAATACGACTCACTATAGGG 3′) found on the vector and reverse
primer Env M which is env specific. SuperTherm Taq Polymerase
(Southern Cross Biotechnology, Cape Town, South Africa) was used
and cycling conditions were as follows: denaturation for 5 min at
94 °C, followed by 35 cycles of 30 s at 94 °C, 30 s at 55 °C, and 4 min at
68 °C. The final extension was for 10 min at 68 °C. The amplified
products were then run on a 1% agarose gel. Clones were considered
positive if they yielded a 3 kb band on an agarose gel. These clones
were then grown up at 37 °C overnight with shaking in 3 ml LB broth
containing 100 μg/ml ampicillin. Plasmid DNAwas then isolated using
Qiaprep Spin Miniprep kit by following the manufacturer's instruc-
tions (Qiagen, Germany). The first five functional env clones identified
from each isolate were selected for further analysis.
Limiting endpoint dilution PCR
A limiting endpoint dilution PCR was performed on one primary
viral isolate, Du36_5 in order to determine whether the bulk PCR
resampling bias resulted in clones biased towards either CCR5 or
CXCR4 coreceptor usage. Single genome amplification was undertak-
en as previously described (Salazar-Gonzalez et al., 2008). Primers
and cycle conditions were the same as used in the bulk PCR reactions.
Once confirmed by agarose gel electrophoresis, 30 PCR products were
purified and cloned and coreceptor usage was tested for the 26 clones
that were functional.
Coreceptor usage assays
Cotransfection was carried out by first combining 50 μl serum
free DMEM and 2.5 μl Fugene reagent (Roche Applied Science,
Germany) and incubating for 5 min at room temperature. This was
then incubated at room temperature together with 0.6 μg gp160
env DNA (i.e. cloned product) and 0.3 μg pNL4-3.Luc.R-E- (Connor
et al., 1995; He et al., 1995). pNL4-3.Luc.R-E- is a full-length HIV
plasmid with two frameshifts that render the clone env and vpr
deleted. The reporter firefly luciferase gene has been inserted into
the nef gene. The transfection mixture was incubated for 30 min ,
and then added to assigned wells of the plate seeded with 293T and
incubated at 37 °C and 5% CO2 for 48 h . The supernatant together
with 7.5 μg/ml DEAE-Dextran (Sigma, Germany) was added to U87.
CD4 cells as well as U87.CD4 cells expressing the coreceptors CXCR4
or CCR5. This was incubated at 37 °C and 5% CO2 for 48 h . The cells
were lysed using Glo Lysis buffer (Promega, Madison, WI, USA) and
incubated with Bright-Glo Assay reagent (Promega, Madison, WI,
USA). The luciferase activity was then determined using the Turner-
Biosystems Modulus Microplate instrument (Promega, Madison, WI,
USA). A negative control consisting of the plasmid pNL4-3.Luc.R-E-
and various positive controls were used in each coreceptor
expressing cell line. The positive controls were previously charac-
terized env clones Du179 (dualtropic), 96BWM01_5 (R5), and
96BW17#10 (X4). In addition, for each assay plate, 100 nM of
CCR5 inhibitor RANTES and 500 nM of CXCR4 inhibitor AMD3100
were used with the respective controls to confirm specificity of
entry into target cells. Experiments were done in duplicate and the
average relative luminescence units (RLUs) for each clone were
calculated. A positive result was considered to be twice the average
of the negative control plus standard deviation.
Sequencing and sequence analysis
The env gene was sequenced after cloning using the ABI PRISM Big
Dye Terminator Cycle Sequencing Ready Reaction kit version 3.1
(Applied Biosystems, CA, USA). Sequences were assembled and edited
using Sequencher 4.8. They were then aligned with Mega 4.
Phylogenetic trees were constructed in Paup 4.0 to evaluate the
clustering of these sequences with each other and with subtype
references. Phylogenetic trees were then visualized using Treeview
1.6.6. The consensus sequence for clones from each isolate was
generated using BioEdit Sequence Alignment Editor Software (Tom
Hall, North Carolina State University). Coreceptor utilization was
predicted using the web-based subtype C-specific position-specific
scoring matrix (C-PSSM) programme (http://indra.mullins.microbiol.
washington.edu/pssm/), a bioinformatics tool that reliably predicts
coreceptor phenotype using V3 loop sequences (Jensen et al., 2006).
Predicted N-linked glycosylation sites were examined using the web-
based programme N-GLYCOSITE (www.hiv.lanl.gov). All reference
sequences were obtained from the Los Alamos database (www.hiv.
lanl.gov).
Nucleotide sequence accession numbers
The sequence data obtained from this study have been submitted
to Genbank under the following accession numbers: FJ846629–
FJ846662 and selected clones will be deposited into the NIH AIDS
Research and Reference Reagent Program repository.
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